Headquarters

Japan

Tel: +81 3-5615-9297
Fax: +81 3-5615-9298
E-mail: info@selleck.co.jp

Europe

DE Tel: 030 4036821-90
DE Fax: 030 4036821-99
UK Tel: 0207 4594182
UK Fax: 0207 4594183
E-mail: eu.order@selleckchem.com

United States

Toll Free: +1 877 796-6397
Fax: +1 832 582-8590
E-mail: sales@selleckchem.com

China

Toll Free: 400-668-6834
Tel: +86 21-68591985
E-mail: info@selleck.cn

Selleck.co.jp

Selleck.co.jp

Inhibitor catalog





阻害剤

Selleckは**120,000種類以上**のシグナル伝達経路研究に使用される阻害剤を供給しています。

HTS化合物ライブラリー

Bioactive Compound Library-Ⅰ
4560 compounds

Bioactive Compound Library-Ⅱ (Provided by Pfizer)
2863 compounds

FDA-approved Drug Library
1890 compounds

Kinase Inhibitor Library
599 inhibitors

Natural Product Library
1605 natural products

Target Selective Inhibitor Library
641 validated bioactive compounds

Express-Pick Library (Provided by Pfizer)
4208 chemical compounds

Epigenetics Compound Library
265 small molecule modulators

Clinical Compound Library
603 clinical compounds

Stem Cell Signaling Compound Library
102 small molecule inhibitors

Metabolism Compound Library
492 chemical compounds

Inhibitor Library
2134 inhibitors

Immunology/Inflammation Compound Library
400 chemical compounds

...

目的の化合物を選択してライブラリーのカスタマイズが出来ます。

2013年1月から現在まで、Selleck製品を使用して、Nature、Science、Cellで発表された学術論文は158件にも及びます。

Nature, 2018, 559(7713):211-216
Nature, 2018, 560(7718):372-376
Nature, 2018, 560(7716):112-116
Nature, 2018, 559(7713):285-289
Nature, 2018, 560(7718):387-391
Nature, 2018, 561(7724):551-555
Nature, 2018, 560(7718):325-330
Nature, 2018, 560(7716):117-121
Nature, 2018, 560(7719):499-503
Nature, 2018, 558(7708):141-145
Nature, 2018, 559(7713):279-284
Nature, 2018, 555(7694):103-106
Nature, 2018, 554(7692):317-322
Nature, 2018, 555(7698):673-677
Nature, 2018, 555(7696):387-391
Nature, 2018, 556(7702):501-504
Nature, 2018, 557(7704):247-251
Nature, 2018, 557(7704):256-260
Nature, 2018, 553(7686):101-105
Nature, 2018, 553(7686):96-100
Nature, 2018, 553(7686):91-95
Nature, 2017, 545(7652):54-59
Nature, 2017, 547(7664):453-457
Nature, 2017, 549(7673):548-552
Nature, 2017, 549(7673):533-537
Nature, 2017, 551(7679):247-250
Nature, 2017, 550(7675):270-274
Nature, 2017, 550(7676):402-406
Nature, 2017, 552(7683):121-125
Nature, 2017, 550(7677):534-538
Nature, 2017, 552(7683):116-120
Nature, 2017, 551(7678):105-109
Nature, 2017, 551(7682):639-643
Nature, 2017, 550(7674):133-136
Nature, 2017, 550(7676):360-365
Nature, 2017, 548(7668):466-470
Nature, 2017, 549(7672):404-408
Nature, 2017, 548(7669):582-587
Nature, 2017, 548(7668):471-475
Nature, 2017, 548(7667):343-346
Nature, 2017, 170(5):860-874.e19
Nature, 2017, 546(7658):431-435
Nature, 2017, 546(7658):416-420
Nature, 2017, 545(7654):365-369
Nature, 2017, 543(7647):728-732
Nature, 2017, 541(7638):481-487
Nature, 2017, 542(7641):362-366
Nature, 2016, 539(7627):54-58
Nature, 2016, 540(7631):119-123
Nature, 2016, 539(7629):437-442
Nature, 2016, 539(7628):304-308
Nature, 2016, 538(7626):477-482
Nature, 2016, 535(7613):517-22
Nature, 2016, 537(7620):422-426
Nature, 2016, 530(7590):358-61
Nature, 2016, 534(7607):341-6
Nature, 2016, 32(7597):107-11
Nature, 2016, 531(7596):651-5
Nature, 2015, 528(7582):422-6
Nature, 2015, 522(7557):492-6
Nature, 2015, 527(7576):100-4
Nature, 2015, 522(7556):349-53
Nature, 2015, 521(7552):316-21
Nature, 2015, 521(7553):541-4
Nature, 2015, 520(7549):683-7
Nature, 2015, 518(7538):254-7
Nature, 2015, 517(7534):391-5
Nature, 2015, 522(7555):226-30
Nature, 2015, 517(7535):460-5
Nature, 2015, 523(7558):92-5
Nature, 2015, 521(7552):357-61
Nature, 2015, 520(7547):368-72
Nature, 2015, 524(7566):471-5
Nature, 2015, 517(7536):583-8
Nature, 2015, 519(7543):370-3
Nature, 2014, 511(7507):90-3
Nature, 2014, 510(7504):283-7
Nature, 2014, 509(7498):105-9
Nature, 2014, 508(7494):118-22
Nature, 2013, 501(7466):237-41
Nature, 2013, 500(7461):222-6
Nature, 2013, 498(7452):109-12
Nature, 2013, 496(7446):523-7
Nature, 2013, 493(7430):51-5
Science, 2018, 361(6405)
Science, 2018, 359(6378)
Science, 2018, 11(528)
Science, 2018, 11(525)
Science, 2018, 10(441)
Science, 2018, 10(436)
Science, 2018, 10(433)
Science, 2018, 11(530)
Science, 2017, 9(420)
Science, 2017, 3(11):e1701679
Science, 2017, 9(414)10
Science, 2017, 358(6367):eaan4368
Science, 2017, eaal3755
Science, 2017, 355(6320):78-83
Science, 2017, 355(6320):84-88
Science, 2016, 354(6315)
Science, 2016, 351(6277):aad3680
Science, 2016, 352(6283):353-8
Science, 2016, 352(6282):189-96
Science, 2016, 353(6302):929-32
Science, 2013, 341(6146):651-4
Science, 2013, 339(6120):700-4
Cell, 2018, 174(6):1477-1491
Cell, 2018, 174(5):1200-1215
Cell, 2018, 174(5):1127-1142
Cell, 2018, 175(1):186-199
Cell, 2018, 174(2):338-349
Cell, 2018, 174(2):406-421
Cell, 2018, 174(2):422-432
Cell, 2018, 174(2):391-405
Cell, 2018, 175(1):85-100
Cell, 2018, 175(2):429-441
Cell, 2018, 174(4):953-967
Cell, 2018, 174(5):1216-1228
Cell, 2018, 174(4):856-869
Cell, 2018, 175(2):442-457
Cell, 2018, 173(1):104-116
Cell, 2018, 173(1):117-129
Cell, 2018, 173(4):972-988
Cell, 2018, 173(6):1413-1425
Cell, 2018, 173(2):470-484
Cell, 2018, 172(4):857-868
Cell, 2018, 173(2):515-528
Cell, 2018, 172(4):841-856
Cell, 2018, 172(3):564-577
Cell, 2018, 172(3):439-453
Cell, 2018, 172(1-2):90-105
Cell, 2018, 172(3):423-438
Cell, 2017, 171(7):1545-1558
Cell, 2017, 171(7):1611-1624
Cell, 2017, 171(5):1094-1109
Cell, 2017, 171(4):824-835.e18
Cell, 2017, 171(3):628-641
Cell, 2017, 161(4):803-16
Cell, 2017, 171(1):217-228
Cell, 2017, 171(3):668-682
Cell, 2017, 170(5):860-874.e19
Cell, 2017, 170(3):548-563.e16
Cell, 2017, 170(5):845-859.e19
Cell, 2017, 170(3):507-521.e18
Cell, 2017, 169(2):243-257.e25
Cell, 2017, 169(2):216-228.e19
Cell, 2017, 168(5):856-866
Cell, 2017, 168(1-2):86-100
Cell, 2016, 167(1):233-247
Cell, 2016, 167(7):1803-1813
Cell, 2016, 164(1-2):293-309
Cell, 2016, 165(1):234-46
Cell, 2015, 162(2):441-51
Cell, 2015, 160(1-2):161-76
Cell, 2014, 159(5):1110-25
Cell, 2014, 158(5):989-99
Cell, 2013, 154(5):1036-46
Cell, 2013, 153(4):840-54

SelleckはPfizer社が開発した化合物のライセンスサプライヤーです

2013年にSelleckはPfizer社とライセンス契約を結んだことで、Pfizer社の多様な化合物が提供可能となりました。これらの化合物は疾患研究において幅広い用途を有しています。

◆ 生物活性化合物はPfizer社のライセンスを得ており、臨床試験で安全かつ効果があることが実証されています。

◆ 取り扱う化合物は抗癌化合物（例：Bosutinib）から、抗生物質耐性研究で使用するグリシルサイクリン抗生物質（例：Tigecycline）まで、多岐にわたります。

◆ 信頼性保証：Pfizer社からライセンスを得た化合物はすべてPfizer社が開発し、検品しています。一部Pfizer社の品質保証に則って製造された化合物もあります。すべての化合物はNMRとHPLCを使用して検品されています。

◆ 詳細な前臨床研究データと安全性情報を利用することが出来ます。

Table of Contents

PI3K/Akt/mTOR

PI3K 1
mTOR 3
Akt 4
GSK-3 4
ATM/ATR 5
PDK 5
S6 Kinase 5
AMPK 6
DNA-PK 6
MELK 6

Epigenetics

HDAC 7
PARP 8
JAK 9
Pim 10
HIF 10
Aurora Kinase 10
Sirtuin 11
DNA Methyltransferase 11
Histone Methyltransferase 11
Epigenetic Reader Domain 12
Histone Demethylase 13
Histone Acetyltransferase 13

Methylation

DNA Methyltransferase 11
LSD1 14
JMJD 14
EZH1/2 14
G9a/GLP 14
PRMT 15
SETD 15
MLL 15
COMT 15
DOT1 16
HNMT 16
SMYD2 16
WDR5 16
SAM MTase 16
PPMTase 16

Immunology & Inflammation

PD-1/PD-L1 17
COX 18
CCR 19
Histamine Receptor 19
IL Receptor 20
gp120/CD4 20
CXCR 20
MALT 20
LTR 20
NOS 20
NADPH-oxidase 21

Protein Tyrosine Kinase

VEGFR 22
EGFR 23
PDGFR 25
c-Met 25
HER2 26
IGF-1R 26
FLT3 27
FGFR 27
c-Kit 28
Src 28
ALK 29
Tie-2 29
c-RET 29
TAM Receptor 29
CSF-1R 30
Ephrin Receptor 30
BTK 30
Trk Receptor 30
ACK 31

Angiogenesis

VEGFR 22
JAK 9
EGFR 23
PDGFR 25
HER2 26
FLT3 27
FGFR 27
HIF 10
VDA 33
Bcr-Abl 33
Src 28
ALK 29

Syk 33
FAK 34
BTK 30

Apoptosis

PD-1/PD-L1 17
Bcl-2 35
Caspase 36
p53 36
TNF-alpha 36
Mdm2 36
Survivin 37
c-RET 29
IAP 37
PERK 37
ASK 37

Autophagy

Autophagy 38
CXCR 20
LRRK2 39

ER stress & UPR

JNK 40
HSP (e.g. HSP90) 40
PERK 37
ASK 37

JAK/STAT

JAK 9
STAT 41
EGFR 23
Pim 10

MAPK

MEK 42
Raf 43
p38 MAPK 43
JNK 40
ERK 44
TOPK 44
MNK 44

Cytoskeletal Signaling

Akt 4
Bcr-Abl 33
Wnt/beta-catenin 45
PKC 46
FAK 34
HSP (e.g. HSP90) 40
Kinesin 46
Microtubule Associated 46
Integrin 47
PAK 47
Dynamin 47

Cell Cycle

CDK 48
PD-1/PD-L1 17
Aurora Kinase 10
Chk 49
ROCK 50
PLK 50
APC 50
Wee1 50
Rho 51
DYRK 51
c-Myc 51

TGF-beta/Smad

TGF-beta/Smad 52
Bcr-Abl 33
PKC 46
ROCK 50

DNA Damage

HDAC 7
ATM/ATR 5
PARP 8
Sirtuin 11
Topoisomerase 53
DNA-PK 6
Telomerase 54
MTH1 54

Stem Cells & Wnt

GSK-3 4
JAK 9
STAT 41
TGF-beta/Smad 52
Wnt/beta-catenin 45
ROCK 50
Gamma-secretase 55
Hedgehog/Smoothened 56
Casein Kinase 56
Hippo Pathway 56

Ubiquitin

Proteasome 57
DUB 57
E3 Ligase 58
p97 58
E1 Activating 58
E2 Conjugating 58

Neuronal Signaling

Beta Amyloid 59
5-HT Receptor 59
COX 18
Gamma-secretase 55
GluR 60
Adrenergic Receptor 61
AChR 62
Histamine Receptor 19
Dopamine Receptor 63
Opioid Receptor 63
GABA Receptor 63
P-gp 64
P2 Receptor 64
OX Receptor 64
BACE 64
Substance P 64
NMDAR 65
CaMK 65
GlyT 65

NF-κB

HDAC 7
NF-κB 66
IκB/IKK 66
NOD1 67

Metabolism

PPAR 68
P450 (e.g. CYP17) 69
HSP (e.g. HSP90) 40
PDE 69
Hydroxylase 70
Factor Xa 70
DHFR 70
Dehydrogenase 71
Procollagen C Proteinase 71
Phospholipase (e.g. PLA) 71
Carbonic Anhydrase 72
MAO 72
Liver X Receptor 72
FAAH 72
CETP 72
Lipase 73
Transferase 73
Ferroptosis 73
Lipoxygenase 73
HMG-CoA Reductase 73
AhR 74
Casein Kinase 56
NAMPT 74
IDO 74
Decarboxylase 74
GLUT 74
PKM 75

GPCR & G Protein

5-HT Receptor 59
Adrenergic Receptor 61
Histamine Receptor 19
Dopamine Receptor 63
Opioid Receptor 63
Cannabinoid Receptor 76
Endothelin Receptor 77
S1P Receptor 77
Hedgehog/Smoothened 56
SGLT 77
LPA Receptor 77
OX Receptor 64
PAFR 77
PKA 78
Adenosine Receptor 78
CaSR 78
CXCR 20
Vasopressin Receptor 78
cAMP 78

Endocrinology & Hormones

5-alpha Reductase 79
Estrogen/progestogen Receptor 79
Androgen Receptor 80
RAAS 80
Opioid Receptor 63
Aromatase 81
GPR 81

Transmembrane Transporters

Calcium Channel 82
Sodium Channel 83
ATPase 84
Potassium Channel 84
GABA Receptor 63
P-gp 64
Proton Pump 84
CFTR 85
TRPV 85
CRM1 85

Proteases

Proteasome 57
Caspase 36
Gamma-secretase 55
HCV Protease 86
DPP-4 87
HIV Protease 87
MMP 87
Serine Protease 87
Tyrosinase 88
Cysteine Protease 88
Glutaminase 88

Microbiology

HCV Protease 86
Integrase 89
Reverse Transcriptase 90
CCR 19
HIV Protease 87

PI3K/Akt/mTOR



PI3K

阻害選択性

Inhibitor Name	PI3K	p110α	p110β	p110δ	p110γ	C2β	Vps34	Other Targets	Clinical Phase
Dactolisib (BEZ235)		++++ IC50: 4 nM	++ IC50: 75 nM	+++ IC50: 7 nM	++++ IC50: 5 nM			mTOR (p70S6K),ATR	Phase 2
Pictilisib (GDC-0941)		++++ IC50: 3 nM	++ IC50: 33 nM	++++ IC50: 3 nM	++ IC50: 75 nM			mTOR	Phase 2
LY294002		+ IC50: 0.5 μM	+ IC50: 0.97 μM	+ IC50: 0.57 μM				DNA-PK	
Idelalisib (CAL-101)				++++ IC50: 2.5 nM	++ IC50: 89 nM				Phase 4
Buparlisib (BKM120)		++ IC50: 52 nM	+ IC50: 166 nM	++ IC50: 116 nM	+ IC50: 262 nM		+ IC50: 2.4 μM	mTOR	Phase 3
PI-103		++++ IC50: 2 nM	++++ IC50: 3 nM	++++ IC50: 3 nM	+++ IC50: 15 nM			DNA-PK,mTOR	
TGX-221			++++ IC50: 5 nM	++ IC50: 0.1 μM					
IC-87114				+ IC50: 0.5 μM	+ IC50: 29 μM				
Wortmannin	++++ IC50: 3 nM							DNA-PK,ATM,MLCK	
XL147 analogue		++ IC50: 39 nM	+ IC50: 383 nM	++ IC50: 36 nM	+++ IC50: 23 nM				Phase 2
ZSTK474	++ IC50: 37 nM	+++ IC50: 16 nM	++ IC50: 44 nM	++++ IC50: 4.6 nM	++ IC50: 49 nM				Phase 1
Alpelisib (BYL719)		++++ IC50: 5 nM							Phase 3
AS-605240		++ IC50: 60 nM	+ IC50: 270 nM	+ IC50: 300 nM	+++ IC50: 8 nM				
PIK-75 HCl		+++ IC50: 5.8 nM		+ IC50: 0.51 μM	++ IC50: 76 nM			DNA-PK	
3-Methyladenine (3-MA)					+ IC50: 60 μM		+ IC50: 25 μM		
A66		++ IC50: 32 nM				+ IC50: 462 nM		PI4Kβ	
Voxtalisib Analogue		++ IC50: 39 nM	++ IC50: 113 nM	++ IC50: 43 nM	+++ IC50: 9 nM			DNA-PK,mTOR	Phase 2
PIK-93		++ IC50: 39 nM	+ IC50: 590 nM	++ IC50: 120 nM	+++ IC50: 16 nM	+ IC50: 140 nM	+ IC50: 320 nM	PI4KIIIβ,DNA-PK,ATM	

阻害選択性

Inhibitor Name	PI3K	p110α	p110β	p110δ	p110γ	C2β	Vps34	Other Targets	Clinical Phase
Omipalisib (GSK458)		++++ Ki: 0.019 nM	++++ Ki: 0.13 nM	++++ Ki: 0.024 nM	++++ Ki: 0.06 nM			mTORC1,mTORC2	Phase 1
PIK-90		+++ IC50: 11 nM	+ IC50: 350 nM	++ IC50: 58 nM	+++ IC50: 18 nM				
PF-04691502		++++ Ki: 1.8 nM	++++ Ki: 2.1 nM	++++ Ki: 1.6 nM	++++ Ki: 1.9 nM			P-Akt,P-Akt,mTOR	Phase 2
AZD6482		+ IC50: 870 nM	+++ IC50: 10 nM	++ IC50: 80 nM				DNA-PK	Phase 1
Apitolisib (RG7422)		++++ IC50: 5 nM	++ IC50: 27 nM	+++ IC50: 7 nM	+++ IC50: 14 nM			mTOR	Phase 2
GSK1059615		++++ IC50: 0.4 nM	++++ IC50: 0.6 nM	++++ IC50: 2 nM	++++ IC50: 5 nM			mTOR	Phase 1
Duvelisib (IPI-145)			++++ Ki: 1564 pM	++++ Ki: 23 pM	++ Ki: 243 pM				Phase 3
Gedatolisib (PKI-587)		++++ IC50: 0.4 nM			+++ IC50: 5.4 nM			mTOR	Phase 2
TG100-115		+ IC50: 1.3 μM	+ IC50: 1.2 μM	+ IC50: 235 nM	++ IC50: 83 nM				Phase 2
AS-252424		+ IC50: 935 nM			++ IC50: 33 nM			Casein Kinase 2	
BGT226 (NVP-BGT226)		++++ IC50: 4 nM	++ IC50: 63 nM		++ IC50: 38 nM			mTOR	Phase 2
CUDC-907		+++ IC50: 19 nM	++ IC50: 54 nM	++ IC50: 39 nM				HDAC1,HDAC3,HDAC10	Phase 2
PIK-294			+ IC50: 490 nM	+++ IC50: 10 nM	+ IC50: 160 nM				
AS-604850		+ IC50: 4.5 μM			+ IC50: 0.25 μM				
Copanlisib (BAY 80-6946)		++++ IC50: 0.5 nM	++++ IC50: 3.7 nM	++++ IC50: 0.7 nM	+++ IC50: 6.4 nM				Phase 3
YM201636		+ IC50: 3.3 μM						PIKfyve	
CH5132799		+++ IC50: 14 nM	++ IC50: 0.12 μM	+ IC50: 0.50 μM	++ IC50: 36 nM				Phase 1
PIK-293				+ IC50: 0.24 μM	+ IC50: 10 μM				
PKI-402		++++ IC50: 2 nM	+++ IC50: 7 nM	+++ IC50: 14 nM	+++ IC50: 16 nM			mTOR	
TG100713		+ IC50: 165 nM	+ IC50: 215 nM	+++ IC50: 24 nM	++ IC50: 50 nM				
VS-5584 (SB2343)		++++ IC50: 2.6 nM	+++ IC50: 21 nM	++++ IC50: 2.7 nM	++++ IC50: 3.0 nM			mTOR	Phase 1
Taselisib (GDC 0032)		++++ Ki: 0.29 nM	+++ Ki: 9.1 nM	++++ Ki: 0.12 nM	++++ Ki: 0.97 nM	+ IC50: 292 nM	+ IC50: 374 nM		Phase 2
CZC24832			+ IC50: 1.1 μM		++ IC50: 27 nM				
Bimiralisib (PQR309)		++++ Kd: 1.5 nM	+++ Kd: 11 nM	+++ Kd: 25 nM	+++ Kd: 25 nM			mTOR	Phase 2
Seletalisib (UCB-5857)				+++ IC50: 12 nM	+ IC50: 282 nM				Phase 2
2-D08		++ IC50: 35 nM						sumoylation,Axl,IRAK4	Phase 4
Tenalisib (RP6530)				+++ IC50: 24.5 nM	++ IC50: 33.2 nM				Phase 2
IPI-3063				++++ IC50: 2.5 nM					
Autophinib							+++ IC50: 19 nM	Autophagy	
IPI-549					+++ IC50: 16 nM				Phase 1
Serabelisib (INK-1117)		+++ IC50: 21 nM							Phase 2
SF2523		++ IC50: 34 nM			+ IC50: 158 nM			DNA-PK,BRD4,mTOR	
GDC-0326		++++ Ki: 0.2 nM	++ Ki: 26.6 nM	++++ Ki: 4 nM	+++ Ki: 10.2 nM				
SAR405							++++ IC50: 1.2 nM		
umbralisib (TGR-1202)				+++ IC50: 22.2 nM					Phase 3
VPS34 inhibitor 1							+++ IC50: 15 nM		
GDC-0084		++++ Ki: 2 nM	++ Ki: 46 nM	++++ Ki: 3 nM	+++ Ki: 10 nM			mTOR	Phase 2
AZD8835		+++ IC50: 6.2 nM	+ IC50: 431 nM	+++ IC50: 5.7 nM	++ IC50: 90 nM				Phase 1
Nemiralisib (GSK2269557)				++++ pKi: 9.9					Phase 2
PIK-III				+ IC50: 1.2μM			+++ IC50: 0.018μM		
VPS34-IN1							+++ IC50: 25 nM		
Voxtalisib (XL765)		++ IC50: 39 nM	++ IC50: 113 nM	++ IC50: 43 nM	+++ IC50: 9 nM			DNA-PK,mTOR	Phase 2
AMG319				+++ IC50: 18 nM	+ IC50: 850 nM				Phase 2
AZD8186		++ IC50: 35 nM	++++ IC50: 4 nM	+++ IC50: 12 nM					Phase 1
PF-4989216		++++ IC50: 2 nM		++++ IC50: 1 nM	++ IC50: 65 nM				
Pilaralisib (XL147)		++ IC50: 39 nM	++ IC50: 36 nM	++ IC50: 36 nM	+++ IC50: 23 nM				Phase 2
PI-3065			+ IC50: 1078 nM	+++ IC50: 15 nM					
HS-173		++++ IC50: 0.8 nM							
Quercetin			+ IC50: 5.4 μM	+ IC50: 3.0 μM	+ IC50: 2.4 μM			PKC,Src,Sirtuin	Phase 4
GSK2636771			√						Phase 2
CAY10505					√				
Deguelin	√							Akt	
LY3023414	√							DNA-PK,mTOR kinase	Phase 2

阻害選択性

Inhibitor Name	PI3K	p110α	p110β	p110δ	p110γ	C2β	Vps34	Other Targets	Clinical Phase
GSK2292767				√					Phase 1
GNE-317	√								

mTOR

阻害選択性

Inhibitor Name	mTOR	mTORC1	mTORC2	Other Targets	Clinical Phase
Dactolisib (BEZ235, NVP-BEZ235)	+++ IC50: 6 nM			p110α,p110γ,p110δ	Phase 2
Rapamycin (Sirolimus)	++++ IC50: ~0.1 nM				Phase 4
Everolimus (RAD001)	+++ IC50: 1.6 nM-2.4 nM				Phase 4
AZD8055	++++ IC50: 0.13 nM				Phase 1
Temsirolimus (CCI-779, NSC 683864)	+ IC50: 1.76 μM				Phase 4
PI-103	+ IC50: 30 nM			p110α,p110δ,p110β	
KU-0063794		++ IC50: ~10 nM	++ IC50: ~10 nM		
Torkinib (PP242)	+++ IC50: 8 nM			p110δ,PDGFR,DNA-PK	
Ridaforolimus (Deforolimus, MK-8669)	++++ IC50: 0.2 nM				Phase 3
Sapanisertib (INK 128, MLN0128)	++++ Ki: 1.4 nM			PI3Kα,PI3Kγ,PI3Kδ	Phase 2
Voxtalisib (SAR245409, XL765) Analogue	+ IC50: 157 nM			PI3Kγ,PI3Kα,PI3Kδ	Phase 2
Torin 1	+++ IC50: 4.32 nM	+++ IC50: 2 nM	++ IC50: 10 nM	DNA-PK,p110γ,C2α	
Omipalisib (GSK2126458, GSK458)		++++ Ki: 0.18 nM	++++ Ki: 0.3 nM	p110α,p110δ,p110γ	Phase 1
OSI-027	+++ IC50: 4 nM	+ IC50: 22 nM	+ IC50: 65 nM	PI3Kγ	Phase 1
PF-04691502	++ Ki: 16 nM			PI3Kδ,PI3Kα,PI3Kγ	Phase 2
Apitolisib (GDC-0980, RG7422)	+ Ki app: 17 nM			p110α,p110δ,p110γ	Phase 2
GSK1059615	++ IC50: 12 nM			PI3Kα,PI3Kβ,PI3Kδ	Phase 1
Gedatolisib (PF-05212384, PKI-587)	++++ IC50: 1.6 nM			PI3Kα,PI3Kγ	Phase 2
WYE-354	+++ IC50: 5 nM				
Vistusertib (AZD2014)	+++ IC50: 2.8 nM			P-Akt (S473),pS6 (S235/236)	Phase 2
Torin 2	++++ IC50: 0.25 nM			ATM,ATR,DNA-PK	
WYE-125132 (WYE-132)	++++ IC50: 0.19 nM				
PP121	++ IC50: 13 nM			PDGFR,Hck,VEGFR	
WYE-687	+++ IC50: 7 nM				
WAY-600	++ IC50: 9 nM				
ETP-46464	++++ IC50: 0.6 nM			ATR,DNA-PK,PI3Kα	
GDC-0349	+++ Ki: 3.8 nM			PI3Kα	Phase 1
XL388	++ IC50: 9.9 nM	+++ IC50: 8 nM	+ IC50: 166 nM		
SF2523	+ IC50: 280 nM			DNA-PK,PI3Kα,PI3Kγ	
CZ415	++ pIC50: 8.07				
CC-223	++ IC50: 16 nM			cFMS,FLT4,DNA-PK	Phase 2
Voxtalisib (XL765, SAR245409)	+ IC50: 157 nM			PI3Kγ,PI3Kα,PI3Kδ	Phase 2
Zotarolimus(ABT-578)	+++ IC50: 2.8 nM				Phase 4
Tacrolimus (FK506)	√				Phase 4
BGT226 (NVP-BGT226)	√			PI3Kα,PI3Kγ,PI3Kβ	Phase 2
Palomid 529 (P529)		√			Phase 1
LY3023414	√			DNA-PK,class I PI3K isoforms	Phase 2
Chrysophanic Acid	√			EGFR	

Akt

阻害選択性

Inhibitor Name	Akt	Akt1	Akt2	Akt3	Other Targets	Clinical Phase
MK-2206 2HCl		+++ IC50: 8 nM	+++ IC50: 12 nM	+ IC50: 65 nM		Phase 2
Perifosine (KRX-0401)	+ IC50: 4.7 μM					Phase 3
GSK690693		++++ IC50: 2 nM	+++ IC50: 13 nM	+++ IC50: 9 nM	PKCθ,PKCη,PrkX	Phase 1
Ipatasertib (GDC-0068)		++++ IC50: 5 nM	++ IC50: 18 nM	+++ IC50: 8 nM		Phase 2
AZD5363		++++ IC50: 3 nM	+++ IC50: 8 nM	+++ IC50: 8 nM	ROCK2	Phase 2
PF-04691502	++++ IC50: 3.8 nM				PI3Kδ,PI3Kα,PI3Kγ	Phase 2
AT7867		++ IC50: 32 nM	++ IC50: 17 nM	++ IC50: 47 nM	PKA,p70 S6K	
Triciribine	+ IC50: 130 nM				HIV-1	Phase 2
CCT128930			+++ IC50: 6 nM		p70 S6K,PKA	
A-674563		+++ Ki: 11 nM			PKA,CDK2,GSK-3β	
PHT-427	+ Ki: 2.7 μM				PDK1	
Miransertib (ARQ 092) HCl		++++ IC50: 5 nM	++++ IC50: 4.5 nM	++ IC50: 16 nM		Phase 2
Akti-1/2		++ IC50: 58 nM	+ IC50: 210 nM	+ IC50: 2119 nM		
Uprosertib (GSK2141795)		+ IC50: 180 nM	+ IC50: 328 nM	++ IC50: 38 nM		Phase 2
Afuresertib (GSK2110183)		++++ Ki: 0.08 nM	++++ Ki: 2 nM	++++ Ki: 2.6 nM		Phase 2
AT13148		++ IC50: 38 nM	+ IC50: 402 nM	++ IC50: 50 nM	PKA,ROCK2,ROCK1	Phase 1
Miltefosine	√				PI3K,PKC	Phase 4
Honokiol	√				MEK	
TIC10 Analogue	√				ERK	
SC66	√					
Deguelin	√				PI3K	
TIC10	√				ERK	

GSK-3

阻害選択性

Inhibitor Name	GSK-3	GSK-3α	GSK-3β	Other Targets	Clinical Phase
CHIR-99021 (CT99021) HCl		+++ IC50: 10 nM	++++ IC50: 6.7 nM		
SB216763		++ IC50: 34.3 nM	++ IC50: ~34.3 nM		
CHIR-98014		++++ IC50: 0.65 nM	++++ IC50: 0.58 nM		
TWS119			++ IC50: 30 nM		
Tideglusib			+ IC50: 60 nM		Phase 3
SB415286		+ IC50: 78 nM	+ IC50: ~78 nM		
BIO	++++ IC50: 5 nM			TYK2,CDK5/p35,CDK2/CyclinA	Phase 4
CHIR-99021 (CT99021)		+++ IC50: 10 nM	++++ IC50: 6.7 nM		
AZD2858	+ IC50: 68 nM				
AZD1080		+++ IC50: 6.9 nM	++ IC50: 31 nM		
AR-A014418			++ Ki: 38 nM		
TDZD-8			+ IC50: 2 μM		
LY2090314		++++ IC50: 1.5 nM	++++ IC50: 0.9 nM		Phase 2
2-D08			+++ IC50: 11 nM	sumoylation,Axl,IRAK4	Phase 4
BIO-acetoxime		+++ IC50: 10 nM	+++ IC50: 10 nM		
IM-12			++ IC50: 53 nM		
1-Azakenpaullone			++ IC50: 18 nM		
Indirubin			+ IC50: 0.6 μM	CDK2/CyclinA,CDK5/p35,CDK1/CyclinB	
Bikinin	√				

ATM/ATR

阻害選択性

Inhibitor Name	ATM	ATR	Other Targets	Clinical Phase
Dactolisib (BEZ235, NVP-BEZ235)		+++ IC50: 21 nM	p110α,p110γ,mTOR (p70S6K)	Phase 2
KU-55933 (ATM Kinase Inhibitor)	+++ IC50: 12.9 nM			
KU-60019	++++ IC50: 6.3 nM			
VE-821		++ Ki: 13 nM		
Wortmannin	++ IC50: 150 nM		PI3K,DNA-PK,MLCK	
Torin 2	++ EC50: 28 nM	++ EC50: 35 nM	mTOR,DNA-PK	
CP-466722	+ IC50: 410 nM			
VE-822		+++ IC50: 19 nM		
ETP-46464	+ IC50: 545 nM	+++ IC50: 14 nM	mTOR,DNA-PK,PI3Kα	
CGK 733	++ IC50: 200 nM	++ IC50: 200 nM		
AZ20		++++ IC50: 5 nM	mTOR	
AZ32	++++ IC50: <0.0062 μM			
AZD1390	++++ IC50: 0.78 nM			Phase 1
BAY 1895344 (BAY-1895344)		+++ IC50: 7 nM		Phase 1
AZD6738		++++ IC50: 1 nM		Phase 2
Schisandrin B (Sch B)		+ IC50: 7.25 μM	P-gp	
AZD0156	√			Phase 1

PDK

阻害選択性

Inhibitor Name	PDK1	Other Targets	Clinical Phase
OSU-03012 (AR-12)	++ IC50: 5 μM		Phase 1
BX-795	++++ IC50: 6 nM	c-Kit,CDK2/CyclinE,Chk1	
BX-912	+++ IC50: 12 nM	PKA,KDR,CDK2/CyclinE	
PHT-427	+ Ki: 5.2 μM	Akt	
GSK2334470	+++ IC50: 10 nM		

S6 Kinase

阻害選択性

Inhibitor Name	p70 S6K	p70 S6K1	RSK1	RSK2	RSK3	RSK4	Other Targets	Clinical Phase
BI-D1870			++ IC50: 31 nM	++ IC50: 24 nM	++ IC50: 18 nM	++ IC50: 15 nM		
AT7867	+ IC50: 85 nM						Akt2,PKA,Akt1	
PF-4708671		+ IC50: 160 nM						
H 89 2HCl		+ IC50: 80 nM					PKA	
LJH685			+++ IC50: 6 nM	+++ IC50: 5 nM	++++ IC50: 4 nM			
LJI308			+++ IC50: 6 nM	++++ IC50: 4 nM	+++ IC50: 13 nM			
LY2584702 Tosylate	++++ IC50: 4 nM							Phase 1
LY2584702	++++ IC50: 4 nM							Phase 1
AT13148	+++ IC50: 8 nM		+ IC50: 85 nM				PKA,ROCK2,ROCK1	Phase 1

AMPK

阻害選択性

Inhibitor Name	AMPK
Dorsomorphin (Compound C) 2HCl	++ Ki: 109 nM
WZ4003	++++ IC50: 20 nM
Dorsomorphin (Compound C)	++ Ki: 109 nM
HTH-01-015	+++ IC50: 100 nM

DNA-PK

阻害選択性

Inhibitor Name	DNA-PK	Other Targets	Clinical Phase
PI-103	++ IC50: 23 nM	p110α,p110δ,p110β	
NU7441 (KU-57788)	+++ IC50: 14 nM		
PIK-75 HCl	++++ IC50: 2 nM	p110α,p110γ,p110δ	
NU7026	+ IC50: 0.23 μM	PI3K	
PP121	+ IC50: 60 nM	PDGFR,Hck,VEGFR	
KU-0060648	++++ IC50: 5 nM	PI3Kδ,PI3Kβ,PI3Kα	
SF2523	+++ IC50: 9 nM	PI3Kα,PI3Kγ,BRD4	
LTURM34	++ IC50: 0.034 μM		
CC-115	+++ IC50: 0.013 μM	mTOR,PI3Kα	Phase 2
LY3023414	√	mTOR kinase,class I PI3K isoforms	Phase 2

MELK

阻害選択性

Inhibitor Name	MELK
OTSSP167	+++ IC50: 0.41 nM

注釈:

1.各阻害剤の半数阻害濃度（IC_{50}）や作用濃度など、詳細についてはwww.selleck.co.jpのウェブサイトをご覧ください。

2.「+」は阻害効果を示す。阻害効果が高い（IC_{50}値が低い）ほど「+」が多く示されている。

3.赤色の「√」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。

Epigenetics



HDAC

阻害選択性

Inhibitor Name	HDAC	HDAC1	HDAC2	HDAC3	HDAC4	HDAC5	HDAC6	HDAC7	HDAC8	HDAC9	HDAC10	HDAC11	HD1	HD2	Other Targets	Clinical Phase
Vorinostat (SAHA)	+++ IC50: ~10 nM															Phase 3
Entinostat (MS-275)		+ IC50: 0.51 μM		+ IC50: 1.7 μM												Phase 3
Panobinostat	++++ IC50: 5 nM															Phase 3
Trichostatin A (TSA)	++++ IC50: ~1.8 nM															Phase 1
Mocetinostat		++ IC50: 0.15 μM	+ IC50: 0.29 μM	+ IC50: 1.66 μM								+ IC50: 0.59 μM				Phase 2
Belinostat (PXD101)	+++ IC50: 27 nM															Phase 2
Romidepsin (FK228)		+++ IC50: 36 nM	+++ IC50: 47 nM													Phase 3
MC1568													++ IC50: 100 nM			
Tubastatin A HCl							+++ IC50: 15 nM		+ IC50: 854 nM							
Givinostat (ITF2357)													++++ IC50: 7.5 nM	+++ IC50: 10 nM		Phase 3
Dacinostat (LAQ824)	+++ IC50: 32 nM															
CUDC-101	++++ IC50: 4.4 nM	++++ IC50: 4.5 nM	+++ IC50: 12.6 nM	++++ IC50: 9.1 nM	+++ IC50: 13.2 nM	+++ IC50: 11.4 nM	++++ IC50: 5.1 nM	+ IC50: 373 nM	++ IC50: 79.8 nM	++ IC50: 67.2 nM	+++ IC50: 26.1 nM				EGFR,HER2	Phase 1
Quisinostat 2HCl		++++ IC50: 0.11 nM	++++ IC50: 0.33 nM	++++ IC50: 4.86 nM	++++ IC50: 0.64 nM	++++ IC50: 3.69 nM			++++ IC50: 4.26 nM		++++ IC50: 0.46 nM	++++ IC50: 0.37 nM				Phase 2
Pracinostat (SB939)		++ IC50: 49 nM	++ IC50: 96 nM	+++ IC50: 43 nM	++ IC50: 56 nM	+++ IC50: 47 nM	+ IC50: 1.008 μM	++ IC50: 137 nM	++ IC50: 140 nM	++ IC50: 70 nM	+++ IC50: 40 nM	++ IC50: 93 nM				Phase 3
PCI-34051									+++ IC50: 10 nM							

阻害選択性

Inhibitor Name	HDAC	HDAC1	HDAC2	HDAC3	HDAC4	HDAC5	HDAC6	HDAC7	HDAC8	HDAC9	HDAC10	HDAC11	HD1	HD2	Other Targets	Clinical Phase
Droxinostat				+ IC50: 16.9 μM			+ IC50: 2.47 μM		+ IC50: 1.46 μM							
Abexinostat		++++ Ki: 7 nM	+++ Ki: 19 nM	++++ Ki: 8.2 nM			+++ Ki: 17 nM		+ IC50: 280 nM		+++ IC50: 24 nM					Phase 3
RGFP966				++ IC50: 80 nM												
AR-42	+++ IC50: 30 nM															Phase 1
Ricolinostat		++ IC50: 58 nM	++ IC50: 48 nM	++ IC50: 51 nM			++++ IC50: 4.7 nM		++ IC50: 100 nM							Phase 2
Tacedinaline (CI994)		+ IC50: 0.9 μM	+ IC50: 0.9 μM	+ IC50: 1.2 μM												Phase 3
CUDC-907		++++ IC50: 1.7 nM	++++ IC50: 5.0 nM	++++ IC50: 1.8 nM			+++ IC50: 27 nM				++++ IC50: 2.8 nM	++++ IC50: 5.4 nM			PI3Kα,PI3Kδ,PI3Kβ	Phase 2
M344	++ IC50: 100 nM															
Tubacin							++++ IC50: 4 nM									
RG2833 (RGFP109)		++ Ki: 32 nM		++ Ki: 5 nM												
Resminostat		+++ IC50: 42.5 nM		++ IC50: 50.1 nM			++ IC50: 71.8 nM									Phase 2
Tubastatin A							+++ IC50: 15 nM									
WT161		++++ IC50: 8.35 nM	+++ IC50: 15.4 nM				++++ IC50: 0.4 nM									
Valproic acid		+ IC50: 0.4 mM														Phase 4
ACY-738							++++ IC50: 1.7 nM									
Tucidinostat		++ IC50: 95 nM	++ IC50: 160 nM	++ IC50: 67 nM							++ IC50: 78 nM					Phase 3
TMP195					++ Ki: 59 nM	++ Ki: 60 nM		+++ Ki: 26 nM		+++ Ki: 15 nM						
Citarinostat		+++ IC50: 35 nM	+++ IC50: 45 nM	+++ IC50: 46 nM			++++ IC50: 2.6 nM		++ IC50: 137 nM							Phase 1
BRD73954							+++ IC50: 36 nM		++ IC50: 120 nM							
BG45		+ IC50: 2 μM	+ IC50: 2.2 μM	+ IC50: 289 nM												
4SC-202		+ IC50: 1.20 μM	+ IC50: 1.12 μM	+ IC50: 0.57 μM		+ IC50: 11.3 μM				+ IC50: 50 μM	+ IC50: 21 μM	+ IC50: 9.7 μM				Phase 2
CAY10603							++++ IC50: 2 pM									
LMK-235					+++ IC50: 11.9 nM	++++ IC50: 4.2 nM										
Splitomicin	+ IC50: 60 μM															
Santacruzamate A			++++ IC50: 119 pM													
Nexturastat A							++++ IC50: 5 nM									
TMP269					++ IC50: 157 nM	++ IC50: 97 nM		+++ IC50: 43 nM		+++ IC50: 23 nM						
HPOB		+ IC50: 2.9 μM	+ IC50: 4.4 μM	+ IC50: 1.7 μM			++ IC50: 56 nM		+ IC50: 2.8 μM		+ IC50: 3.0 μM					
Valproic acid sodium salt	√														GABA receptor, Autophagy	Phase 4
Curcumin	√														Nrf2,NF-κB,p300 histone acetylatransferase	Phase 4
Scriptaid	√															
Sodium Phenylbutyrate	√															Phase 4
Tasquinimod					√											Phase 3
(-)-Parthenolide		√													p53,MDM2 ubiquitination, NF-κB	

PARP

阻害選択性

Inhibitor Name	PARP	PARP1	PARP2	PARP3	Clinical Phase
Olaparib (AZD2281, Ku-0059436)		++ IC50: 5 nM	++++ IC50: 1 nM		Phase 4
Veliparib (ABT-888)		++ Ki: 5.2 nM	+++ Ki: 2.9 nM		Phase 3
Rucaparib (AG-014699,PF-01367338) phosphate	+++ Ki: 1.4 nM				Phase 3
Talazoparib (BMN 673)		++++ IC50: 0.57 nM			Phase 3
AG-14361		++ Ki: <5 nM			
INO-1001 (3-Aminobenzamide)	++ IC50: <50 nM				Phase 2

阻害選択性

Inhibitor Name	PARP	PARP1	PARP2	PARP3	Clinical Phase
A-966492		++++ Ki: 1 nM	+++ Ki: 1.5 nM		
PJ34 HCl	++ EC50: 20 nM				
Niraparib (MK-4827)		+++ IC50: 3.8 nM	+++ IC50: 2.1 nM		Phase 3
UPF 1069		+ IC50: 8.0 μM	++ IC50: 0.3 μM		
ME0328		+ IC50: 6.3 μM		+ IC50: 0.89 μM	
Pamiparib (BGB-290)		++++ IC50: 0.83 nM	++++ IC50: 0.11 nM		Phase 3
NMS-P118		++ Kd: 0.009 μM			
E7449		++++ IC50: 1 nM	++++ IC50: 1.2 nM		Phase 2
Picolinamide	+ IC50: 95 μM				
Benzamide	+ IC50: 3.3 μM				
Niraparib (MK-4827) tosylate		+++ IC50: 3.8 nM	+++ IC50: 2.1 nM		
NU1025	+ IC50: 400 nM				
Iniparib (BSI-201)		√			Phase 3
AZD2461	√				Phase 1
BGP-15 2HCl	√				Phase 2

JAK

阻害選択性

Inhibitor Name	JAK1	JAK2	JAK3	Tyk2	Other Targets	Clinical Phase
Ruxolitinib (INCB018424)	+++ IC50: 3.3 nM	++++ IC50: 2.8 nM				Phase 4
Tofacitinib (CP-690550) Citrate		++ IC50: 20 nM	++++ IC50: 1 nM			Phase 4
AZD1480		++++ IC50: 0.26 nM				Phase 1
Fedratinib (SAR302503, TG101348)		+++ IC50: 3 nM			FLT3,RET	Phase 3
AT9283		++++ IC50: 1.2 nM	++++ IC50: 1.1 nM	+++ IC50: 1 nM-10 nM	Aurora A,Aurora B,Abl1 (T315I)	Phase 2
Momelotinib (CYT387)	+++ IC50: 11 nM	++ IC50: 18 nM	+ IC50: 155 nM			Phase 2
Tofacitinib (CP-690550,Tasocitinib)	+ IC50: 112 nM	++ IC50: 20 nM	++++ IC50: 1 nM			Phase 4
WP1066		+ IC50: 2.3 μM			STAT3	Phase 1
TG101209		+++ IC50: 6 nM	+ IC50: 169 nM		RET,FLT3	
Gandotinib (LY2784544)	++ IC50: 19.8 nM	++++ IC50: 3 nM	++ IC50: 48.0 nM	++ IC50: 44 nM	FLT3,FLT4,FGFR2	Phase 2
NVP-BSK805 2HCl	++ IC50: 31.63 nM	++++ IC50: ~0.5 nM	++ IC50: 18.68 nM	+++ IC50: 10.76 nM		
Baricitinib (LY3009104, INCB028050)	+++ IC50: 5.9 nM	+++ IC50: 5.7 nM		++ IC50: 53 nM		Phase 3
AZ 960		++++ IC50: <3 nM				
CEP-33779		++++ IC50: 1.8 nM				
Pacritinib (SB1518)		++ IC50: 19 nM	+ IC50: 520 nM	++ IC50: 50 nM	FLT3 (D835Y),FLT3	Phase 3
WHI-P154			+ IC50: 1.8 μM		EGFR,Src,VEGFR	
XL019	+ IC50: 134.3 nM	++++ IC50: 2.2 nM	+ IC50: 214.2 nM		PDGFRβ,FLT3	Phase 1
S-Ruxolitinib (INCB018424)	+++ IC50: 3.3 nM	++++ IC50: 2.8 nM		++ IC50: 19 nM		Phase 3
ZM 39923 HCl	+ pIC50: 4.4		+ pIC50: 7.1		TGM2,EGFR	
PF-06651600			++ IC50: 33.1 nM			Phase 3
FM-381			++++ IC50: 127 pM			
Oclacitinib maleate	+++ IC50: 10nM	++ IC50: 18nM	+ IC50: 99nM	+ IC50: 84nM		
Decernotinib (VX-509)	+++ IC50: 11 nM	+++ Ki: 13 nM	++++ Ki: 2.5 nM	+++ Ki: 13 nM		Phase 3
Cerdulatinib (PRT062070, PRT2070)	+++ IC50: 12 nM	+++ IC50: 6 nM	+++ IC50: 8 nM	++++ IC50: 0.5 nM	ARK5,MST1,Fms	Phase 2
Filgotinib (GLPG0634)	+++ IC50: 10 nM	++ IC50: 28 nM	+ IC50: 810 nM	+ IC50: 116 nM		Phase 3
FLLL32		+ IC50: <5 μM				
BMS-911543		++++ IC50: 1.1 nM	+ IC50: 75 nM	++ IC50: 66 nM	SET-2	Phase 2
Itacitinib (INCB39110)	√					Phase 3
Peficitinib (ASP015K, JNJ-54781532)		√				Phase 2
GLPG0634 analogue		√				Phase 2
Go6976		√			FLT3,PKCα,PKCβ1	
Curcumol		√				Phase 3

Pim

阻害選択性

Inhibitor Name	Pim1	Pim2	Pim3	Other Targets	Clinical Phase
SGI-1776 free base	++ IC50: 7 nM	+ IC50: 363 nM	+ IC50: 69 nM	FLT3	Phase 1
SMI-4a	++ IC50: 17 nM				
PIM447 (LGH447)	++++ Ki: 6 pM	++++ Ki: 18 pM	++++ Ki: 9 pM		Phase 1
CX-6258 HCl	+++ IC50: 5 nM	+ IC50: 25 nM	++ IC50: 16 nM		
AZD1208	+++ IC50: 0.4 nM	+++ IC50: 5 nM	+++ IC50: 1.9 nM		Phase 1

HIF

阻害選択性

Inhibitor Name	HIF	HIF1	PHD1	PHD2	PHD3	Other Targets	Clinical Phase
IOX2				+++ IC50: 21 nM			
LW 6	++ IC50: 4.4 μM					BCRP,MDH2	
MK-8617			++++ IC50: 1 nM	++++ IC50: 1 nM	++++ IC50: 14 nM		
FG-2216				++ IC50: 3.9 μM			Phase 2
Molidustat (BAY 85-3934)			++ IC50: 480 nM	+++ IC50: 280 nM	+++ IC50: 450 nM		Phase 3
KC7F2	+ IC50: 20 μM	+ IC50: 20 μM					
Roxadustat (FG-4592)	√						Phase 3
2-Methoxyestradiol (2-MeOE2)	√					Microtubule Associated	Phase 2
Chetomin	√						
Daprodustat (GSK1278863)			√				Phase 3
Lificiguat(YC-1)	√					sGC	
PX-478 2HCl	√						Phase 1
DMOG			√				
BAY 87-2243	√						Phase 1

Aurora Kinase

阻害選択性

Inhibitor Name	Aurora A	Aurora B	Aurora C	Other Targets	Clinical Phase
Alisertib (MLN8237)	++++ IC50: 1.2 nM				Phase 3
Tozasertib (VX-680, MK-0457)	++++ Ki app: 0.6 nM	++ Ki app: 18 nM	+++ Ki app: 4.6 nM	Bcr-Abl,FLT3	Phase 2
Barasertib (AZD1152-HQPA|AZD2811)		++++ IC50: 0.37 nM			Phase 2
ZM 447439	+ IC50: 110 nM	+ IC50: 130 nM		LCK,Src,MEK1	
MLN8054	+++ IC50: 4 nM	+ IC50: 172 nM			Phase 1
Danusertib (PHA-739358)	+++ IC50: 13 nM	+ IC50: 79 nM	+ IC50: 61 nM	Abl,TrkA,RET	Phase 2
AT9283	++++ IC50: ~3.0 nM	++++ IC50: ~3.0 nM		JAK3,JAK2,Abl1 (T315I)	Phase 2
JNJ-7706621	+++ IC50: 11 nM	++ IC50: 15 nM		CDK2/CyclinE,CDK2/CyclinA,CDK1/CyclinB	
Hesperadin		+ IC50: 250 nM		TbAUK1	
Aurora A Inhibitor I (TC-S 7010)	++++ IC50: 3.4 nM				
KW-2449	+ IC50: 48 nM			FLT3 (D835Y),Abl (T315I),FLT3	Phase 1
SNS-314	+++ IC50: 9 nM	++ IC50: 31 nM	++++ IC50: 3 nM		Phase 1
ENMD-2076	+++ IC50: 14 nM	+ IC50: 350 nM		FLT3,RET,VEGFR3/FLT4	Phase 2
PHA-680632	++ IC50: 27 nM	+ IC50: 135 nM	+ IC50: 120 nM	FGFR1,PLK1,FLT3	
MK-5108 (VX-689)	++++ IC50: 0.064 nM				Phase 1
CYC116	+++ Ki: 8 nM	+++ Ki: 9 nM		VEGFR2,FLT3,CDK2/CyclinE	Phase 1
AMG-900	+++ IC50: 5 nM	+++ IC50: 4 nM	++++ IC50: 1 nM	p38α	
PF-03814735	++++ IC50: 0.8 nM	+++ IC50: 5 nM		FLT1,FAK,TrkA	Phase 1
CCT129202	+ IC50: 42 nM	+ IC50: 198 nM	+ IC50: 227 nM		
GSK1070916		++++ IC50: 3.5 nM	+++ IC50: 6.5 nM	FLT1,Tie-2,SIK	Phase 1
TAK-901	++ IC50: 21 nM	++ IC50: 15 nM		JAK3,c-Src,YES1	Phase 1
CCT137690	++ IC50: 15 nM	++ IC50: 25 nM	++ IC50: 19 nM		
MK-8745	++++ IC50: 0.6 nM				

阻害選択性

Inhibitor Name	Aurora A	Aurora B	Aurora C	Other Targets	Clinical Phase
ENMD-2076 L-(+)-Tartaric acid	+++ IC50: 14 nM	+ IC50: 350 nM		FLT3,RET,VEGFR3/FLT4	Phase 2
SNS-314 Mesylate	+++ IC50: 9 nM	++ IC50: 31 nM	++++ IC50: 3 nM		
BI-847325	++ IC50: 25 nM	++++ IC50: 3 nM	++ IC50: 15 nM	MEK2,MEK1	
Reversine	+++ IC50: 12 nM	+++ IC50: 13 nM	++ IC50: 20 nM	human A3 adenosine receptor	

Sirtuin

阻害選択性

Inhibitor Name	SIRT1	SIRT2	SIRT3	Sirtuin	SIRT6	Other Targets	Clinical Phase
Selisistat (EX 527)	++++ IC50: 38 nM						Phase 2
Sirtinol	+ IC50: 131 μM	++ IC50: 38 μM					
OSS_128167	+ IC50: 1578 μM			++ IC50: 89 μM	++ IC50: 89 μM		
3-TYP	++++ IC50: 88 nM		++++ IC50: 16 nM				
Thiomyristoyl		++++ IC50: 28 nM					Phase 4
SirReal2							
AGK2		+++ IC50: 3.5 μM					
Tenovin-6	++ IC50: 21 μM		++ IC50: 67 μM			p53	
Nicotinamide (Vitamin B3)				√			Phase 4
Salermide	√						

DNA Methyltransferase

阻害選択性

Inhibitor Name	DNA Methyltransferase	Other Targets	Clinical Phase
Decitabine	++++ IC50: 1 ng/mL		Phase 4
RG108	++ IC50: 115 nM		
SGI-1027	+ IC50: 7.5 μM		
Lomeguatrib	+++ IC50: 5 nM		
Azacitidine	√		
Zebularine	√	Cytidine deaminase	
Thioguanine	√		Phase 4
Procainamide HCl	√	Sodium channel	Phase 4

Histone Methyltransferase

阻害選択性

Inhibitor Name	Histone Methyltransferase	Menin-MLL interaction	Other Targets	Clinical Phase
Pinometostat (EPZ5676)	++++ Ki: 80 pM			Phase 2
EPZ005687	++ Ki: 24 nM			
GSK343	+++ IC50: 4 nM			
BIX 01294	+ IC50: 2.7 μM			
Tazemetostat (EPZ-6438)	+++ Ki: 2.5 nM			
3-deazaneplanocin A (DZNeP) HCl	++++ Ki: 50 pM			
UNC1999	++++ IC50: 2 nM			
MM-102	+ IC50: 0.4 μM			
SGC 0946	++++ IC50: 0.3 nM			
Entacapone	+ IC50: 151 nM			Phase 4
LLY-283	++ IC50: 20 nM			
JNJ-64619178	++++ IC50: 0.14 nM			Phase 1
PF-06726304	++++ Ki: 0.7 nM			
A-196	++ IC50: 25 nM			
SGC2085	++ IC50: 50 nM			

阻害選択性

Inhibitor Name	Histone Methyltransferase	Menin-MLL interaction	Other Targets	Clinical Phase
MI-503		++ IC50: 14.7 nM		
MI-463		++ IC50: 15.3 nM		
EPZ020411 2HCl	+++ IC50: 119 nM			
MS049	++ IC50: 34 nM			
CPI-1205	++++ IC50: 2 nM			Phase 2
Amodiaquine dihydrochloride dihydrate	++ Ki: 18.6 nM			
HLCL-61 HCL	+ IC50: 16.74 μM			
GSK591	+++ IC50: 4 nM			
EPZ011989	+++ IC50: 103 nM			
Chaetocin	+ IC50: 0.8 μM			
MS023	+++ IC50: 4 nM			
SGC707	++ IC50: 31 nM			
AMI-1	+ IC50: 3.0 μM			
CPI-169	++++ IC50: 0.24 nM			
CPI-360	+ IC50: 102.3 nM			
GSK503	+++ IC50: 8 nM			
EPZ015666(GSK3235025)	+++ Ki: 5 nM			
UNC0379	+ IC50: 7.3 μM			
EI1	+++ IC50: 13 nM			
MI-2 (Menin-MLL Inhibitor)		+ IC50: 446 nM		
MI-3 (Menin-MLL Inhibitor)		+ IC50: 648 nM		
PFI-2 HCl	++++ IC50: 2 nM			
UNC0642	+++ IC50: <2.5 nM		GLP	
UNC0638	++ IC50: <15 nM		GLP	
GSK126	+++ IC50: 9.9 nM			
EPZ004777	++++ IC50: 0.4 nM			
JQ-EZ-05 (JQEZ5)	√			
GSK3326595 (EPZ015938)	√			
UNC3866	√		CBX4 chromodomains,CBX7 chromodomains	
MI-136		√		
LLY-507	√			
BRD4770	√			

Epigenetic Reader Domain

阻害選択性

Inhibitor Name	Epigenetic Reader Domain	Other Targets	Clinical Phase
(+)-JQ1	+++ IC50: 33 nM		
I-BET151 (GSK1210151A)	+ IC50: 0.5 μM		
PFI-1 (PF-6405761)	++ IC50: 98 nM		
I-BET-762	+++ IC50: 35 nM		Phase 2
Apabetalone (RVX-208)	+ IC50: 0.51 μM		Phase 3
SGC-CBP30	++++ IC50: 21 nM		
Bromosporine	++++ IC50: 0.29 μM		
OTX015	++++ EC50: 10-19 nM		Phase 2
UNC1215	+++ IC50: 40 nM		
UNC669	+ IC50: 6 μM		
SF2523	+ IC50: 241 nM	DNA-PK,PI3Kα,PI3Kγ	
AZD5153	++++ IC50: 5 nM		Phase 1
EED226	++ Kd: 82 nM		
GSK6853	++++ pIC50: 8.1		
CPI-637	+++ IC50: 0.03 μM		
BI-9564	++++ Kd: 5.9 nM		
BI-7273	++++ IC50: 19 nM		

阻害選択性

Inhibitor Name	Epigenetic Reader Domain	Other Targets	Clinical Phase
I-BRD9	++ pIC50: 5.3		
PF-CBP1 HCl	+ IC50: 125nM	p300/CBP	
PFI-4	++ IC50: 80 nM		
OF-1	++ Kd: 100 nM		Phase 4
GSK1324726A (I-BET726)	+++ IC50: 41 nM		
PFI-3	++ Kd: 72 nM		
MS436	++ Ki: <0.085 μM		
CPI-203	+++ IC50: 37 nM	IL-6,MYC	
GSK2801	+ Kd: 136 nM		
ABBV-744	√		
KG-501 (2-naphthol-AS-E-phosphate)	√		
Mivebresib(ABBV-075)	√		Phase 1

Histone Demethylase

阻害選択性

Inhibitor Name	Histone demethylase	Other Targets	Clinical Phase
GSK J4 HCl	++ IC50: 60 nM		
OG-L002	+++ IC50: 20 nM		
JIB-04	++ IC50: 290 nM		
Daminozide	+ IC50: 1.5 μM	PHF8	
CP2	+++ IC50: 29 nM		Phase 3
CPI-455 HCl	++++ IC50: 10 nM		
GSK2879552 2HCl	+ Ki: 1.7 μM		Phase 2
ORY-1001 (RG-6016) 2HCl	+++ IC50: 20 nM		
GSK J1	+++ IC50: 28 nM		
GSK-LSD1 2HCl	++++ IC50: 16 nM		
SP2509	++++ IC50: 13 nM		
ML324	+ IC50: 920 nM		
IOX1	++ IC50: 0.1 μM		

Histone Acetyltransferase

阻害選択性

Inhibitor Name	Histone Acetyltransferase	Other Targets	Clinical Phase
C646	+++ Ki: 400 nM		
Curcumin	++ IC50: ~25 μM	Nrf2,NF-κB,HDAC	Phase 4
A-485	++++ IC50: 0.06 μM		
Anacardic Acid	+++ IC50: 8.5 μM	PCAF(p300/CREB-binding protein-associated factor)	
MG149	+ IC50: 47 μM		
Remodelin	√		

注釈：

1.各阻害剤の半数阻害濃度（IC_{50}）や作用濃度など、詳細についてはwww.selleck.co.jpのウェブサイトをご覧ください。

2.「+」は阻害効果を示す。阻害効果が高い（IC_{50}値が低い）ほど「+」が多く示されている。

3.赤色の「√」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。

Methylation

DNA Methyltransferase

詳細情報はP11に記載されています

LSD1

阻害選択性

Inhibitor Name	LSD1
OG-L002	++ IC50: 20 nM
ORY-1001 (RG-6016) 2HCl	++ IC50: 20 nM
GSK-LSD1 2HCl	+++ IC50: 16 nM
SP2509	++++ IC50: 13 nM

JMJD

阻害選択性

Inhibitor Name	JMJD3	JMJD2	JMJD	JMJD1	Other Targets	Clinical Phase
GSK J4 HCl	+++ IC50: 60 nM					
JIB-04	++ IC50: 855 nM	++ IC50: 290 nM	+++ IC50: 230 nM			
Daminozide			+ IC50: 1.5 μM		PHF8	
CP2		++++ IC50: 29 nM				Phase 3
CPI-455 HCl			++++ IC50: 10 nM			
GSK J1	++++ IC50: 28 nM		+++ IC50: 53 nM			
ML324		++ IC50: 920 nM				
IOX1	+ IC50: 1.6 μM	++ IC50: 0.6 μM	+ IC50: 1.8 μM	+++ IC50: 0.1 μM	KDM4E,KDM5C,PHD2	

EZH1/2

阻害選択性

Inhibitor Name	EZH2	EZH1	Clinical Phase
EPZ005687	++ Ki: 24 nM		
GSK343	+++ IC50: 4 nM	+ IC50: 240 nM	
Tazemetostat (EPZ-6438)	++ Ki: 2.5 nM		
UNC1999	++++ IC50: 2 nM	++ IC50: 45 nM	
PF-06726304	++++ Ki: 0.7 nM		
CPI-1205	++++ IC50: 2 nM	+ IC50: 52 nM	Phase 2
EPZ011989	+++ Ki: <3 nM	+ IC50: 103 nM	
CPI-169	++++ IC50: 0.24 nM	+++ IC50: 6.1 nM	
CPI-360		+ IC50: 102.3 nM	
GSK503	+++ IC50: 8 nM		
EI1	++ IC50: 13 nM		
GSK126	+++ IC50: 9.9 nM		
JQ-EZ-05 (JQEZ5)		√	

G9a/GLP

阻害選択性

Inhibitor Name	G9a/GLP	Other Targets
BIX 01294	+ IC50: 2.7 μM	
A-366	+++ IC50: 3.3 nM	

阻害選択性

Inhibitor Name	G9a/GLP	Other Targets
Chaetocin	++ IC50: 2.5 μM	dSU(VAR)3-9,Neurospora crassa DIM5
UNC0642	++++ IC50: <2.5 nM	
UNC0638	+++ IC50: <15 nM	
BRD4770	√	

PRMT

阻害選択性

Inhibitor Name	PRMT5	PRMT4	PRMT6	PRMT1	PRMT8	PRMT3	Other Targets	Clinical Phase
LLY-283	+++ IC50: 20 nM							
JNJ-64619178	++++ IC50: 0.14 nM							Phase 1
SGC2085		++ IC50: 50 nM						
EPZ020411 2HCl			+++ IC50: 10 nM	++ IC50: 119 nM	+ IC50: 223 nM			
MS049		++ IC50: 34 nM	++ IC50: 43 nM					
HLCL-61 HCL	+ IC50: 16.74 μM							
GSK591	++++ IC50: 4 nM							
MS023		++ IC50: 83 nM	++++ IC50: 4 nM	+++ IC50: 30 nM	++++ IC50: 5 nM	++ IC50: 119 nM		
SGC707						+++ IC50: 31 nM		
AMI-1				+ IC50: 8.8 μM			yeast Hmt1p	
EPZ015666(GSK3235025)	++++ Ki: 5 nM							
GSK3326595 (EPZ015938)	√							Phase 2

SETD

阻害選択性

Inhibitor Name	SETD	Other Targets
A-196	+++ IC50: 25 nM	
Cyproheptadine hydrochloride sesquihydrate	++ IC50: 1 μM	5-HT2
UNC0379	+ IC50: 7.3 μM	
PFI-2 HCl	++++ IC50: 2 nM	

MLL

阻害選択性

Inhibitor Name	Menin-MLL interaction	MLL
MM-102		+++ IC50: 0.4 μM
MI-503	++++ IC50: 14.7 nM	
MI-463	+++ IC50: 15.3 nM	
MI-2 (Menin-MLL Inhibitor)	++ IC50: 446 nM	
MI-3 (Menin-MLL Inhibitor)	+ IC50: 648 nM	
MI-136	√	

COMT

阻害選択性

Inhibitor Name	COMT	Clinical Phase
Entacapone	++ IC50: 151 nM	Phase 4
Tolcapone	+++ Ki: 30 nM	Phase 4

DOT1

阻害選択性

Inhibitor Name	DOT1L	Clinical Phase
Pinometostat (EPZ5676)	++++ Ki: 80 pM	Phase 2
SGC 0946	+++ IC50: 0.3 nM	
EPZ004777	++ IC50: 0.4 nM	

HNMT

阻害選択性

Inhibitor Name	HNMT
Amodiaquine dihydrochloride dihydrate	+++ Ki: 18.6 nM

SMYD2

阻害選択性

Inhibitor Name	SMYD2
LLY-507	√

WDR5

阻害選択性

Inhibitor Name	WDR5	Other Targets
OICR-9429	+++ Kd: 93 nM	Wdr5-MLL interaction

SAM MTase

阻害選択性

Inhibitor Name	SAM MTase
Adenosine Dialdehyde (ADOX)	+++ IC50: 40 nM

PPMTase

阻害選択性

Inhibitor Name	PPMTase	Clinical Phase
Salirasib	+++ Ki: 2.6 μM	Phase 2

注釈:

1.各阻害剤の半数阻害濃度（IC_{50}）や作用濃度など、詳細についてはwww.selleck.co.jpのウェブサイトをご覧ください。

2.「+」は阻害効果を示す。阻害効果が高い（IC_{50}値が低い）ほど「+」が多く示されている。

3.赤色の「√」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。

Immunology & Inflammation



PD-1/PD-L1

阻害選択性

Inhibitor Name	PD-1/PD-L1 interaction	Other Targets
Durvalumab	++++ IC50: 0.1 nM	PD-L1/CD80
Atezolizumab	+++ Kd: 0.4 nM	
Nivolumab	+++ IC50: 2.52 nM	PD-1/PD-L2 interaction
PD-1/PD-L1 Inhibitor 3	++ IC50: 5.6 nM	
PD-1/PD-L1 inhibitor 1	++ IC50: 0.006 μM	
BMS202 (PD-1/PD-L1 inhibitor 2)	+ IC50: 0.018 μM	
Spartalizumab	√	
Camrelizumab	√	
AUNP-12	√	
Pembrolizumab	√	

COX

阻害選択性

Inhibitor Name	COX	COX-1	COX-2	Other Targets	Clinical Phase
Celecoxib			++++ IC50: 40 nM		Phase 4
Ibuprofen		+ IC50: 13 μM	+ IC50: 370 μM		Phase 4
Indomethacin		++ IC50: 0.28 μM	+ IC50: 14 μM		Phase 4
Rofecoxib			++++ IC50: 18 nM		Phase 4
Diclofenac Sodium		+++ IC50: 60 nM	+++ IC50: 200 nM		Phase 4
Lumiracoxib		++ Ki: 3 μM	+++ Ki: 60 nM		Phase 4
Lornoxicam		++++ IC50: 5 nM	++++ IC50: 8 nM		Phase 4
Naproxen Sodium		+ IC50: 8.7 μM	+ IC50: 5.2 μM		Phase 4
Ketorolac		++ IC50: 1.23 μM	++ IC50: 3.50 μM		Phase 4
Valdecoxib			++++ IC50: 5 nM		Phase 4
Tolfenamic Acid			+++ IC50: 0.2 μM		Phase 1
Amfenac Sodium Monohydrate		++ IC50: 250 nM	+++ IC50: 150 nM		
Nimesulide			+ IC50: 26 μM		Phase 4
Indometacin Sodium		+++ IC50: 0.11 μM	++ IC50: 0.78 μM		
NS-398 (NS398)			++ IC50: 3.8 μM		
Meclofenamate Sodium		++++ IC50: 40 nM	+++ IC50: 50 nM		
Carprofen			++++ IC50: 30 nM		
Nepafenac		√			Phase 4
Sulindac	√				Phase 3
Meloxicam	√				Phase 4
Dexamethasone Sodium Phosphate			√	IL receptor	Phase 4
Aspirin		√			Phase 4
Suprofen		√			
Piroxicam	√				Phase 4
Ketoprofen		√			Phase 4
Etodolac	√				Phase 4
Ibuprofen Lysine	√				Phase 1
Pranoprofen	√				Phase 4
Asaraldehyde			√		
Zaltoprofen		√			
Acemetacin	√				
Bromfenac Sodium		√			Phase 4
Nabumetone	√				Phase 1
Niflumic acid			√	GABA receptor	
Phenacetin	√				
Deracoxib			√	PDE4	
Phenidone	√			LOX	
Etoricoxib			√		Phase 4
Diflunisal	√			p300	
Parecoxib			√		
Salicylic acid	√			Ethylene biosynthesis	Phase 4
Xanthohumol		√			Phase 1
Oxaprozin		√			Phase 1
Mefenamic Acid		√			Phase 4
Ampiroxicam	√				
Flunixin Meglumin	√				
Salicin		√			
Rutaecarpine			√		

CCR

阻害選択性

Inhibitor Name	CCR	Clinical Phase
Maraviroc	++ IC50: 3.3 nM	Phase 4
DAPTA	+++ IC50: 0.06 nM	Phase 2

Histamine Receptor

阻害選択性

Inhibitor Name	Histamine receptor	H1 receptor	H2 receptor	H3 receptor	H4 receptor	Other Targets	Clinical Phase
Clemastine Fumarate		++++ IC50: 3 nM					Phase 3
Loratadine		+ IC50: 4 μM					Phase 4
Bepotastine Besilate		+ pIC50: 5.7					Phase 4
Desloratadine		++ IC50: 51 nM					Phase 4
Ciproxifan Maleate				+++ IC50: 9.2 nM			
Mizolastine		+++ IC50: 47 nM					Phase 1
Chlorpheniramine Maleate		+++ IC50: 12 nM					Phase 4
Fexofenadine HCl		++ IC50: 246 nM					Phase 4
Tripelennamine HCl		+ IC50: 30 μM					
Nizatidine			++++ IC50: 0.9 nM			AChE	Phase 4
Hydroxyzine 2HCl		+++ IC50: 10 nM-19 nM					Phase 4
JNJ-7777120					++++ Ki: 4.5 nM		
Rupatadine Fumarate		++ Ki: 102 nM				PAFR	Phase 4
Azatadine dimaleate	+++ IC50: 6.5 nM					Cholinergic	
Emedastine		++++ Ki: 1.3 nM					
Bilastine		+++ Ki: 44.15 nM					Phase 4
S 38093				++ Ki: 1.2 μM			
Alcaftadine		++++ pKi: 8.5	++ pKi: 7.2			H4 receptor	Phase 4
Betahistine 2HCl				+ IC50: 1.9 μM			Phase 4
Roxatidine Acetate HCl			+ IC50: 3.2 μM				
Latrepirdine 2HCl	√					5-HT,GluR	Phase 3
Azelastine HCl	√						Phase 4
Ranitidine Hydrochloride			√				Phase 4
Mianserin HCl	√						Phase 4
Diphenhydramine HCl		√					Phase 4
Cetirizine DiHCl	√						
Meclizine 2HCl		√					Phase 3
Epinastine HCl	√						Phase 4
Lafutidine			√				Phase 3
Cimetidine			√				Phase 3
Ebastine		√					Phase 4
Buclizine HCl	√					Cholinergic	
Cyproheptadine HCl	√						Phase 4
Ketotifen Fumarate		√					Phase 4
Brompheniramine hydrogen maleate		√					Phase 3
Olopatadine HCl	√						Phase 4
Emedastine Difumarate		√					
Triprolidine Hydrochloride		√					
Levocetirizine Dihydrochloride		√					
CarbinoxaMine Maleate		√					
Doxylamine Succinate		√					Phase 3
Cyclizine 2HCl		√					
Levodropropizine	√						Phase 3
Pemirolast potassium		√					Phase 2
Famotidine			√				Phase 4
Hesperetin	√					TGF-β	

IL Receptor

阻害選択性

Inhibitor Name	IL Receptor	Other Targets	Clinical Phase
Dexamethasone (DHAP)	√		Phase 4
Dexamethasone Sodium Phosphate	√	COX-2	Phase 4
Dexamethasone Acetate	√		Phase 4

gp120/CD4

阻害選択性

Inhibitor Name	gp120/CD4
BMS-378806	+++ EC50: 0.85 nM-26.5 nM
YYA-021	√

CXCR

阻害選択性

Inhibitor Name	CXCR1	CXCR2	CXCR4	Other Targets	Clinical Phase
Plerixafor 8HCl (AMD3100 8HCl)	IC50: 0.25 μM		++ IC50: 44 nM	CXCL12	Phase 4
Plerixafor (AMD3100)	Ki: 110 nM		++ IC50: 44 nM	CXCL12	Phase 4
WZ811			++++ EC50: 0.3 nM		
SB225002		+++ IC50: 22 nM			
Tannic acid			√		Phase 3
Reparixin (Repertaxin)	√			CXCL8	Phase 3
AMD3465 hexahydrobromide			√		

MALT

阻害選択性

Inhibitor Name	MALT1
MI-2 (MALT1 inhibitor)	+++ IC50: 5.84 μM

LTR

阻害選択性

Inhibitor Name	LTR	Other Targets	Clinical Phase
Zafirlukast	√		Phase 2
Montelukast Sodium	√		Phase 4
MK571	√	MRP1,cMOAT,MRP4	

NOS

阻害選択性

Inhibitor Name	nNOS	eNOS	iNOS	Clinical Phase
L-NAME HCl	+++ Ki: 15 nM	+++ Ki: 39 nM		Phase 3
1400W 2HCl	++ Ki: 2 μM	+ Ki: 50 μM	++++ Kd: <7 nM	
Agmatine sulfate			√	

NADPH-oxidase

阻害選択性

Inhibitor Name	NOX1	NOX4	NADPH-oxidase	Other Targets	Clinical Phase
2-Acetylphenothiazine (ML171)	+++ IC50: 0.25 μM	++ IC50: 5 μM		NOX3,NOX2,xanthine oxidase	
GKT137831	++++ Ki: 110 nM	+++ Ki: 140 nM			Phase 2
Apocynin			+ IC50: 10 μM		Phase 1

注釈：

1.各阻害剤の半数阻害濃度（IC_{50}）や作用濃度など、詳細についてはwww.selleck.co.jpのウェブサイトをご覧ください。

2.「+」は阻害効果を示す。阻害効果が高い（IC_{50}値が低い）ほど「+」が多く示されている。

3.赤色の「√」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。

Protein Tyrosine Kinase



VEGFR

阻害選択性

Inhibitor Name	VEGFR1	VEGFR2	VEGFR3	Other Targets	Clinical Phase
Sorafenib Tosylate		++ IC50: 15 nM		Raf-1,B-Raf,B-Raf (V599E)	Phase 3
Sunitinib Malate		+ IC50: 80 nM		FLT3,Kit,PDGFRβ	Phase 4
Cabozantinib (XL184, BMS-907351)		++++ IC50: 0.035 nM		c-Met	Phase 4
Ponatinib (AP24534)		++++ IC50: 1.5 nM		Abl,PDGFRα,FGFR1	Phase 3
Axitinib	++++ IC50: 0.1 nM	++++ IC50: 0.18 nM	++++ IC50: 0.1 nM-0.3 nM	PDGFRβ,Kit,PDGFRα	Phase 3
Foretinib (GSK1363089)	+++ IC50: 6.8 nM	++++ IC50: 0.86 nM	++++ IC50: 2.8 nM	Met,Tie-2,RON	Phase 2
Vandetanib (ZD6474)		+ IC50: 40 nM	+ IC50: 110 nM	EGFR	Phase 4
Nintedanib (BIBF 1120)	++ IC50: 34 nM	+++ IC50: 13 nM	+++ IC50: 13 nM	LCK,FLT3,FGFR2	Phase 4
Regorafenib (BAY 73-4506)	+++ IC50: 13 nM	+++ IC50: 4.2 nM	+ IC50: 46 nM	RET,Raf-1,Kit	Phase 4
Pazopanib HCl (GW786034 HCl)	+++ IC50: 10 nM	++ IC50: 30 nM	+ IC50: 47 nM	FGFR,PDGFR,c-Kit	Phase 4
Cediranib (AZD2171)	+++ IC50: 5 nM	++++ IC50: 0.5 nM	++++ IC50: <=3 nM	c-Kit,PDGFRβ,FGFR1	Phase 3
PD173074		+ IC50: 100 nM-200 nM		FGFR1	
Dovitinib (TKI-258, CHIR-258)	+++ IC50: 10 nM	+++ IC50: 13 nM	+++ IC50: 8 nM	FLT3,c-Kit,FGFR1	Phase 3

阻害選択性

Inhibitor Name	VEGFR1	VEGFR2	VEGFR3	Other Targets	Clinical Phase
Linifanib (ABT-869)	++++ IC50: 3 nM	++++ IC50: 4 nM	+ IC50: 190 nM	CSF-1R,FLT3,Kit	Phase 3
Vatalanib (PTK787) 2HCl	+ IC50: 77 nM	+ IC50: 37 nM	+ IC50: 660 nM	PDGFRβ,c-Kit,c-Fms	Phase 3
RAF265 (CHIR-265)		++ EC50: 30 nM		B-Raf	Phase 2
Tivozanib (AV-951)	++ IC50: 30 nM	+++ IC50: 6.5 nM	++ IC50: 15 nM	EphB2,PDGFRα,PDGFRβ	Phase 3
Motesanib Diphosphate (AMG-706)	++++ IC50: 2 nM	++++ IC50: 3 nM	+++ IC50: 6 nM	Kit,RET,PDGFR	Phase 3
Lenvatinib (E7080)	++ IC50: 22 nM	++++ IC50: 4.0 nM	+++ IC50: 5.2 nM	PDGFRβ,FGFR1,PDGFRα	Phase 4
Brivanib (BMS-540215)	+ IC50: 380 nM	++ IC50: 25 nM		FGFR1	Phase 3
Glesatinib (MGCD265)	++++ IC50: 3 nM	++++ IC50: 3 nM	++++ IC50: 4 nM	Met,RON,Tie-2	Phase 2
AEE788 (NVP-AEE788)	+ IC50: 59 nM	+ IC50: 77 nM		EGFR,HER2/ErbB2,c-Abl	Phase 2
ENMD-2076		+ IC50: 58.2 nM	++ IC50: 15.9 nM	FLT3,RET,Aurora A	Phase 2
OSI-930	+++ IC50: 8 nM	+++ IC50: 9 nM		CSF-1R,LCK,C-Raf	Phase 1
CYC116		+ Ki: 44 nM		Aurora A,Aurora B,FLT3	Phase 1
Ki8751		++++ IC50: 0.9 nM		c-Kit,PDGFRα	
Telatinib		+++ IC50: 6 nM	++++ IC50: 4 nM	c-Kit,PDGFRα	Phase 2
Pazopanib	+++ IC50: 10 nM	++ IC50: 30 nM	+ IC50: 47 nM	c-Kit,PDGFR,FGFR	Phase 4
KRN 633	+ IC50: 170 nM	+ IC50: 160 nM	+ IC50: 125 nM	PDGFRα,c-Kit,BTK	
SAR131675			++ IC50: 23 nM		
Dovitinib (TKI-258) Dilactic Acid	+++ IC50: 10 nM	+++ IC50: 13 nM	+++ IC50: 8 nM	FLT3,c-Kit,FGFR1	Phase 3
Apatinib mesylate		++++ IC50: 1 nM		RET	Phase 4
BMS-794833		++ IC50: 15 nM		Met	
Cabozantinib malate (XL184)		++++ IC50: 0.035 nM		c-Met	Phase 4
Brivanib Alaninate (BMS-582664)	+ IC50: 380 nM	++ IC50: 25 nM		FGFR1	Phase 3
Golvatinib (E7050)		++ IC50: 16 nM		c-Met	Phase 2
Semaxanib (SU5416)		+ IC50: 1.23 μM			Phase 3
ZM 323881 HCl		++++ IC50: <2 nM			
ZM 306416	+ IC50: 0.33 μM			Src,Abl	
ENMD-2076 L-(+)-Tartaric acid		+ IC50: 58.2 nM	++ IC50: 15.9 nM	FLT3,RET,Aurora A	Phase 2
Fruquintinib (HMPL-013)	++ IC50: 33 nM	+ IC50: 35 nM	++++ IC50: 0.5 nM		Phase 3
Nintedanib Ethanesulfonate Salt	++ IC50: 34 nM	+++ IC50: 13 nM	+++ IC50: 13 nM	FGFR2,PDGFRα,PDGFRβ	
Apatinib		++++ IC50: 1 nM		RET	Phase 4
Cediranib Maleate	+++ IC50: 5 nM	++++ IC50: 0.5 nM	++++ IC50: <=3 nM	c-Kit,PDGFRβ,FGFR1	Phase 3
Anlotinib (AL3818) dihydrochloride		++++ IC50: 0.2 nM	++++ IC50: 0.7 nM	c-Kit	Phase 4
Regorafenib Monohydrate	+++ IC50: 13 nM			RET,Raf-1,murine VEGFR2	
2-D08		++ IC50: 17 nM		sumoylation,Axl,IRAK4	Phase 4
Sitravatinib (MGCD516)	+++ IC50: 6 nM	+++ IC50: 5 nM	++++ IC50: 2 nM	DDR2,EPHA3,Axl	Phase 2
BFH772		++++ IC50: 3 nM			Phase 2
BAW2881 (NVP-BAW2881)	+ IC50: 820 nM	+++ IC50: 9 nM	+ IC50: 420 nM	C-Raf-1,B-RAFV599E,c-Abl	
SU5402		++ IC50: 20 nM		FGFR1,PDGFRβ	
Sunitinib		+ IC50: 80 nM		c-Kit,FLT3 ,PDGFRβ	Phase 4
Dovitinib (TKI258) Lactate	+++ IC50: 10 nM	+++ IC50: 13 nM	+++ IC50: 8 nM	FLT3,c-Kit,FGFR1	Phase 3
LY2874455		+++ IC50: 7 nM		FGFR2,FGFR1,FGFR4	Phase 1
SKLB1002		++ IC50: 32 nM			
AZD2932		+++ IC50: 8 nM		PDGFRβ,Flt3,c-Kit	

EGFR

阻害選択性

Inhibitor Name	EGFR/ErbB1	HER2/ErbB2	ErbB3	ErbB4	mutant EGFR	Other Targets	Clinical Phase
Erlotinib HCl (OSI-744)	++++ IC50: 2 nM						Phase 4
Gefitinib (ZD1839)	++ IC50: 26 nM						Phase 4
Lapatinib (GW-572016) Ditosylate	++ IC50: 10.8 nM	+++ IC50: 9.2 nM		+ IC50: 367 nM			Phase 4
Afatinib (BIBW2992)	++++ IC50: 0.5 nM	++ IC50: 14 nM		++++ IC50: 1 nM			Phase 4
Neratinib (HKI-272)	+ IC50: 92 nM	+ IC50: 59 nM				KDR,Src	Phase 3

阻害選択性

Inhibitor Name	EGFR/ErbB1	HER2/ErbB2	ErbB3	ErbB4	mutant EGFR	Other Targets	Clinical Phase
Canertinib (CI-1033)	++++ IC50: 1.5 nM	+++ IC50: 9.0 nM					Phase 2
Lapatinib	++ IC50: 10.8 nM	+++ IC50: 9.2 nM		+ IC50: 367 nM			Phase 4
AG-490 (Tyrphostin B42)	+ IC50: 0.1 μM						
CP-724714		++ IC50: 10 nM					Phase 2
Dacomitinib (PF299804, PF299)	+++ IC50: 6.0 nM	+ IC50: 45.7 nM		+ IC50: 73.7 nM			Phase 3
WZ4002	++++ IC50: 2 nM						
Sapitinib (AZD8931)	+++ IC50: 4 nM	+++ IC50: 3 nM	+++ IC50: 4 nM				Phase 2
CUDC-101	+++ IC50: 2.4 nM	++ IC50: 15.7 nM				HDAC,HDAC1,HDAC6	Phase 1
AG-1478 (Tyrphostin AG-1478)	+++ IC50: 3 nM						
PD153035 HCl	++++ Ki: 5.2 pM						
Pelitinib (EKB-569)	+ IC50: 38.5 nM	+ IC50: 1.255 μM				Src,MEK/ERK,Raf	Phase 2
AEE788 (NVP-AEE788)	++++ IC50: 2 nM	+++ IC50: 6 nM		+ IC50: 160 nM		c-Abl,FLT1,c-Fms	Phase 2
AC480 (BMS-599626)	++ IC50: 20 nM	++ IC50: 30 nM		+ IC50: 190 nM			Phase 1
AP26113-analog (ALK-IN-1)					++ IC50: 36.8 nM	ALK,IGF1R,INSR	
OSI-420	++++ IC50: 2 nM						
WZ3146	++++ IC50: 5 nM						
AST-1306	++++ IC50: 0.5 nM	+++ IC50: 3.0 nM		++++ IC50: 0.8 nM			
Rociletinib (CO-1686, AVL-301)	++ Ki: 21.5 nM						Phase 3
Varlitinib	+++ IC50: 7 nM	++++ IC50: 2 nM					Phase 3
Icotinib	+++ IC50: 5 nM						Phase 4
TAK-285	++ IC50: 23 nM	++ IC50: 17 nM		+ IC50: 260 nM		MEK1,Aurora B,LCK	Phase 1
WHI-P154	+++ IC50: 4 nM					Src,VEGFR,JAK3	
Daphnetin	+ IC50: 7.67 μM					PKA,PKC	
PD168393	++++ IC50: 0.70 nM						
CNX-2006	++ IC50: <20 nM				++ IC50: <20 nM		
Tyrphostin 9	+ IC50: 460 μM					PDGFR	
AG-18	+ IC50: 35 μM						
Avitinib (AC0010)					++++ IC50: 0.18 nM	JAK3,BTK	Phase 3
Lazertinib (YH25448,GNS-1480)	++++ IC50: 2 nM				++++ IC50: 1.7 nM	Del19,L858R	Phase 2
Gefitinib hydrochloride	++ IC50: 15.5 nM				+ IC50: 823.3 nM		
Cetuximab	++++ Kd: 0.39 nM						
Lifirafenib (BGB-283)	++ IC50: 29 nM				+ IC50: 495 nM	WT A-RAF,C-RAF (Y340/341D),BRAF(V600E)	Phase 1
Nazartinib (EGF816, NVS-816)	++ Ki: 0.031 μM				++ Ki: 0.031 μM		Phase 2
Brigatinib (AP26113)					+ IC50: 43.7 nM	ALK,ROS1,FLT3	Phase 3
AZD3759	++++ IC50: 0.3 nM						Phase 3
Afatinib (BIBW2992) Dimaleate	++++ IC50: 0.4 nM	++ IC50: 14 nM					Phase 4
Erlotinib	++++ IC50: 2 nM						Phase 4
CL-387785 (EKI-785)	++++ IC50: 370 pM						
Poziotinib (HM781-36B)	+++ IC50: 3.2 nM	+++ IC50: 5.3 nM		++ IC50: 23.5 nM			Phase 2
Osimertinib (AZD9291)	++ IC50: 11.44 nM						Phase 3
AZ5104	++++ IC50: <1 nM			+++ IC50: 7 nM		ACK1,BLK,BRK	
HER2-Inhibitor-1		√					
WZ8040	√						
Genistein	√					topo II	Phase 4
Naquotinib(ASP8273)	√						Phase 3
Olmutinib (HM61713, BI 1482694)	√					BTK	Phase 2
Butein	√						
Chrysophanic Acid	√					mTOR	

PDGFR

阻害選択性

Inhibitor Name	PDGFR	PDGFRα	PDGFRβ	Other Targets	Clinical Phase
Sorafenib Tosylate			++ IC50: 57 nM	Raf-1,VEGFR2/Flk1,B-Raf	Phase 3
Imatinib Mesylate (STI571)	+ IC50: 100 nM			c-Kit,v-Abl	Phase 4
Sunitinib Malate			++++ IC50: 2 nM	FLT3,Kit,VEGFR2	Phase 4
Ponatinib (AP24534)		++++ IC50: 1.1 nM		Abl,VEGFR2,FGFR1	Phase 3
Axitinib		+++ IC50: 5.0 nM	++++ IC50: 1.6 nM	VEGFR1/FLT1,VEGFR2/Flk1,VEGFR3	Phase 3
Imatinib (STI571)	+ IC50: 100 nM			c-Kit,v-Abl	Phase 4
Nintedanib (BIBF 1120)		++ IC50: 59 nM	++ IC50: 65 nM	VEGFR2,VEGFR3,LCK	Phase 4
Pazopanib HCl (GW786034 HCl)	+ IC50: 84 nM			VEGFR1,VEGFR2,VEGFR3	Phase 4
Dovitinib (TKI-258, CHIR-258)			+++ IC50: 27 nM	FLT3,c-Kit,VEGFR3/FLT4	Phase 3
Linifanib (ABT-869)			++ IC50: 66 nM	VEGFR1/FLT1,CSF-1R,VEGFR2/KDR	Phase 3
Crenolanib (CP-868596)		++++ Kd: 2.1 nM	++++ Kd: 3.2 nM		Phase 2
Masitinib (AB1010)		+ IC50: 540 nM	+ IC50: 800 nM	Kit,Lyn B,Abl1	Phase 3
Tivozanib (AV-951)		++ IC50: 40 nM	++ IC50: 49 nM	VEGFR2,VEGFR3,EphB2	Phase 3
Amuvatinib (MP-470)		++ IC50: 40 nM		c-Kit (D816H),FLT3 (D835Y)	Phase 2
Motesanib Diphosphate (AMG-706)	+ IC50: 84 nM			VEGFR1,VEGFR2,VEGFR2/Flk1	Phase 3
Orantinib (TSU-68, SU6668)			+++ Ki: 8 nM		Phase 3
CP-673451		+++ IC50: 10 nM	++++ IC50: 1 nM		
Ki8751		++ IC50: 67 nM		VEGFR2,c-Kit	
Telatinib		+++ IC50: 15 nM		c-Kit,VEGFR3,VEGFR2	Phase 2
PP121	++++ IC50: 2 nM			Hck,VEGFR,mTOR	
Pazopanib	+ IC50: 84 nM			VEGFR1,VEGFR2,VEGFR3	Phase 4
Dovitinib (TKI-258) Dilactic Acid			+++ IC50: 27 nM	FLT3,c-Kit,FGFR1	Phase 3
MK-2461			+++ IC50: 22 nM	c-Met,c-Met,c-Met	Phase 2
Tyrphostin AG 1296	+ IC50: 0.3 μM-0.5 μM			c-Kit (Swiss 3T3),FGFR (Swiss 3T3)	
Tyrphostin 9	+ IC50: 0.5 μM			EGFR	
Nintedanib Ethanesulfonate Salt		++ IC50: 59 nM	++ IC50: 65 nM	VEGFR3,VEGFR2,VEGFR1	
Toceranib phosphate	+++ Ki: 5 nM			Flk-1/DFR	
Regorafenib Monohydrate			+++ IC50: 22 nM	RET,Raf-1,murine VEGFR2	
Avapritinib (BLU-285)		++++ IC50: 0.5 nM		c-Kit (D816V)	Phase 3
Sunitinib			++++ IC50: 2 nM	c-Kit,FLT3 ,VEGFR2	Phase 4
Dovitinib (TKI258) Lactate			+++ IC50: 27 nM	FLT3,c-Kit,FGFR1	Phase 3
AZD2932			++++ IC50: 4 nM	Flt3,VEGFR-2,c-Kit	
Sennoside B	√				

c-Met

阻害選択性

Inhibitor Name	c-Met	Other Targets	Clinical Phase
Crizotinib (PF-02341066)	+ IC50: 11 nM	ALK	Phase 4
Cabozantinib (XL184, BMS-907351)	+++ IC50: 1.3 nM	VEGFR2/KDR	Phase 4
Foretinib (GSK1363089)	++++ IC50: 0.4 nM	KDR,Tie-2,VEGFR3/FLT4	Phase 2
PHA-665752	++ IC50: 9 nM	RON,Flk1	
SU11274	+ IC50: 0.01 μM		
SGX-523	+++ IC50: 4 nM		Phase 1
BMS-777607	+++ IC50: 3.9 nM	Axl,RON,Tyro3	Phase 2
Tivantinib (ARQ 197)	+ Ki: 0.355 μM		Phase 3
JNJ-38877605	+++ IC50: 4 nM		Phase 1
PF-04217903	++ IC50: 4.8 nM		Phase 1
Glesatinib (MGCD265)	++++ IC50: 1 nM	RON,VEGFR2,VEGFR1	Phase 2
Capmatinib (INCB28060)	++++ IC50: 0.13 nM		
BMS-754807	++ IC50: 5.6 nM	Insulin Receptor,IGF-1R,TrkB	Phase 2
BMS-794833	+++ IC50: 1.7 nM	VEGFR2	

阻害選択性

Inhibitor Name	c-Met	Other Targets	Clinical Phase
AMG-208	++ IC50: 9 nM		Phase 2
MK-2461	++++ IC50: 1.0 nM	c-Met (Y1235D),c-Met (Y1230C),c-Met (N1100)	Phase 2
Golvatinib (E7050)	+ IC50: 14 nM	VEGFR2	Phase 2
AMG-458	++++ Ki: 0.5 nM		
Tepotinib (EMD 1214063)	+++ IC50: 4 nM		Phase 2
NVP-BVU972	+ IC50: 14 nM		
Savolitinib(AZD6094, HMPL-504)	++ IC50: 5 nM		Phase 3
S49076	++++ IC50: 1 nM	Mer,Axl,FGFR3	
Merestinib (LY2801653)	+++ Ki: 2 nM		Phase 2
AMG 337	++++ IC50: 1 nM		Phase 2
NPS-1034	+ IC50: 48 nM	Axl	

HER2

阻害選択性

Inhibitor Name	HER2	Other Targets	Clinical Phase
Lapatinib (GW-572016) Ditosylate	+++ IC50: 9.2 nM	EGFR,ErbB4	Phase 4
Afatinib (BIBW2992)	++ IC50: 14 nM	EGFR (L858R),EGFR (wt),ErbB4	Phase 4
Neratinib (HKI-272)	+ IC50: 59 nM	EGFR,KDR,Src	Phase 3
Canertinib (CI-1033)	+++ IC50: 9.0 nM	EGFR	Phase 2
Lapatinib	+++ IC50: 9.2 nM	EGFR,ErbB4	Phase 4
CP-724714	++ IC50: 10 nM		Phase 2
Sapitinib (AZD8931)	++++ IC50: 3 nM	ErbB3,EGFR	Phase 2
CUDC-101	++ IC50: 15.7 nM	EGFR,HDAC,HDAC1	Phase 1
Mubritinib (TAK 165)	++++ IC50: 6.0 nM		Phase 1
AEE788 (NVP-AEE788)	++++ IC50: 6 nM	EGFR,c-Abl,FLT1	Phase 2
AC480 (BMS-599626)	+ IC50: 30 nM	HER1,HER4	Phase 1
TAK-285	+ IC50: 17 nM	EGFR/HER1,HER4,MEK1	Phase 1
Tyrphostin AG 879	+ IC50: 1.0 μM	Trk	
Lapatinib ditosylate monohydrate	+++ IC50: 9.2 nM	EGFR,ErbB4	
Irbinitinib (ARRY-380, ONT-380)	+++ IC50: 8 nM	p95 HER2	Phase 2
Afatinib (BIBW2992) Dimaleate	++ IC50: 14 nM	EGFR (L858R),EGFR (wt),EGFR (L858R/T790M)	Phase 4
Poziotinib (HM781-36B)	++++ IC50: 5.3 nM	HER1,HER4	Phase 2
HER2-Inhibitor-1	√		
Pertuzumab	√		
Trastuzumab	√		

IGF-1R

阻害選択性

Inhibitor Name	IGF-1R	Insulin Receptor	Other Targets	Clinical Phase
Linsitinib (OSI-906)	+++ IC50: 35 nM	++ IC50: 75 nM	IRR	Phase 3
NVP-AEW541	++ IC50: 0.15 μM	++ IC50: 0.14 μM	FLT3,Tek,FLT1	
GSK1904529A	+++ IC50: 27 nM	+++ IC50: 25 nM		
NVP-ADW742	+ IC50: 0.17 μM			
BMS-536924	++ IC50: 100 nM	+++ IC50: 73 nM	FAK,MEK,LCK	
AG-1024	+ IC50: 7 μM	+ IC50: 57 μM		
GSK1838705A	+++ IC50: 2 nM	++++ IC50: 1.6 nM	ALK	
BMS-754807	++++ IC50: 1.8 nM	++++ IC50: 1.7 nM	TrkB,Met,TrkA	Phase 2
PQ 401	+ IC50: <1 μM			
Picropodophyllin (PPP)	++++ IC50: 1 nM			Phase 3
AZD3463	√		ALK	

FLT3

阻害選択性

Inhibitor Name	FLT3	Other Targets	Clinical Phase
Quizartinib (AC220)	+++ IC50: 1.1 nM		Phase 3
Dovitinib (TKI-258, CHIR-258)	++++ IC50: 1 nM	c-Kit,VEGFR3/FLT4,FGFR1	Phase 3
Amuvatinib (MP-470)	+ IC50: 81 nM	c-Kit (D816H),PDGFRα (V561D)	Phase 2
Tandutinib (MLN518)		c-Kit,PDGFRβ,CSF-1R	Phase 2
TG101209		JAK2,RET,JAK3	
KW-2449	++++ IC50: 6.6 nM	Abl (T315I),Abl,FGFR1	Phase 1
ENMD-2076		RET,Aurora A,VEGFR3/FLT4	Phase 2
Dovitinib (TKI-258) Dilactic Acid	++++ IC50: 1 nM	c-Kit,VEGFR3/FLT4,FGFR1	Phase 3
Pacritinib (SB1518)		JAK2 (V617F),JAK2,TYK2	Phase 3
TCS 359	+ IC50: 42 nM		
ENMD-2076 L-(+)-Tartaric acid	++ IC50: 1.86 nM	RET,Aurora A,VEGFR3/FLT4	Phase 2
Gilteritinib (ASP2215)	++++ IC50: 0.29 nM		Phase 3
TAK-659	++ IC50: 4.6 nM	Syk,ZAP-70,JAK3	Phase 2
UNC2025	++++ IC50: 0.8 nM	Mer,Axl,Tyro3	
AMG 925		CDK4	
Dovitinib (TKI258) Lactate		c-Kit,VEGFR3/FLT4,FGFR1	Phase 3
G-749	++++ IC50: 0.4 nM	Mer,Aurora B,RET	
AZD2932	++ IC50: 7 nM	PDGFRβ,VEGFR-2,c-Kit	
R406	√	Syk	
Go6976	√	JAK2,PKCα,PKCβ1	

FGFR

阻害選択性

Inhibitor Name	FGFR	FGFR1	FGFR2	FGFR3	FGFR4	Other Targets	Clinical Phase
Ponatinib (AP24534)		++++ IC50: 2.2 nM				Abl,PDGFRα,VEGFR2	Phase 3
BGJ398 (NVP-BGJ398)		++++ IC50: 0.9 nM	++++ IC50: 1.4 nM	++++ IC50: 1.0 nM	+ IC50: 60 nM		Phase 2
Nintedanib (BIBF 1120)		+ IC50: 69 nM	++ IC50: 37 nM	+ IC50: 108 nM	+ IC50: 610 nM	VEGFR3,VEGFR2,LCK	Phase 4
PD173074		++ IC50: ~25 nM				VEGFR2	
Dovitinib (TKI-258, CHIR-258)		+++ IC50: 8 nM		+++ IC50: 9 nM		FLT3,c-Kit,VEGFR3/FLT4	Phase 3
AZD4547		++++ IC50: 0.2 nM	++++ IC50: 2.5 nM	++++ IC50: 1.8 nM		KDR	Phase 3
Danusertib (PHA-739358)		++ IC50: 47 nM				Aurora A,Abl,TrkA	Phase 2
Brivanib (BMS-540215)		+ IC50: 148 nM				VEGFR2,Flk1,VEGFR1	Phase 3
Dovitinib (TKI-258) Dilactic Acid		+++ IC50: 8 nM		+++ IC50: 9 nM		FLT3,c-Kit,VEGFR3/FLT4	Phase 3
MK-2461		+ IC50: 65 nM	++ IC50: 39 nM	+ IC50: 50 nM		c-Met,c-Met,c-Met	Phase 2
Brivanib Alaninate (BMS-582664)		+ IC50: 148 nM				VEGFR2,Flk1,VEGFR1	Phase 3
SSR128129E		+ IC50: 1.9 μM					Phase 3
Derazantinib(ARQ-087)		+++ IC50: 4.5 nM	++++ IC50: 1.8 nM	+++ IC50: 4.5 nM	++ IC50: 34 nM	RET,DDR2,PDGFRβ	Phase 2
Nintedanib Ethanesulfonate Salt		+ IC50: 69 nM	++ IC50: 37 nM	+ IC50: 108 nM		VEGFR3,VEGFR2,VEGFR1	
H3B-6527					++++ IC50: <1.2 nM		Phase 1
Roblitinib (FGF401)					++++ IC50: 1.1 nM		Phase 2
PRN1371		++++ IC50: 0.6 nM	++++ IC50: 1.3 nM	+++ IC50: 4.1 nM	++ IC50: 19.3 nM	CSF1R	Phase 1
PD-166866 (PD166866)		+ IC50: 52.4 nM					
BLU-554 (BLU554)					+++ IC50: 5 nM		Phase 1
S49076		++ IC50: 18 nM	++ IC50: 17 nM	++ IC50: 15 nM		Met,Mer,Axl	
SU5402		++ IC50: 30 nM				VEGFR2,PDGFRβ	
BLU9931				+ IC50: 150 nM	++++ IC50: 3 nM		
FIIN-2		+++ IC50: 3.09 nM	+++ IC50: 4.3 nM	++ IC50: 27 nM	++ IC50: 45.3 nM		
Dovitinib (TKI258) Lactate		+++ IC50: 8 nM		+++ IC50: 9 nM		FLT3,c-Kit,VEGFR3/FLT4	Phase 3
CH5183284 (Debio-1347)		++ IC50: 9.3 nM	+++ IC50: 7.6 nM	++ IC50: 22 nM	+ IC50: 290 nM		Phase 2
LY2874455		++++ IC50: 2.8 nM	++++ IC50: 2.6 nM	+++ IC50: 6.4 nM	+++ IC50: 6 nM	VEGFR2	Phase 1
Erdafitinib (JNJ-42756493)	√						Phase 3

c-Kit

阻害選択性

Inhibitor Name	c-Kit	Other Targets	Clinical Phase
Dasatinib	++ IC50: 37 nM	Abl,Src	Phase 4
Imatinib Mesylate (STI571)	+ IC50: 100 nM	PDGFR,v-Abl	Phase 4
Axitinib	++++ IC50: 1.7 nM	VEGFR1/FLT1,VEGFR2/Flk1,VEGFR3	Phase 3
Pazopanib HCl (GW786034 HCl)	+ IC50: 140 nM	VEGFR1,VEGFR2,VEGFR3	Phase 4
Dovitinib (TKI-258, CHIR-258)	++++ IC50: 2 nM	FLT3,VEGFR3/FLT4,FGFR1	Phase 3
Masitinib (AB1010)	+ IC50: 200 nM	Lyn B,PDGFRα,PDGFRβ	Phase 3
Tivozanib (AV-951)	++ IC50: 78 nM	VEGFR2,VEGFR3,EphB2	Phase 3
Amuvatinib (MP-470)	+++ IC50: 10 nM	PDGFRα (V561D),FLT3 (D835Y)	Phase 2
Motesanib Diphosphate (AMG-706)	+++ IC50: 8 nM	VEGFR1,VEGFR2,VEGFR3	Phase 3
OSI-930	+ IC50: 80 nM	FLT1,KDR,CSF-1R	Phase 1
Ki8751	++ IC50: 40 nM	VEGFR2,PDGFRα	
Telatinib	++++ IC50: 1 nM	VEGFR3,VEGFR2,PDGFRα	Phase 2
Pazopanib	++ IC50: 74 nM	VEGFR1,VEGFR2,VEGFR3	Phase 4
Dovitinib (TKI-258) Dilactic Acid	++++ IC50: 2 nM	FLT3,FGFR1,VEGFR3/FLT4	Phase 3
Tyrphostin AG 1296	+ IC50: 1.8 μM	PDGFR,FGFR (Swiss 3T3)	
Ripretinib (DCC-2618)	+++ IC50: 8 nM	PDGFR	Phase 3
Regorafenib Monohydrate	+++ IC50: 7 nM	RET,Raf-1,murine VEGFR2	
Avapritinib (BLU-285)	++++ IC50: 0.5 nM	PDGFRα (D842V)	Phase 3
Sitravatinib (MGCD516)	+++ IC50: 6 nM	DDR2,EPHA3,Axl	Phase 2
Pexidartinib (PLX3397)	+++ IC50: 10 nM	CSF-1R,Flt3	Phase 3
Dasatinib Monohydrate	++ IC50: 37 nM	Abl ,Src	Phase 4
Dovitinib (TKI258) Lactate	++++ IC50: 2 nM	FLT3,VEGFR3/FLT4,FGFR1	Phase 3
AZD2932	+++ IC50: 9 nM	PDGFRβ,Flt3,VEGFR-2	
Sunitinib Malate	√	FLT3,PDGFRβ,VEGFR2	Phase 4
PDGFR inhibitor 1	√	PDGFR	
Sunitinib	√	FLT3 ,PDGFRβ ,VEGFR2	Phase 4

Src

阻害選択性

Inhibitor Name	Src	Lck	Fyn	Lyn	Yes	Other Targets	Clinical Phase
Dasatinib	++++ IC50: 0.8 nM					Abl,c-Kit (D816V),c-Kit (wt)	Phase 4
Saracatinib (AZD0530)	++++ IC50: 2.7 nM	+++ IC50: <4 nM	++ IC50: 10 nM	+++ IC50: 5 nM		c-YES,EGFR (L861Q), EGFR (L858R)	Phase 3
Bosutinib (SKI-606)	++++ IC50: 1.2 nM					Abl	Phase 4
KX2-391	++ GI50: 26 nM						Phase 3
NVP-BHG712	+ IC50: 1.266 μM					EphB4,C-Raf,c-Abl	
PP2		+++ IC50: 4 nM	+++ IC50: 5 nM				
PP121	++ IC50: 14 nM					PDGFR,Hck,VEGFR	
PP1		+++ IC50: 5 nM	++ IC50: 6 nM			Kit,EGFR	Phase 3
MNS (3,4-Methylenedioxy-β-nitrostyrene, MDBN)	+ IC50: 29.3 μM					p97,Syk	Phase 2
Dasatinib hydrochloride	++++ IC50: 0.8 nM					Abl,c-Kit (D816V),c-Kit (wt)	
UM-164	++++ Kd: 2.7 nM					p38α,p38β	
TPX-0005	+++ IC50: 5.3 nM					WT ALK,ALK(L1196M), ALK(G1202R)	Phase 2
CCT196969	+ IC50: 0.03 μM	++ IC50: 0.02 μM				CRAF,V600E-BRAF,BRAF	
SU6656	+ IC50: 280 nM		+ IC50: 170 nM	+ IC50: 130 nM	++ IC50: 20 nM		
Dasatinib Monohydrate	++++ IC50: 0.8 nM					Abl ,c-Kit (D816V),c-Kit (wt)	Phase 4
WH-4-023	++ IC50: 6 nM	++++ IC50: 2 nM					
AD80	√					S6 Kinase,Raf,RET V804M	
Quercetin	√					Sirtuin,PKC,PI3Kγ	Phase 4

ALK

阻害選択性

Inhibitor Name	ALK	Other Targets	Clinical Phase
Crizotinib (PF-02341066)	+ IC50: 24 nM	c-Met	Phase 4
TAE684 (NVP-TAE684)	++ IC50: 3 nM		
Alectinib (CH5424802)	++ IC50: 1 nM		Phase 3
Ceritinib (LDK378)	++++ IC50: 0.2 nM	Insulin Receptor,IGF-1R	Phase 2
AP26113-analog (ALK-IN-1)	++++ IC50: 0.07 nM	EGFR(C797S/del19),IGF1R,EGFR(del19)	
GSK1838705A	+++ IC50: 0.5 nM	Insulin Receptor,IGF-1R	
AZD3463	+++ Ki: 0.75 nM	IGF-1R	
ASP3026	+ IC50: 3.5 nM		Phase 1
Alectinib hydrochloride	++ IC50: 1.9 nM		
Ensartinib (X-396)	+ IC50: <4 nM	Met	Phase 3
Belizatinib (TSR-011)	+++ IC50: 0.7 nM	TrkC,TrkB,TrkA	
TPX-0005	++ IC50: 1.08 nM	Src	Phase 2
Brigatinib (AP26113)	+++ IC50: 0.37 nM	FLT3,IGF1R,EGFR(C797S/del19)	Phase 3
Lorlatinib (PF-6463922)	++++ Ki: <0.02 nM	LTK (TYK1),FER,FES (FPS)	Phase 2
Entrectinib (RXDX-101)	√	TrkB,TrkA,TrkC	Phase 3

Tie-2

阻害選択性

Inhibitor Name	Tie-2	Other Targets	Clinical Phase
Glesatinib (MGCD265)	+++ IC50: 7 nM	Met,RON,VEGFR2	Phase 2
Tie2 kinase inhibitor	++ IC50: 0.25 μM		
Pexmetinib (ARRY-614)	√	p38 MAPK	Phase 1

c-RET

阻害選択性

Inhibitor Name	c-RET	Other Targets	Clinical Phase
Regorafenib (BAY 73-4506)	++++ IC50: 1.5 nM	Raf-1,VEGFR2,Kit	Phase 4
Danusertib (PHA-739358)	++ IC50: 31 nM	Aurora A,Abl,TrkA	Phase 2
TG101209	++ IC50: 17 nM	JAK2,FLT3,JAK3	
Apatinib	+++ IC50: 13 nM	VEGFR2	Phase 4
Regorafenib Monohydrate		Raf-1,murine VEGFR2,KIT	
2-D08	+++ IC50: 11 nM	sumoylation,Axl,IRAK4	Phase 4
BMS-935177	+ IC50: 110 nM	BTK,TEC,BLK	
AD80	++++ IC50: 0.4 nM	Raf,S6 Kinase,Src	
BAW2881 (NVP-BAW2881)	+ IC50: 410 nM	hVEGFR2,C-Raf-1,B-RAFV599E	

TAM Receptor

阻害選択性

Inhibitor Name	Mer	AxL	Tyro3	Other Targets	Clinical Phase
BMS-777607	++ IC50: 14 nM	++++ IC50: 1.1 nM	+++ IC50: 4.3 nM	RON,Met,FLT3	Phase 2
R428 (BGB324)		++ IC50: 14 nM			Phase 2
UNC2250	++++ IC50: 1.7 nM		+ IC50: 100 nM		
2-D08				sumoylation,IRAK4,ROS1	Phase 4
Gilteritinib (ASP2215)		++++ IC50: 0.73 nM		FLT3	Phase 3
Sitravatinib (MGCD516)	+++ IC50: 2 nM	++++ IC50: 1.5 nM		DDR2,EPHA3,VEGFR3 (FLT4)	Phase 2
RXDX-106 (CEP-40783)	+ IC50: 29 nM	+++ IC50: 7 nM	++ IC50: 19 nM	c-Met,VEGFR2	Phase 1

阻害選択性

Inhibitor Name	Mer	AxL	Tyro3	Other Targets	Clinical Phase
S49076	+++ IC50: 2 nM	+++ IC50: 7 nM		Met,FGFR3,FGFR2	
UNC2025	++++ IC50: 0.74 nM		++ IC50: 17 nM	FLT3	
TP-0903		+ IC50: 27 nM			Phase 2
NPS-1034		++ IC50: 10.3 nM		Met	
LDC1267	+++ IC50: <5 nM	+ IC50: 29 nM	++ IC50: 8 nM		
UNC2881	+++ IC50: 4.3 nM	+ IC50: 360 nM	+ IC50: 250 nM		

CSF-1R

阻害選択性

Inhibitor Name	CSF-1R	Other Targets	Clinical Phase
Linifanib (ABT-869)	+++ IC50: 3 nM	VEGFR1/FLT1,FLT3,VEGFR2/KDR	Phase 3
OSI-930	++ IC50: 15 nM	FLT1,KDR,LCK	Phase 1
GW2580	+ IC50: 30 nM		
CEP-32496	+++ Kd: 9 nM	RET,PDGFRβ,LCK	
Pexidartinib (PLX3397)	++ IC50: 20 nM	Kit,Flt3	Phase 3
BLZ945	++++ IC50: 1 nM		Phase 2

Ephrin receptor

阻害選択性

Inhibitor Name	Ephrin receptor	Other Targets
NVP-BHG712	+++ ED50: 25 nM	C-Raf,c-Src,c-Abl

BTK

阻害選択性

Inhibitor Name	BTK	Other Targets	Clinical Phase
Ibrutinib (PCI-32765)	++++ IC50: 0.5 nM	BLK,Bmx,FGR	Phase 4
Spebrutinib (CC-292, AVL-292)	++++ IC50: <0.5 nM		Phase 2
CNX-774	+++ IC50: <1 nM		
BTK inhibitor 1 (Compound 27)	++++ IC50: 0.11 nM		
ARQ 531	+++ IC50: 0.85 nM	BRK,LCK,YES	Phase 1
BMS-935177	++ IC50: 2.8 nM	TEC,BLK,BMX	
ONO-4059 (GS-4059) hydrochloride	+++ IC50: 2.2 nM		Phase 1
Olmutinib (HM61713, BI 1482694)	+ IC50: 13.9 nM	mutant EGFR	Phase 2
Acalabrutinib (ACP-196)	++ IC50: 3nM		Phase 3
ONO-4059 analogue	+ IC50: 23.9 nM		
LFM-A13	+ Ki: 1.4 μM		
RN486	++ IC50: 4 nM		
CGI1746	+++ IC50: 1.9 nM		
Btk inhibitor 2	√		Phase 3

Trk receptor

阻害選択性

Inhibitor Name	TrkA	TrkB	TrkC	Trk receptor	Other Targets	Clinical Phase
BMS-754807	++ IC50: 7.4 nM	+++ IC50: 4.1 nM			Insulin Receptor,IGF-1R,Met	Phase 2
GW441756	++++ IC50: 2 nM					
BMS-935177	+ IC50: 30 nM	+ IC50: 100 nM			BTK,TEC,BLK	

阻害選択性

Inhibitor Name	TrkA	TrkB	TrkC	Trk receptor	Other Targets	Clinical Phase
PF-06273340	+++ IC50: 6 nM	++++ IC50: 4 nM	++++ IC50: 3 nM			Phase 1
Sitravatinib (MGCD516)	+++ IC50: 5 nM	++ IC50: 9 nM			DDR2,EPHA3,Axl	Phase 2
ANA-12		++ Kd: 10 nM				
GNF-5837	++ IC50: 8 nM	+ IC50: 12 nM	+++ IC50: 7 nM			
Belizatinib (TSR-011)	√				ALK	
Larotrectinib (LOXO-101) sulfate				√		Phase 2
Entrectinib (RXDX-101)	√				ALK,ROS1	Phase 3

ACK

阻害選択性

Inhibitor Name	TNK2
XMD16-5	√
XMD8-87	√

注釈：

1.各阻害剤の半数阻害濃度（IC_{50}）や作用濃度など、詳細についてはwww.selleck.co.jpのウェブサイトをご覧ください。

2.「+」は阻害効果を示す。阻害効果が高い（IC_{50}値が低い）ほど「+」が多く示されている。

3.赤色の「√」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。

Angiogenesis



VEGFR
詳細情報はP22に記載されています

JAK
詳細情報はP9に記載されています

EGFR
詳細情報はP23に記載されています

PDGFR
詳細情報はP25に記載されています

HER2
詳細情報はP26に記載されています

FLT3
詳細情報はP27に記載されています

FGFR
詳細情報はP27に記載されています

HIF
詳細情報はP10に記載されています

Src
詳細情報はP28に記載されています

ALK
詳細情報はP29に記載されています

BTK
詳細情報はP30に記載されています

VDA

阻害選択性

Inhibitor Name	VDA	Other Targets	Clinical Phase
DMXAA (Vadimezan)	++ Ki: 20 μM		Phase 2
Plinabulin (NPI-2358)	+++ IC50: 9.8 nM-18 nM		Phase 3
Verteporfin	√	YAP/TEAD interaction	Phase 4

Bcr-Abl

阻害選択性

Inhibitor Name	Bcr-Abl	Abl	Other Targets	Clinical Phase
Dasatinib	++++ IC50: 0.6 nM	++++ IC50: 0.6 nM	Src,c-Kit (D816V),c-Kit (wt)	Phase 4
Imatinib Mesylate (STI571)		+ IC50: 600 nM	c-Kit,PDGFR	Phase 4
Ponatinib (AP24534)	++++ IC50: 0.37 nM	++++ IC50: 0.37 nM	PDGFRα,VEGFR2,FGFR1	Phase 3
Nilotinib (AMN-107)	++ IC50: <30 nM			Phase 4
Danusertib (PHA-739358)	++ IC50: 25 nM	++ IC50: 25 nM	Aurora A,TrkA,RET	Phase 2
AT9283		+++ IC50: 4 nM	JAK3,JAK2,Aurora B	Phase 2
Degrasyn (WP1130)	+ IC50: 1.8 μM		DUB	
Bafetinib (INNO-406)	++ IC50: 5.8 nM	++ IC50: 5.8 nM	Lyn	Phase 2
KW-2449	++ IC50: 14 nM	+++ IC50: 4 nM	FLT3 (D835Y),FLT3,FGFR1	Phase 1
NVP-BHG712		+ IC50: 1.667 μM	EphB4,C-Raf,c-Src	
PP121	++ IC50: 18 nM	++ IC50: 18 nM	PDGFR,Hck,VEGFR	
Rebastinib (DCC-2036)		+++ IC50: 4 nM	FLT3,KDR,Tie-2	Phase 2
GZD824 Dimesylate(HQP1351)	++++ IC50: 0.34 nM	++++ IC50: 0.15 nM		
GNF-2	+ IC50: 268 nM			
Nilotinib hydrochloride	++ IC50: <30 nM			
Dasatinib hydrochloride	++++ IC50: 0.6 nM	++++ IC50: 0.6 nM	Src,c-Kit (D816V),c-Kit (wt)	
Asciminib (ABL001)	++++ IC50: 0.45 nM	++++ IC50: 0.45 nM		Phase 3
GNF-7	+++ IC50: <5 nM	+ IC50: 133 nM		
Radotinib	+ IC50: 34 nM			Phase 3
Dasatinib Monohydrate	++++ IC50: 0.6 nM	++++ IC50: 0.6 nM	Src,c-Kit (D816V),c-Kit (wt)	Phase 4
GNF-5	+ IC50: 220 nM			
PD173955	+++ IC50: 1 nM-2 nM		Src	

Syk

阻害選択性

Inhibitor Name	Syk	Other Targets	Clinical Phase
R406	++ IC50: 41 nM	Flt3	
R788 (Fostamatinib) Disodium	++ IC50: 41 nM		Phase 3
R406 (free base)	++ IC50: 41 nM		
PRT062607 (P505-15, BIIB057) HCl	++++ IC50: 1 nM	FGR,MLK1	Phase 2
Fostamatinib (R788)	++ IC50: 41 nM	Adenosine A3 receptor,Adenosine transporter, Monoamine transporter	Phase 3
MNS (3,4-Methylenedioxy-β-nitrostyrene, MDBN)	+ IC50: 2.5 μM	p97,Src	Phase 2
TAK-659	++++ IC50: 3.2 nM		Phase 2
PRT-060318 2HCl	++++ IC50: 4nM		
Entospletinib (GS-9973)	+++ IC50: 7.7 nM		
RO9021	+++ IC50: 5.6 nM		
BAY-61-3606	+++ Ki: 7.5 nM		
Piceatannol	√	Lyn,cAK,PKC	

FAK

阻害選択性

Inhibitor Name	FAK	Other Targets	Clinical Phase
PF-00562271 Besylate	++++ IC50: 1.5 nM	CDK2/CyclinE,CDK3/CyclinE,CDK1/CyclinB	Phase 1
PF-562271	++++ IC50: 1.5 nM	CDK2/CyclinE,CDK3/CyclinE,CDK1/CyclinB	
PF-573228	+ IC50: 4 nM		
TAE226 (NVP-TAE226)	++ IC50: 3.5 nM	Insulin Receptor,IGF-1R,c-Met	
PF-03814735	+ IC50: 22 nM	Aurora A,Aurora B,FLT1	Phase 1
PF-562271 HCl	++++ IC50: 1.5 nM	CDK2/CyclinE,CDK3/CyclinE,CDK1/CyclinB	
GSK2256098	++++ Ki: 0.4 nM		Phase 2
PF-431396	++ IC50: 2 nM		
PND-1186 (VS-4718)	++++ IC50: 1.5 nM		Phase 1
Y15	√		
Defactinib (VS-6063, PF-04554878)	√		Phase 2
Solanesol (Nonaisoprenol)	√		

注釈:

1.各阻害剤の半数阻害濃度（IC_{50}）や作用濃度など、詳細についてはwww.selleck.co.jpのウェブサイトをご覧ください。

2.「+」は阻害効果を示す。阻害効果が高い（IC_{50}値が低い）ほど「+」が多く示されている。

3.赤色の「√」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。

Apoptosis



PD-1/PD-L1

詳細情報はP17に記載されています

c-RET

詳細情報はP29に記載されています

Bcl-2

阻害選択性

Inhibitor Name	Bcl-2	Bcl-B	Bcl-w	Bcl-xL	Mcl-1	Bax	Bfl-1	Other Targets	Clinical Phase
ABT-737	+++ EC50: 30.3 nM	+ EC50: 1.82 μM	+++ EC50: 197.8 nM	+++ EC50: 78.7 nM					
Navitoclax (ABT-263)	++++ Ki: <=1 nM		++++ Ki: <=1 nM	++++ Ki: <=0.5 nM					Phase 2
Obatoclax Mesylate (GX15-070)	+++ Ki: 0.22 μM								Phase 3
TW-37	++ Ki: 0.29 μM			+ Ki: 1.11 μM	+++ Ki: 0.26 μM				
Venetoclax (ABT-199, GDC-0199)	++++ Ki: <0.01 nM								Phase 3
AT101	++ Ki: 0.32 μM			++ Ki: 0.48 μM	+++ Ki: 0.18 μM				Phase 2
HA14-1	+ IC50: 9 μM								
Sabutoclax	++ IC50: 0.32 μM			++ IC50: 0.31 μM	+++ IC50: 0.20 μM		++ IC50: 0.62 μM		
BH3I-1				+ Ki: 2.4 μM				p53/MDM2	
A-1331852				++++ Ki: <0.01 nM					
A-1155463				++++ Ki: <0.01 nM					
A-1210477					+++ IC50: 26.2 nM				
UMI-77					++ Ki: 490 nM				
WEHI-539				++++ IC50: 1.1 nM					
Gambogic Acid	+ IC50: 1.06 μM	++ IC50: 0.66 μM	++++ IC50: 0.02 μM	+ IC50: 1.47 μM	+ IC50: 0.79 μM		+ IC50: 1.06 μM	Caspase	
BTSA1						√			
Marinopyrrole A (Maritoclax)					√				

Caspase

阻害選択性

Inhibitor Name	Caspase	Caspase-1	Caspase-3	Caspase-8	Caspase-9	Caspase-4	Capase-7	Caspase-2	Caspase-5	Caspase-6	Caspase-10	Clinical Phase
Belnacasan		++++ Ki: 0.8 nM				++++ Ki: <0.6 nM						Phase 2
Ac-DEVD-CHO		+++ Ki: 18 nM	++++ Ki: 230 pM	++++ Ki: 0.92 nM	++ Ki: 60 nM	++ Ki: 132 nM	+++ Ki: 1.6 nM	+ Ki: 1.71 μM	++ Ki: 205 nM	+++ Ki: 31 nM	+++ Ki: 12 nM	
Q-VD-Oph		++ IC50: 25 nM-400 nM	++ IC50: 25 nM-400 nM	++ IC50: 25 nM-400 nM	++ IC50: 25 nM-400 nM							
Z-VAD-FMK	√											
Z-IETD-FMK				√								
Emricasan	√											Phase 2
Z-VAD(OH)-FMK	√											
Z-DEVD-FMK			√									

p53

阻害選択性

Inhibitor Name	p53
Pifithrin-α (PFTα) HBr	√
Pifithrin-μ	√
ReACp53	√

TNF-alpha

阻害選択性

Inhibitor Name	TNF-α	Other Targets	Clinical Phase
Pomalidomide	+++ IC50: 13 nM		Phase 3
Necrostatin-1	+ EC50: 490 nM		
QNZ (EVP4593)	++++ IC50: 7 nM	NF-κB	
GSK'963	++ IC50: 29 nM		Phase 4
GSK2982772	++++ IC50: 1 nM		Phase 2
Thalidomide	√	E3 Ligase	Phase 4
Acetylcysteine	√	ROS/ROS1	Phase 4
Adalimumab	√		
GSK481	√		

Mdm2

阻害選択性

Inhibitor Name	Mdm2	MDMX	Other Targets	Clinical Phase
Nutlin-3	++ IC50: 180 nM			
NSC 207895		+ IC50: 2.5 μM	p53	
Nutlin-3a	+++ IC50: 90 nM			
Nutlin-3b	+ IC50: 13.6 μM			
MX69	++ Kd: 2.34 μM			
NVP-CGM097	++++ IC50: 1.7 nM			
MI-773 (SAR405838)	++++ Ki: 0.88 nM		p53	Phase 1
Idasanutlin (RG-7388)	+++ IC50: 6 nM			Phase 3
RG-7112	+++ Kd: 11 nM			
HDM201	√			Phase 2
YH239-EE	√			

Survivin

阻害選択性

Inhibitor Name	Survivin	Clinical Phase
YM155 (Sepantronium Bromide)	+++ IC50: 0.54 nM	Phase 2

IAP

阻害選択性

Inhibitor Name	cIAP	XIAP	Other Targets	Clinical Phase
Birinapant	++++ Kd: <1 nM	++ Kd: 45 nM		Phase 2
GDC-0152	+++ Ki: 17 nM	++ Ki: 28 nM	MLXBIR3SG	Phase 1
AT406 (SM-406)	++++ Ki: 1.9 nM	+ Ki: 66.4 nM		Phase 1
AZD5582	+++ IC50: 15 nM	+++ IC50: 15 nM		
Embelin		+ IC50: 4.1 μM	5-LO,mPGES-1	
BV-6	√			
LCL161	√			Phase 2

PERK

阻害選択性

Inhibitor Name	PERK
GSK2606414	++++ IC50: 0.4 nM
GSK2656157	+++ IC50: 0.9 nM
ISRIB (trans-isomer)	++ IC50: 5 nM
Salubrinal	√

ASK

阻害選択性

Inhibitor Name	ASK1	Clinical Phase
Selonsertib (GS-4997)	+++ pIC50: 8.3	Phase 2
NQDI-1	++ IC50: 3 μM	

注釈:

1.各阻害剤の半数阻害濃度 (IC_{50}) や作用濃度など、詳細についてはwww.selleck.co.jpのウェブサイトをご覧ください。

2.「+」は阻害効果を示す。阻害効果が高い (IC_{50}値が低い) ほど「+」が多く示されている。

3.赤色の「√」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。

Autophagy



CXCR

詳細情報は**P20**に記載されています

Autophagy

阻害選択性

Inhibitor Name	Autophagy	Other Targets	Clinical Phase
EAD1	+ IC50: 5.8 μM		
Autophinib	+++ IC50: 40 nM	Vps34	
MRT68921 HCl	++++ IC50: 1.1 nM		
SBI-0206965	++ IC50: 108 nM		
Valproic acid sodium salt (Sodium valproate)	√	HDAC,GABA receptor	Phase 4
ROC-325	√		
Lys05	√		
Hydroxychloroquine Sulfate	√	TLR9	Phase 4

LRRK2

阻害選択性

Inhibitor Name	LRRK2	Other Targets
LRRK2-IN-1	++ IC50: 6 nM	DCLK2
GSK2578215A	++ IC50: 8.9 nM	
GNE-9605	+++ IC50: 19 nM	
GNE-7915	+++ IC50: 9 nM	
GNE-0877	++++ Ki: 0.7 nM	
URMC-099	+ IC50: 11 nM	Abl1,MLK3,MLK1

注釈：

1.各阻害剤の半数阻害濃度（IC_{50}）や作用濃度など、詳細についてはwww.selleck.co.jpのウェブサイトをご覧ください。

2.「+」は阻害効果を示す。阻害効果が高い（IC_{50}値が低い）ほど「+」が多く示されている。

3.赤色の「√」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。

ER stress & UPR

PERK
詳細情報はP37に記載されています

ASK
詳細情報はP37に記載されています

JNK
阻害選択性

Inhibitor Name	JNK1	JNK2	JNK3	JNK	Other Targets	Clinical Phase
SP600125	+++ IC50: 40 nM	+++ IC50: 40 nM	++ IC50: 90 nM	+ IC50: 0.4 μM	Aurora A,TrkA,FLT3	
JNK-IN-8	++++ IC50: 4.7 nM	+++ IC50: 18.7 nM	++++ IC50: 1 nM		Kit (V559D,T670I),Kit (V559D)	
Tanzisertib(CC-930)	++ IC50: 0.061 μM	+++ IC50: 0.007 μM	++++ IC50: 0.006 μM			Phase 2
BI-78D3				+ IC50: 280 nM		
JNK Inhibitor IX		+ pIC50: 6.5	++ pIC50: 6.7			
Vacquinol-1				√		

HSP (e.g. HSP90)
阻害選択性

Inhibitor Name	HSP70	HSP90	HSP90α	HSP90β	HSP105	Other Targets	Clinical Phase
Tanespimycin (17-AAG)		+++ IC50: 5 nM					Phase 3
Luminespib (AUY-922, NVP-AUY922)		+++ IC50: 13 nM	+++ IC50: 13 nM	+++ IC50: 21 nM			Phase 2
Alvespimycin (17-DMAG) HCl		+ IC50: 62 nM					Phase 2
Ganetespib (STA-9090)		+++ IC50: 4 nM					Phase 3
BIIB021		++++ Ki: 1.7 nM					Phase 2
Onalespib (AT13387)		+++ IC50: 18 nM					Phase 2
Geldanamycin		+ Kd: 0.78 μM				p185	
NVP-BEP800		+ IC50: 58 nM		+ IC50: 58 nM			
SNX-2112 (PF-04928473)		++ Ka: 30 nM	++ Ka: 30 nM	++ Ka: 30 nM			
PF-04929113 (SNX-5422)		++ Kd: 41 nM				HER2	Phase 2
KW-2478		++++ IC50: 3.8 nM					Phase 2
XL888		++ IC50: 24 nM					Phase 1
Apoptozole	+ Kd: 0.14 μM						
VER155008	+ IC50: 0.5 μM						
VER-50589		+++ IC50: 21 nM		+++ IC50: 21 nM			
CH5138303		++++ Kd: 0.48 nM	++++ Kd: 0.48 nM				
VER-49009		++ IC50: 47 nM		++ IC50: 47 nM			
NMS-E973		+++ DC50: <10 nM					
PU-H71		+ IC50: 51 nM					Phase 1
HSP990 (NVP-HSP990)		++++ IC50: 0.6 nM	++++ IC50: 0.6 nM	++++ IC50: 0.8 nM			Phase 1
TRC051384	√						
KNK437					√		

注釈：
1.各阻害剤の半数阻害濃度（IC_{50}）や作用濃度など、詳細についてはwww.selleck.co.jpのウェブサイトをご覧ください。
2.「+」は阻害効果を示す。阻害効果が高い（IC_{50}値が低い）ほど「+」が多く示されている。
3.赤色の「√」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。

JAK/STAT



JAK 詳細情報はP9に記載されています

EGFR 詳細情報はP23に記載されています

Pim 詳細情報はP10に記載されています

STAT
阻害選択性

Inhibitor Name	STAT1	STAT3	STAT5	STAT6	Other Targets	Clinical Phase
S3I-201		+ IC50: 86 μM				
Stattic		+ IC50: 5.1 μM				
Niclosamide		++ IC50: 0.7 μM				Phase 2
AS1517499				++++ IC50: 21 nM		
C188-9		++++ Kd: 4.7 nM				
BP-1-102		+++ Kd: 504 nM				
SH-4-54		+++ Kd: 300 nM	+++ Kd: 464 nM			
Cryptotanshinone		++ IC50: 4.6 μM				
Fludarabine	√					Phase 4
Nifuroxazide	√					
HJC0152		√				
SH5-07 (SH-5-07)		√				
APTSTAT3-9R		√				
Ochromycinone (STA-21)		√				Phase 2
Napabucasin		√				Phase 3
HO-3867		√				
Artesunate		√			EXP1(a membrane glutathione S-transferase)	Phase 4

注釈：
1.「+」は阻害効果を示す。阻害効果が高い（IC_{50}値が低い）ほど「+」が多く示されている。
2.赤色の「√」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。

MAPK



JNK

詳細情報はP40に記載されています

MEK

阻害選択性

Inhibitor Name	MEK	MEK1	MEK1/2	MEK2	MEK5	Other Targets	Clinical Phase
Selumetinib (AZD6244)		+++ IC50: 14 nM		+ Kd: 530 nM			Phase 3
PD0325901	++++ IC50: 0.33 nM						Phase 2
Trametinib (GSK1120212)		++++ IC50: 0.92 nM		++++ IC50: 1.8 nM			Phase 4
U0126-EtOH		+ IC50: 0.07 μM		++ IC50: 0.06 μM			
PD184352 (CI-1040)		++ IC50: 17 nM		++ IC50: 17 nM			Phase 2
PD98059		+ IC50: 2 μM					
BIX 02189					++++ IC50: 1.5 nM	ERK5	
Pimasertib (AS-703026)			+ IC50: 5 nM-2 μM				Phase 2
BIX 02188					+++ IC50: 4.3 nM		
TAK-733		++++ IC50: 3.2 nM					Phase 1
AZD8330			+++ IC50: 7 nM			ERK phosphorylation	Phase 1
Binimetinib (MEK162, ARRY-162, ARRY-438162)	+++ IC50: 12 nM						Phase 3
SL-327		+ IC50: 0.18 μM		+ IC50: 0.22 μM		AP-1	
Refametinib (RDEA119, Bay 86-9766)		++ IC50: 19 nM		++ IC50: 47 nM			Phase 2
GDC-0623		++++ IC50: 0.13 nM					Phase 1
BI-847325		++ IC50: 25 nM		+++ IC50: 4 nM		Aurora B (Xenopus laevis),Aurora C (Human),Aurora A (Human)	

阻害選択性

Inhibitor Name	MEK	MEK1	MEK1/2	MEK2	MEK5	Other Targets	Clinical Phase
Cobimetinib (GDC-0973, RG7420)		+++ IC50: 4.2 nM					Phase 3
PD318088			√				
Honokiol	√					Akt-phosphorylation	
Myricetin		√				PI3Kγ	

Raf

阻害選択性

Inhibitor Name	Raf	C-Raf/Raf-1	B-Raf	A-raf	Other Targets	Clinical Phase
Vemurafenib (PLX4032, RG7204)		+ IC50: 48 nM	+ IC50: 31 nM		SRMS,ACK1,MAP4K5 (KHS1)	Phase 4
Sorafenib Tosylate	+++ IC50: 6 nM	+++ IC50: 6 nM	++ IC50: 22 nM		VEGFR2/Flk1,mPDGFRβ,PDGFRβ	Phase 3
PLX-4720		+++ IC50: 6.7 nM	++ IC50: 13 nM		BRK	
Dabrafenib (GSK2118436)		+++ IC50: 6.3 nM	++++ IC50: 0.7 nM			Phase 4
GDC-0879			++++ IC50: 0.13 nM			
RAF265 (CHIR-265)			+ IC50: 3 nM-60 nM		VEGFR2	Phase 2
AZ 628		+ IC50: 29 nM	+ IC50: 34 nM			
NVP-BHG712		+ IC50: 0.395 μM			EphB4,c-Src,c-Abl	
SB590885			++++ Ki: 0.16 nM			
ZM 336372		+ IC50: 70 nM				
Sorafenib	+++ IC50: 6 nM	+++ IC50: 6 nM	++ IC50: 22 nM		mVEGFR2(Flk1),mVEGFR3, mPDGFRβ	Phase 4
GW5074		++ IC50: 9 nM				
TAK-632		++++ IC50: 1.4 nM	++ IC50: 8.3 nM		Aurora B,PDGFRβ,FGFR3	
CEP-32496		+ Kd: 39 nM	++ Kd: 14 nM		RET,PDGFRβ,LCK	
Dabrafenib Mesylate		+++ IC50: 6.3 nM	++++ IC50: 0.7 nM			
Regorafenib Monohydrate	++++ IC50: 2.5 nM	++++ IC50: 2.5 nM	++ IC50: 28 nM		RET,murine VEGFR2,KIT	
RAF709		++++ IC50: 0.4 nM	++++ IC50: 1 nM			
Lifirafenib (BGB-283)		+++ IC50: 7 nM	++ IC50: 23 nM	++++ IC50: 1 nM	EGFR,EGFR(T790M/L858R)	Phase 1
CCT196969		++ IC50: 0.01 μM	+ IC50: 0.1 μM		LCK,Src,V600E-BRAF	
BAW2881 (NVP-BAW2881)		++ IC50: 24 nM			hVEGFR2,B-RAFV599E,c-Abl	
LY3009120		+++ IC50: 4.3 nM	+++ IC50: 5.8 nM			Phase 1
RO5126766 (CH5126766)		+ IC50: 56 nM	+++ IC50: 8.2 nM		MEK1	Phase 1
Encorafenib (LGX818)			√			Phase 3
LXH254			√			Phase 1
PLX7904	√					
MLN2480	√					Phase 2

p38 MAPK

阻害選択性

Inhibitor Name	p38 MAPK	p38α	p38β	Other Targets	Clinical Phase
SB203580	+ IC50: 0.3 μM-0.5 μM			PKB	
Doramapimod (BIRB 796)		++++ IC50: 38 nM			Phase 2
SB202190 (FHPI)		++ IC50: 50 nM	++ IC50: 100 nM		
Ralimetinib (LY2228820)		++++ IC50: 7 nM			Phase 2
VX-702		+++ IC50: 4 nM-20 nM			Phase 2
PH-797804		++ IC50: 26 nM	+ IC50: 102 nM		Phase 2
VX-745		+++ IC50: 10 nM	+ IC50: 220 nM		Phase 2
TAK-715		++++ IC50: 7.1 nM	+ IC50: 0.20 μM		Phase 2
Pamapimod (R-1503, Ro4402257)		+++ IC50: 0.014 μM	+ IC50: 0.48 μM		
BMS-582949	+++ IC50: 13 nM				Phase 2
SB239063		++ IC50: 44 nM	++ IC50: 44 nM		
Losmapimod (GW856553X)		++++ pKi: 8.1	+++ pKi: 7.6		Phase 3
Skepinone-L		++++ IC50: 5 nM			
Pexmetinib (ARRY-614)	√			Tie-2	Phase 1

ERK

阻害選択性

Inhibitor Name	ERK1	ERK2	ERK5	ERK	Other Targets	Clinical Phase
SCH772984	+++ IC50: 4 nM	++++ IC50: 1 nM				
Magnolin	++ IC50: 87 nM	++ IC50: 16.5 nM				
LY3214996	+++ IC50: 5 nM	+++ IC50: 5 nM				Phase 1
Pluripotin (SC1)	++ Kd: 98 nM				RasGAP	
VX-11e		+++ Ki: <2 nM				
DEL-22379			+ IC50: 0.5 μM	+ IC50: 0.5 μM		
Ulixertinib (BVD-523, VRT752271)		++++ IC50: <0.3 nM				Phase 2
GDC-0994	++++ IC50: 1.1 nM	++++ IC50: 0.3 nM				Phase 1
FR 180204	+ Ki: 0.31 μM	++ Ki: 0.14 μM				
ERK5-IN-1			+ IC50: 162 nM			

TOPK

阻害選択性

Inhibitor Name	TOPK
OTS964	++ IC50: 28 nM
OTS514 hydrochloride	+++ IC50: 2.6 nM

MNK

阻害選択性

Inhibitor Name	MNK1	MNK2	Clinical Phase
eFT-508 (eFT508)	+++ IC50: 2.4 nM	++++ IC50: 1 nM	Phase 2
CGP 57380	++ IC50: 2.2 μM		

注釈:

1.各阻害剤の半数阻害濃度（IC_{50}）や作用濃度など、詳細についてはwww.selleck.co.jpのウェブサイトをご覧ください。

2.「+」は阻害効果を示す。阻害効果が高い（IC_{50}値が低い）ほど「+」が多く示されている。

3.赤色の「↓」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。

Cytoskeletal Signaling



Akt

詳細情報はP4に記載されています

Bcr-Abl

詳細情報はP33に記載されています

FAK

詳細情報はP34に記載されています

HSP (e.g. HSP90)

詳細情報はP40に記載されています

Wnt/beta-catenin

阻害選択性

Inhibitor Name	Wnt/beta-catenin	Other Targets	Clinical Phase
XAV-939	++++ IC50: 4 nM		
ICG-001	+ IC50: 3 μM		
IWR-1-endo	++ IC50: 180 nM		
Wnt-C59 (C59)	++++ IC50: 74 pM		
IWP-2	+++ IC50: 27 nM		
IWP-L6	++++ EC50: 0.5 nM		
iCRT3	+++ IC50: 8.2 nM		
LF3	+ IC50: 1.65 μM		

阻害選択性

Inhibitor Name	Wnt/beta-catenin	Other Targets	Clinical Phase
PNU-74654	++ Kd: 450 nM		
KYA1797K	+ IC50: 0.75 μM		
PRI-724	++ IC50: 150 nM		Phase 2
WIKI4	+++ IC50: 15 nM		
LGK-974	√		Phase 1
KY02111	√		
Isoquercitrin	√		
IQ-1	√		
Salinomycin (from Streptomyces albus)	√		
FH535	√	PPARγ,PPARδ	

PKC

阻害選択性

Inhibitor Name	PKC	PKCα	PKCβ	PKCγ	PKCδ	PKCε	PKCζ	PKCη	PKCθ	Other Targets	Clinical Phase
Enzastaurin (LY317615)		++ IC50: 39 nM	+++ IC50: 6 nM	+ IC50: 83 nM		+ IC50: 110 nM					Phase 3
Sotrastaurin		++++ Ki: 0.95 nM	++++ Ki: 0.64 nM		++++ Ki: 2.1 nM	++++ Ki: 3.2 nM		++++ Ki: 1.8 nM	++++ Ki: 0.22 nM		Phase 2
Staurosporine		++++ IC50: 2 nM		++++ IC50: 5 nM	+++ IC50: 20 nM	++ IC50: 73 nM		++++ IC50: 4 nM		c-Fgr,phosphorylase kinase, S6 kinase	Phase 2
Go 6983		+++ IC50: 7 nM	+++ IC50: 7 nM	+++ IC50: 6 nM	+++ IC50: 10 nM		++ IC50: 60 nM				
Bisindolylmaleimide I (GF109203X)		+++ IC50: 20 nM	+++ IC50: 16 nM	+++ IC50: 20 nM							
Bisindolylmaleimide IX (Ro 31-8220 Mesylate)		++++ IC50: 5 nM	+++ IC50: 14 nM	++ IC50: 27 nM		++ IC50: 24 nM					
Daphnetin	+ IC50: 25.01 μM									EGFR,PKA	
Dequalinium Chloride	+ IC50: 7 μM-18 μM										Phase 3
Ruboxistaurin (LY333531 HCl)		+ IC50: 0.36 μM	++++ IC50: 4.7 nM	+ IC50: 0.3 μM	+ IC50: 0.25 μM			++ IC50: 0.052 μM			Phase 3
Midostaurin (PKC412)		++ IC50: 22 nM	++ IC50: 30 nM	++ IC50: 24 nM	+ IC50: 330 nM	+ IC50: 1.25 μM		+ IC50: 160 nM		PPK,KDR,c-Syk	Phase 3
Go6976	+++ IC50: 7.9 nM	++++ IC50: 2.3 nM	+++ IC50: 6.2 nM							FLT3,JAK2	
2-Methoxy-1,4-naphthoquinone			√								
Quercetin	√									Sirtuin,Src,PI3Ky	Phase 4
Myricitrin		√									

Kinesin

阻害選択性

Inhibitor Name	Kinesin	Clinical Phase
Ispinesib (SB-715992)	+++ Ki app: 1.7 nM	Phase 2
SB743921 HCl	++++ IC50: 14.4 nM	Phase 2
AZ 3146	+ IC50: ~35 nM	
GSK923295	++ Ki: 3.2 nM	Phase 1
BAY 1217389	+++ IC50: 0.63 nM	Phase 1
MPI-0479605	++ IC50: 1.8 nM	
ARQ 621	√	Phase 1

Microtubule Associated

阻害選択性

Inhibitor Name	Microtubule Associated	Other Targets	Clinical Phase
Paclitaxel	++++ IC50: 0.1 pM		Phase 4
Vincristine sulfate	+ IC50: 32 μM		Phase 4
Patupilone (EPO906, Epothilone B)	+++ EC0.01: 1.8 μM		Phase 3
Lexibulin (CYT997)	++++ IC50: 10 nM-100 nM		Phase 2

阻害選択性

Inhibitor Name	Microtubule Associated	Other Targets	Clinical Phase
Epothilone A	++ EC0.01: 2 μM		
Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium	++ IC50: 2.4 μM		Phase 3
CW069	+ IC50: 75 μM		
Combretastatin A4	+++ Kd: 0.4 μM		Phase 1
CK-636	++ IC50: 4 μM		
Docetaxel	√		Phase 4
ABT-751 (E7010)	√		Phase 2
Nocodazole	√	Abl,Abl (E255K),Abl (T315I)	
Cabazitaxel	√		Phase 4
Albendazole	√		Phase 4
Docetaxel Trihydrate	√		Phase 4
TAI-1	√		
INH6	√		
INH1	√		
Vinorelbine Tartrate	√		Phase 4
Triclabendazole	√		
Griseofulvin	√		Phase 3

Integrin

阻害選択性

Inhibitor Name	Integrin	Clinical Phase
Cilengitide trifluoroacetate	+++ IC50: 4.1 nM	Phase 3
A-205804	++ IC50: 20 nM	
Cyclo(RGDyK)	++ IC50: 20 nM	
SB273005	++++ IC50: 0.3 nM	
RGD (Arg-Gly-Asp) Peptides	√	
Tirofiban	√	Phase 4
Lifitegrast	√	Phase 4
Tirofiban Hydrochloride	√	Phase 2
ATN-161 (Ac-PHSCN-NH2)	√	Phase 2
Cyclo (-RGDfK)	√	Phase 3

PAK

阻害選択性

Inhibitor Name	PAK	PAK1	PAK3	PAK2	PAK4	PAK5	PAK6	Other Targets
IPA-3	+ IC50: 2.5 μM	+ IC50: 2.5 μM						
FRAX1036	++ Ki: 72.4 nM	++ Ki: 23.3 nM		++ Ki: 72.4 nM	+ Ki: 2.4 μM			
FRAX486	+++ IC50: 14 nM	+++ IC50: 14 nM	++ IC50: 39 nM	++ IC50: 33 nM	+ IC50: 575 nM			
FRAX597	++++ IC50: 13 nM	++++ IC50: 8 nM	+++ IC50: 19 nM	++++ IC50: 13 nM				
PF-3758309	++++ IC50: 99 nM	++++ Ki: 13.7 nM	++ IC50: 99 nM	+ IC50: 190 nM	+++ Ki: 18.7 nM	+++ Ki: 18.1 nM	+++ Ki: 17.1 nM	
KPT-9274	√							NAMPT

Dynamin

阻害選択性

Inhibitor Name	Dynamin
Dynasore	++ IC50: ~15 μM
Mdivi-1	+++ IC50: 1 μM-10 μM
Dyngo-4a	++++ IC50: 0.38 μM

注釈：

1.「+」は阻害効果を示す。阻害効果が高い（IC_{50}値が低い）ほど「+」が多く示されている。

2.赤色の「√」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。

Cell Cycle



PD-1/PD-L1

詳細情報はP17に記載されています

Aurora Kinase

詳細情報はP10に記載されています

CDK

阻害選択性

Inhibitor Name	CDK1	CDK2	CDK3	CDK4	CDK5	CDK6	CDK7	CDK9	CLK	CDK	Cdc	CDK8	Other Targets	Clinical Phase
Palbociclib (PD-0332991) HCl				++++ IC50: 9 nM		+++ IC50: 15 nM								Phase 4
Roscovitine (Seliciclib,CYC202)	+ IC50: 0.65 μM	+ IC50: 0.7 μM			++ IC50: 0.16 μM						+ IC50: 0.65 μM		ERK2	Phase 2
SNS-032 (BMS-387032)		+++ IC50: 38 nM			+ IC50: 340 nM		++ IC50: 62 nM	++++ IC50: 4 nM					GSK-3α	Phase 1
Dinaciclib (SCH727965)	++++ IC50: 3 nM	++++ IC50: 1 nM			++++ IC50: 1 nM			++++ IC50: 4 nM						Phase 3
Flavopiridol (Alvocidib)	+++ IC50: 30 nM	+++ IC50: 40 nM		+++ IC50: 20-40 nM		++ IC50: 60 nM	+ IC50: 875 nM	+++ IC50: 20 nM						Phase 2
AT7519	++ IC50: 210 nM	++ IC50: 47 nM	+ IC50: 360 nM	++ IC50: 100 nM	+++ IC50: 13 nM	++ IC50: 170 nM		+++ IC50: <10 nM					GSK-3β	Phase 2

阻害選択性

Inhibitor Name	CDK1	CDK2	CDK3	CDK4	CDK5	CDK6	CDK7	CDK9	CLK	CDK	Cdc	CDK8	Other Targets	Clinical Phase
Flavopiridol HCl	+++ IC50: 40 nM	+++ IC50: 40 nM		+++ IC50: 40 nM		+++ IC50: 40 nM	+ IC50: 300 nM							Phase 2
JNJ-7706621	++++ IC50: 9 nM	++++ IC50: 3 nM	++ IC50: 58 nM	+ IC50: 253 nM		++ IC50: 175 nM							Aurora A,Aurora B, VEGFR2	
AZD5438	+++ IC50: 16 nM	++++ IC50: 6 nM						+++ IC50: 20 nM						Phase 1
MK-8776 (SCH 900776)		++ IC50: 0.16 μM											Chk1	Phase 2
PHA-793887	++ IC50: 60 nM	++++ IC50: 8 nM		++ IC50: 62 nM	++++ IC50: 5 nM		+++ IC50: 10 nM	++ IC50: 138 nM					GSK-3β	Phase 1
BS-181 HCl							+++ IC50: 21 nM							
Palbociclib (PD0332991) Isethionate				++++ IC50: 9 nM		+++ IC50: 15 nM								Phase 4
A-674563		++ Ki: 46 nM											Akt1,PKA,GSK-3β	
abemaciclib mesylate (LY2835219)				++++ IC50: 2 nM		+++ IC50: 10 nM								Phase 2
BMS-265246	++++ IC50: 6 nM	++++ IC50: 9 nM		+ IC50: 230 nM										
PHA-767491	+ IC50: 250 nM	+ IC50: 240 nM			+ IC50: 460 nM			+++ IC50: 34 nM		+++ IC50: 10 nM	+++ IC50: 10 nM		GSK-3β,MK2,PLK1	
Milciclib (PHA-848125)	+ IC50: 398 nM	++ IC50: 45 nM		++ IC50: 160 nM	+ IC50: 265 nM		++ IC50: 150 nM						TrkA	Phase 2
R547	++++ Ki: 2 nM	++++ Ki: 3 nM		++++ Ki: 1 nM										
NU6027	+ Ki: 2.5 μM	+ Ki: 1.3 μM											ATR,DNA-PK	
P276-00	++ IC50: 79 nM	+ IC50: 224 nM		++ IC50: 63 nM		+ IC50: 396 nM	+ IC50: 2.87 μM	+++ IC50: 20 nM					GSK-3β	Phase 2
Atuveciclib (BAY-1143572)								+++ IC50: 13 nM					GSK-3α,GSK3β	Phase 1
Abemaciclib				++++ IC50: 2 nM		+++ IC50: 10 nM								Phase 3
NU2058	+ IC50: 26 μM	+ IC50: 17 μM												
MSC2530818												++++ IC50: 2.6 nM		
Senexin A												+ Kd: 0.83 μM	CDK19	
LY2857785							+ IC50: 0.246 μM	+++ IC50: 0.011 μM				+++ IC50: 0.016 μM		
LDC4297 (LDC044297)							++++ IC50: 0.13 nM							
ON123300				++++ IC50: 3.87 nM		++++ IC50: 9.82 nM							ARK5,PDGFRβ, FGFR1	
Kenpaullone	+ IC50: 0.4μM	+ IC50: 0.68μM			+ IC50: 0.85μM								GSK-3β,ERK2,c-Src	
K03861		++++ Kd: 18.6 nM												
THZ1 2HCl							++++ IC50: 3.2 nM							
AT7519 HCl	++ IC50: 210 nM	++ IC50: 47 nM	+ IC50: 360 nM	++ IC50: 100 nM	+++ IC50: 13 nM	++ IC50: 170 nM		+++ IC50: <10 nM					GSK-3β	Phase 2
Purvalanol A	++++ IC50: 4 nM	+++ IC50: 35 nM		+ IC50: 850 nM								++++ IC50: 4 nM		
Ro-3306	+++ Ki: 20 nM												PKCδ,SGK,ERK	
SU9516	+++ IC50: 40 nM	+++ IC50: 22 nM		++ IC50: 200 nM										
XL413 (BMS-863233)										++++ IC50: 3.4 nM	++++ IC50: 3.4 nM		Pim1,CK2	Phase 2
LDC000067		+ IC50: 2.441 μM						++ IC50: 44 nM						
ML167									++ IC50: 136 nM					
TG003									+++ IC50: 15 nM					
Ribociclib (LEE011)				√										Phase 3
Wogonin								√					N-acetyltransferase	

Chk

阻害選択性

Inhibitor Name	Chk1	Chk2	Other Targets	Clinical Phase
AZD7762	+++ IC50: 5 nM	++ IC50: <10 nM		Phase 1
Rabusertib (LY2603618)	++ IC50: 7 nM			Phase 2
MK-8776 (SCH 900776)	+++ IC50: 3 nM		CDK2	Phase 2
CHIR-124	++++ IC50: 0.3 nM		FLT3,PDGFR,GSK-3	

阻害選択性

Inhibitor Name	Chk1	Chk2	Other Targets	Clinical Phase
PF-477736	++++ Ki: 0.49 nM	+ Ki: 47 nM	VEGFR2,Fms,YES	Phase 1
GDC-0575 (ARRY-575, RG7741)	+++ IC50: 1.2 nM			Phase 1
Chk2 Inhibitor II (BML-277)		+ IC50: 15 nM		
CCT245737	+++ IC50: 1.4 nM			
SAR-020106	+ IC50: 13.3 nM			
Prexasertib HCl (LY2606368)	++++ Ki: 0.9 nM	++ IC50: 8 nM	RSK	Phase 2

ROCK

阻害選択性

Inhibitor Name	ROCK	ROCK1	ROCK2	Other Targets	Clinical Phase
Y-27632 2HCl		++ Ki: 140 nM	+ Ki: 300 nM		
Thiazovivin	+ IC50: ~0.5 μM				
Fasudil (HA-1077) HCl			+ Ki: 330 nM	PKA,PKG,PKC	Phase 3
GSK429286A		+++ IC50: 14 nM	++ IC50: 63 nM		
RKI-1447		+++ IC50: 14.5 nM	+++ IC50: 6.2 nM		
GSK180736A (GSK180736)	++ IC50: 100 nM			GRK2,PKA,GRK5	
Hydroxyfasudil (HA-1100) HCl		+ IC50: 0.73 μM	+ IC50: 0.72 μM	PKA	
Y-39983 HCl	++++ IC50: 3.6 nM				
Netarsudil (AR-13324) 2HCl	++++ Ki: 2 nM			norepinephrine transporter (NET)	Phase 3
GSK269962A HCl		++++ IC50: 1.6 nM	++++ IC50: 4 nM	MSK1,RSK1	
Ripasudil (K-115) hydrochloride dihydrate		++ IC50: 51 nM	+++ IC50: 19 nM		Phase 4
KD025 (SLx-2119)			++ IC50: 60 nM		Phase 2
AT13148		+++ IC50: 6 nM	++++ IC50: 4 nM	PKA,p70S6K,Akt1	Phase 1

PLK

阻害選択性

Inhibitor Name	PLK1	PLK2	PLK3	PLK4	Other Targets	Clinical Phase
BI 2536	++++ IC50: 0.83 nM	++ IC50: 3.5 nM	+ IC50: 9.0 nM			Phase 2
Volasertib (BI 6727)	++++ IC50: 0.87 nM					Phase 3
Rigosertib (ON-01910)	+ IC50: 9 nM	+ IC50: 260 nM			PDGFR,Bcr-Abl,Flt1	Phase 3
GSK461364	+++ Ki: 2.2 nM					Phase 1
MLN0905	+++ IC50: 2 nM					
Ro3280	++ IC50: 3 nM					
CFI-400945				++ IC50: 2.8 nM	TrkA,TrkB,Tie-2	Phase 2
SBE 13 HCl	++++ IC50: 200 pM					
NMS-P937 (NMS1286937)	+++ IC50: 2 nM					Phase 1
HMN-214	√					

APC

阻害選択性

Inhibitor Name	APC
TAME	√

Wee1

阻害選択性

Inhibitor Name	Wee1	Other Targets	Clinical Phase
Adavosertib (MK-1775)	+++ IC50: 5.2 nM		Phase 2
PD0166285	++ IC50: 24 nM	Myt1,Chk1	

Rho

阻害選択性

Inhibitor Name	Rho	Clinical Phase
NSC 23766	+ IC50: 50 μM	
EHop-016	+++ IC50: 1.1 μM	
ZCL278	+ Kd: 11.4 μM	
MBQ-167	+++ IC50: 78 nM	
KRpep-2d	++++ IC50: 1.6 nM	
ARS-853 (ARS853)	++ IC50: 2.5 μM	
Salirasib	++ Ki: 2.6 μM	Phase 2
ML141	+++ IC50: 200 nM	
EHT 1864 2HCl	++++ Kd: 40 nM	
Zoledronic Acid	√	Phase 4
Azathioprine	√	Phase 4
CCG-1423	√	
K-Ras(G12C) inhibitor 9	√	
K-Ras(G12C) inhibitor 6	√	
K-Ras(G12C) inhibitor 12	√	
6H05	√	

DYRK

阻害選択性

Inhibitor Name	DYRK	DYRK1	DYRK2	Other Targets
AZ191		++++ IC50: 17 nM		
Harmine hydrochloride		+++ IC50: 33 nM	++ IC50: 1.9 μM	MNB
ID-8	√			

c-Myc

阻害選択性

Inhibitor Name	c-Myc
10074-G5	+++ Kd: 2.8 μM
10058-F4	√

注釈：

1.各阻害剤の半数阻害濃度（IC_{50}）や作用濃度など、詳細についてはwww.selleck.co.jpのウェブサイトをご覧ください。

2.「+」は阻害効果を示す。阻害効果が高い（IC_{50}値が低い）ほど「+」が多く示されている。

3.赤色の「√」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。

TGF-beta/Smad



Bcr-Abl 詳細情報は**P33**に記載されています

PKC 詳細情報は**P46**に記載されています

ROCK 詳細情報は**P50**に記載されています

TGF-beta/Smad

阻害選択性

Inhibitor Name	ALK1	ALK2	ALK3	ALK4	TGFβRI/ALK5	ALK6	TGFβRII	TGF-β	Smad3	Other Targets	Clinical Phase
SB431542					+ IC50: 94 nM						
LDN-193189		++++ IC50: 5 nM	+++ IC50: 30 nM								
Galunisertib (LY2157299)					++ IC50: 56 nM						Phase 3
LY2109761					++ Ki: 38 nM		+ Ki: 300 nM				
SB525334					+++ IC50: 14.3 nM						
SB505124				+ IC50: 129 nM	++ IC50: 47 nM						
GW788388					+++ IC50: 18 nM						
LY364947					++ IC50: 59 nM		+ IC50: 0.4 μM			RIPK2,CK1δ, MLK-7K	
RepSox					++++ IC50: 4 nM						
LDN-193189 2HCl		++++ IC50: 5 nM	+++ IC50: 30 nM								
K02288	++++ IC50: 1.8 nM	++++ IC50: 1.1 nM	++ IC50: 34.4 nM			++++ IC50: 6.4 nM					
LDN-214117		+++ IC50: 24 nM									
SD-208					++ IC50: 48 nM						
Vactosertib (TEW-7197)				+++ IC50: 13 nM	+++ IC50: 11 nM						Phase 1
ML347	++ IC50: 46 nM	+++ IC50: 32 nM									
LDN-212854	++++ IC50: 2.4 nM	++++ IC50: 1.3 nM	++ IC50: 85.8 nM	+ IC50: 2133 nM	+ IC50: 9276 nM						
DMH1		+ IC50: 107.9 nM									
Pirfenidone								√			Phase 4
Alantolactone									√	STAT3	
SIS3 HCl									√		
Hesperetin								√		Histamine receptor	

注釈：

1.「+」は阻害効果を示す。阻害効果が高い（IC_{50}値が低い）ほど「+」が多く示されている。

2.赤色の「√」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。

DNA Damage



HDAC
詳細情報は**P7**に記載されています

ATM/ATR
詳細情報は**P5**に記載されています

PARP
詳細情報は**P8**に記載されています

Sirtuin
詳細情報は**P11**に記載されています

DNA-PK
詳細情報は**P6**に記載されています

Topoisomerase

阻害選択性

Inhibitor Name	Topoisomerase	Topo I	Topo II	Topo IV	Other Targets	Clinical Phase
Camptothecin		++ IC50: 0.68 μM				Phase 2
Topotecan HCl		++++ IC50: 2 nM				Phase 4
Idarubicin HCl			+++ IC50: 3.3 ng/mL		Multicellular spheroids	Phase 4
Daunorubicin HCl	+++ Ki: 20 nM					Phase 4
Betulinic acid		++ IC50: 5 μM			HIV-1,Aminopeptidase N	Phase 2
Flumequine			+ IC50: 15 μM			
Doxorubicin (Adriamycin) HCl			√			Phase 4
Etoposide			√			Phase 4
Epirubicin HCl	√					Phase 4
Mitoxantrone 2HCl			√			Phase 4
Moxifloxacin HCl			√			Phase 4
Irinotecan HCl Trihydrate		√				Phase 4
SN-38		√				Phase 2
Amonafide			√			Phase 3
Teniposide			√			Phase 4
Gatifloxacin	√					Phase 4

阻害選択性

Inhibitor Name	Topoisomerase	Topo I	Topo II	Topo IV	Other Targets	Clinical Phase
Dexrazoxane HCl (ICRF-187, ADR-529)			√			Phase 3
Genistein			√		EGFR	Phase 4
Levofloxacin			√			Phase 4
Pirarubicin			√			Phase 4
Ciprofloxacin				√		Phase 4
Marbofloxacin			√			
Novobiocin Sodium			√			
Enoxacin			√			
Ofloxacin			√			Phase 4
Nalidixic acid			√			
Ellagic acid		√				Phase 2
Beta-Lapachone		√			IDO1	Phase 2
Clinafloxacin				√		
Levofloxacin hydrate			√			
Voreloxin (SNS-595) hydrochloride			√			Phase 3
Pefloxacin Mesylate Dihydrate			√			
(S)-10-Hydroxycamptothecin		√				Phase 1

Telomerase

阻害選択性

Inhibitor Name	Telomerase	Other Targets
BIBR 1532	+++ IC50: 100 nM	
Costunolide	++ IC50: 65 μM	FPTase
RHPS 4 methosulfate	√	

MTH1

阻害選択性

Inhibitor Name	MTH1
TH287	++++ IC50: 0.8 nM
TH588	+++ IC50: 5 nM
(S)-crizotinib	++ IC50: 72 nM

注釈:

1.各阻害剤の半数阻害濃度（IC_{50}）や作用濃度など、詳細についてはwww.selleck.co.jpのウェブサイトをご覧ください。

2.「+」は阻害効果を示す。阻害効果が高い（IC_{50}値が低い）ほど「+」が多く示されている。

3.赤色の「√」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。

Stem Cells & Wnt



GSK-3
詳細情報はP4に記載されています

JAK
詳細情報はP9に記載されています

STAT
詳細情報はP41に記載されています

TGF-beta/Smad
詳細情報はP52に記載されています

Wnt/beta-catenin
詳細情報はP45に記載されています

ROCK
詳細情報はP50に記載されています

Gamma-secretase

阻害選択性

Inhibitor Name	γ secretase	Aβ	Notch	Other Targets	Clinical Phase
DAPT (GSI-IX)		+ IC50: 20 nM			Phase 4
RO4929097	+++ IC50: 4 nM		+++ IC50: 5 nM	Aβ40	Phase 2
Semagacestat (LY450139)		++ IC50: 10.9 nM	++ IC50: 14.1 nM		Phase 3
Avagacestat (BMS-708163)		++++ IC50: 0.27 nM			Phase 2
Dibenzazepine (YO-01027)	+++ IC50: 2.6 nM		+++ IC50: 2.9 nM		
LY411575	++++ IC50: 0.078 nM		++++ IC50: 0.39 nM		
IMR-1			+ IC50: 26 μM		
L-685,458	++ Ki: 17 nM				

阻害選択性

Inhibitor Name	γ secretase	Aβ	Notch	Other Targets	Clinical Phase
FLI-06			+ EC50: 2.3 μM		
Crenigacestat (LY3039478)			++++ IC50: ~1 nM		Phase 2
Nirogacestat (PF-03084014, PF-3084014)	++ IC50: 6.2 nM				Phase 2
MK-0752		√		Aβ	Phase 2
NGP 555	√				Phase 1

Hedgehog/Smoothened

阻害選択性

Inhibitor Name	Hedgehog	Smoothened	GLI	Other Targets	Clinical Phase
Vismodegib (GDC-0449)	+++ IC50: 3 nM				Phase 4
Cyclopamine		++ IC50: 46 nM			
Sonidegib (Erismodegib, NVP-LDE225)		++++ IC50: 1.3 nM			Phase 3
PF-5274857		+++ IC50: 5.8 nM			
GANT61			+ IC50: 5 μM		
SANT-1		++++ Kd: 1.2 nM			
Glasdegib (PF-04449913)		++ IC50: 5 nM			Phase 3
Taladegib (LY2940680)		√			Phase 2
BMS-833923		√			Phase 2
Jervine	√			Shh	
HPI-4 (Ciliobrevin A)	√				
MK-4101		√			

Casein Kinase

阻害選択性

Inhibitor Name	CK1	CK2	Other Targets	Clinical Phase
Silmitasertib (CX-4945)		++++ IC50: 1 nM		Phase 2
TBB		+ Ki: 0.4 μM	CK1	
Ellagic Acid hydrate		+++ IC50: 0.04 μM	Lyn,PKA	
D 4476	++ IC50: 200 nM		ALK5	

Hippo pathway

阻害選択性

Inhibitor Name	YAP/TEAD interaction	MST1	MST2	Other Targets	Clinical Phase
XMU-MP-1		++ IC50: 71.1 nM	+++ IC50: 38.1 nM		
YAP-TEAD Inhibitor 1 (Peptide 17)	++++ IC50: 25 nM				
Verteporfin	√			VDA	Phase 4
Super-TDU	√				

注釈:

1.各阻害剤の半数阻害濃度（IC_{50}）や作用濃度など、詳細についてはwww.selleck.co.jpのウェブサイトをご覧ください。

2.「+」は阻害効果を示す。阻害効果が高い（IC_{50}値が低い）ほど「+」が多く示されている。

3.赤色の「√」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。

Ubiquitin



Proteasome

阻害選択性

Inhibitor Name	Proteasome	20S proteasome	Clinical Phase
Bortezomib (PS-341)		++++ Ki: 0.6 nM	Phase 4
MG-132		+ IC50: 100 nM	
Carfilzomib (PR-171)	+++ IC50: 5 nM		Phase 4
Ixazomib Citrate (MLN9708)		+++ IC50: 3.4 nM	Phase 3
Ixazomib (MLN2238)		++++ IC50: 3.4 nM	
ONX-0914 (PR-957)		++ IC50: ~10 nM	
Oprozomib (ONX 0912)		++ IC50: 36 nM	Phase 2
Delanzomib (CEP-18770)		+++ IC50: 3.8 nM	Phase 2
Celastrol		+ IC50: 2.5 μM	
VR23	++++ IC50: 1 nM		
PI-1840		++ IC50: 27 nM	
Epoxomicin		√	

DUB

阻害選択性

Inhibitor Name	DUB	USP/UBP	UCH	Other Targets	Clinical Phase
PR-619		++ EC50: 7.20 μM	+++ EC50: 2.95 μM	JOSD2,SENP6 core,DEN1	
P5091 (P005091)		++ IC50: 4.3 μM			
TCID			+++ IC50: 0.6 μM		Phase 1

阻害選択性

Inhibitor Name	DUB	USP/UBP	UCH	Other Targets	Clinical Phase
LDN-57444			++++ IC50: 0.88 μM		
IU1		++ IC50: 4.7 μM			
P22077		+ IC50: 8.6 μM			
VLX1570	+ IC50: ~10 μM				Phase 2
ML323	++++ IC50: 76 nM				
b-AP15			+++ IC50: 2.1 μM		
Degrasyn (WP1130)	√			Bcr-Abl	

E3 Ligase

阻害選択性

Inhibitor Name	E3 Ligase	CRBN	Other Targets	Clinical Phase
Nutlin-3	+++ IC50: 180 nM			
JNJ-26854165 (Serdemetan)	√		p53	Phase 1
Thalidomide	√		TNF-alpha	Phase 4
TAME	√			
Tenovin-1	√		p53	
RITA (NSC 652287)	√		p53	Phase 2
Avadomide(CC-122)		√		Phase 2

p97

阻害選択性

Inhibitor Name	p97	Other Targets	Clinical Phase
NMS-873	++++ IC50: 30 nM		
DBeQ	+++ IC50: 1.5 μM		
MNS (3,4-Methylenedioxy-β-nitrostyrene, MDBN)	++ IC50: 1.7 μM	Syk,Src	Phase 2

E1 Activating

阻害選択性

Inhibitor Name	E1 Activating
PYR-41	+++ IC50: <10 μM

E2 conjugating

阻害選択性

Inhibitor Name	E2 conjugating	Other Targets
BAY 11-7082	√	IkBα phosphorylation
NSC697923	√	

注釈:

1.各阻害剤の半数阻害濃度（IC_{50}）や作用濃度など、詳細についてはwww.selleck.co.jpのウェブサイトをご覧ください。

2.「+」は阻害効果を示す。阻害効果が高い（IC_{50}値が低い）ほど「+」が多く示されている。

3.赤色の「√」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。

Neuronal Signaling



COX

詳細情報はP18に記載されています

Gamma-secretase

詳細情報はP55に記載されています

Histamine Receptor

詳細情報はP19に記載されています

Beta Amyloid

阻害選択性

Inhibitor Name	Beta Amyloid	Other Targets	Clinical Phase
DAPT (GSI-IX)	++ IC50: 20 nM		Phase 4
RO4929097	+++ IC50: 14 nM	γ secretase,γ secretase(ICN)	Phase 2
MK-0752	+++ IC50: 5 nM		Phase 2
Avagacestat (BMS-708163)	++++ IC50: 0.27 nM		Phase 2
LY2811376	+ EC50: ~300 nM	BACE1	Phase 1
Tabersonine hydrochloride	√		
EUK 134	√		

5-HT Receptor

阻害選択性

Inhibitor Name	5-HT	5-HT1	5-HT2	5-HT3	5-HT4	5-HT6	5-HT7	5-HT5	Other Targets	Clinical Phase
Ketanserin			+++ Ki: 2.5 nM							Phase 4
RS-127445			++++ pIC50: 10.4							
Asenapine maleate		+++ pKi: 8.4	++++ pKi: 9.75			++++ pKi: 9.6	++++ pKi: 9.94	+++ pKi: 8.84	α2B-adrenergic receptor, D3 receptor,H1 receptor	Phase 4
WAY-100635 Maleate	+++ IC50: 0.95 nM									
Risperidone		++ Ki: 14.9 nM	++++ Ki: 0.17 nM				++ Ki: 6.6 nM	+ Ki: 206 nM	α2c-adrenergic receptor, D2 receptor,D3 receptor	Phase 4
Vortioxetine (Lu AA21004) HBr		++ Ki: 15 nM		+++ Ki: 3.7 nM			++ Ki: 19 nM		SERT	Phase 4
Blonanserin			++ Ki: 3.98 nM						dopamine D2 receptor	Phase 3
BMY 7378 Dihydrochloride		++ pIC50: 5.9	+ pIC50: 5.5						α1D-adrenoceptor,Dopamine D2 receptor,α2C-adrenoceptor	
PRX-08066 Maleic acid			+++ IC50: 3.4 nM							Phase 2
SB742457						++++ pKi: 9.63				Phase 2
SB269970 HCl							++ pKi: 8.3			
BRL-15572(dihydrochloride)		++ pKi: 5.2	+ pKi: 6.6			+ pKi: 5.9	+ pKi: 6.3			
Desvenlafaxine	+ Ki: 40.2 nM								Norepinephrine (NE)	Phase 4

阻害選択性

Inhibitor Name	5-HT	5-HT1	5-HT2	5-HT3	5-HT4	5-HT6	5-HT7	5-HT5	Other Targets	Clinical Phase
Sertraline HCl	++ Ki: 13 nM									Phase 4
Lamotrigine	+ IC50: 240 μM								Sodium channel	Phase 4
Escitalopram Oxalate	+++ Ki: 0.89 nM									Phase 4
Azasetron HCl				++++ IC50: 0.33 nM						
Loxapine Succinate			++ Ki: 6.6 nM						D4 receptor (human),D2 receptor (Human), D2 receptor (bovine)	Phase 4
SB 271046 hydrochloride						+++ pKi: 8.92				
Amitriptyline HCl			+ IC50: 235 nM		++ IC50: 7.31 nM				Serotonin receptor,Norepinephrine receptor, Sigma 1 receptor	Phase 4
Palonosetron				++++ Ki: 0.17 nM						
Iurasidone		++ Ki: 6.4 nM	++++ Ki: 0.5 nM				++++ Ki: 0.5 nM		D2 receptor	Phase 4
Tropisetron				++ Ki: 5.3 nM					α7 nAChR	Phase 4
Perospirone hydrochloride		+++ Ki: 2.9 nM	+++ Ki: 0.61 nM						D2 receptor	
Ramosetron Hydrochloride				++++ Ki: 0.091 nM						Phase 3
Flibanserin		+++ Ki: 1 nM	+ Ki: 49 nM						D4 receptor	Phase 4
Sarpogrelate hydrochloride			++++ Kd: 0.2 nM							Phase 3
Citalopram HBr	+++ IC50: 1.8 nM									Phase 3
Ondansetron Hydrochloride Dihydrate				+ IC50: 810 nM						Phase 1
Cyproheptadine hydrochloride sesquihydrate			+++ IC50: 0.6 nM						SETD7/9	
Pimavanserin			+++ pIC50: 8.7							Phase 3
Desvenlafaxine Succinate	+ Ki: 40.2 nM								Norepinephrine (NE)	Phase 4
VUF 10166				++++ Ki: 0.04 nM						
Atomoxetine HCl	+ Ki: 77 nM								Norepinephrine (NE) transporter, DA transporter	Phase 4
LY310762 HCl		+ Ki: 249 nM								
Olanzapine			√						D2 receptor	Phase 4
Clozapine			√							Phase 4
Fluoxetine HCl	√									Phase 4
Latrepirdine 2HCl	√								Histamine receptor,GluR	Phase 3
Agomelatine			√							Phase 4
Venlafaxine HCl	√									Phase 4
Paroxetine HCl	√								AChR	Phase 4
Dapoxetine HCl	√									Phase 4
Ziprasidone HCl	√								Dopamine receptor	Phase 4
Iloperidone	√									Phase 4
Mirtazapine	√									Phase 4
Granisetron HCl				√						Phase 4
Fluvoxamine maleate	√									Phase 4
Clomipramine HCl	√									Phase 4
Tropisetron HCl				√						Phase 4
Ondansetron HCl				√						Phase 4
Duloxetine HCl	√									Phase 4
Ondansetron				√						Phase 4
Nafronyl oxalate salt			√							
Duloxetine	√								norepinephrine reuptake	
Granisetron				√						Phase 4
Alosetron Hydrochloride				√						Phase 2
Cyclobenzaprine HCl			√							Phase 4
Palonosetron HCl				√						Phase 4
Trazodone HCl	√									Phase 4

GluR

阻害選択性

Inhibitor Name	NMDA receptor	AMPA receptor	mGluR5	GluR	Other Targets	Clinical Phase
(-)-Huperzine A (HupA)				+++ Ki: 7 nM		
CTEP (RO4956371)			++++ IC50: 2.2 nM			

阻害選択性

Inhibitor Name	NMDA receptor	AMPA receptor	mGluR5	GluR	Other Targets	Clinical Phase
IEM 1754 2HBr		+ IC50: 6 μM				
MPEP			++ IC50: 36 nM			
Riluzole	√				Sodium channel,Glutamate release	Phase 4
Latrepirdine 2HCl				√	5-HT,Histamine receptor	Phase 3
Evans Blue		√			vesicular glutamate uptake	

Adrenergic Receptor

阻害選択性

Inhibitor Name	Adrenergic Receptor	α-adrenergic receptor	β-adrenergic receptor	Other Targets	Clinical Phase
Asenapine maleate		++++ pKi: 8.9		5-HT2C,5-HT2A,5-HT7	Phase 4
Nebivolol HCl			+++ IC50: 0.8 nM		Phase 4
BMY 7378 Dihydrochloride		+++ pKi: 6.54	+ pIC50: 5.1	5-HT1A,Dopamine D2 receptor, 5-HT1C	
Propranolol HCl			++ IC50: 12 nM		Phase 4
Naftopidil		+++ Ki: 1.2 nM			Phase 4
Naftopidil DiHCl		++ IC50: 0.2 μM		5-HT1A	
Timolol Maleate			+++ Ki: 1.97 nM		Phase 4
Betaxolol HCl			+ IC50: 6 μM		Phase 3
Rauwolscine hydrochloride		++ Ki: 12 nM			
Atenolol			+ Kd: 0.25 μM		Phase 4
Piribedil		++ pKi: 7.1		D3 receptor,D2 receptor	Phase 3
Tamsulosin hydrochloride		++++ Ki: 0.18 nM			Phase 4
ICI-118551 Hydrochloride			++++ Ki: 0.7nM		
Levobetaxolol HCl			++++ Ki: 0.76 nM		Phase 3
Doxazosin Mesylate		√			Phase 2
Alfuzosin HCl		√			Phase 4
Silodosin		√			Phase 4
Phentolamine Mesylate		√			Phase 3
Prazosin HCl		√			Phase 4
Bisoprolol fumarate			√		Phase 4
Terazosin HCl Dihydrate		√			Phase 4
Metoprolol Tartrate			√		Phase 4
Carvedilol		√			Phase 4
Maprotiline HCl	√				Phase 3
Sotalol HCl			√	Potassium channel	Phase 4
Phenoxybenzamine HCl		√			Phase 4
Acebutolol HCl			√		Phase 4
Metroprolol succinate			√		Phase 4
Landiolol hydrochloride			√		
Metoprolol			√		Phase 4
Dapiprazole Hydrochloride	√				
Atipamezole		√			
Atipamezole hydrochloride		√			
Labetalol HCl		√			Phase 4
Carteolol HCl			√		Phase 4
Tolazoline HCl		√			
Esmolol HCl			√		Phase 4
Cisatracurium Besylate	√				Phase 4
Betaxolol			√		Phase 3
Ivabradine HCl	√				Phase 4
Yohimbine HCl		√			Phase 4

AChR

阻害選択性

Inhibitor Name	AChR	mAChR	nAChR	AChE	Other Targets	Clinical Phase
Donepezil HCl				+++ IC50: 8.12 nM		Phase 4
(-)-Huperzine A (HupA)				++++ Ki: 7 nM		
PNU-120596			++ EC50: 216 nM			
Galanthamine HBr				++ IC50: 0.35 μM		
Atropine sulfate monohydrate		++++ IC50: 2.5 nM				Phase 4
Aclidinium Bromide		++++ Ki: 0.16 nM				Phase 4
Scopolamine HBr		+++ IC50: 55.3 nM				Phase 4
Rivastigmine Tartrate	+ IC50: 5.5 μM					Phase 4
5-hydroxymethyl Tolterodine		++++ Kb: 0.84 nM				
Gallamine Triethiodide	+ IC50: 68.0 μM					
Darifenacin HBr		++++ pKi: 8.9				Phase 4
Jatrorrhizine chloride				++ IC50: 872 nM		
Tropisetron			++++ Ki: 6.9 nM		5-HT3 receptor	Phase 4
Donepezil				++++ IC50: 6.7 nM		Phase 4
Acotiamide				++ IC50: 3 μM		
Jatrorrhizine				++ IC50: 872 nM		
Palmatine				++ IC50: 0.51 μM	BChE	
Loganin				+ IC50: 3.95 μM	BChE,BACE1	
Itopride hydrochloride				++ IC50: 2.04 μM	dopamine D2-receptor	Phase 3
Vinblastine sulfate			+ IC50: 8.9 μM			Phase 4
Benzethonium Chloride			+++ IC50: 49 nM			
Flavoxate HCl		+ IC50: 12.2 μM				Phase 4
Homatropine Bromide		+++ IC50: 162.5 nM				
Homatropine Methylbromide		+++ IC50: 162.5 nM				
Procaine HCl			+ IC50: 45.5 μM		5-HT3,Sodium channel, NMDA receptor	Phase 4
Hyoscyamine	+++ IC50: 7.5 nM					
Tropicamide		+++ IC50: 8 nM				Phase 4
Tiotropium Bromide hydrate	√					Phase 4
Fesoterodine Fumarate	√					Phase 4
Tolterodine tartrate	√					Phase 4
Pancuronium dibromide	√					
Paroxetine HCl	√				5-HT	Phase 4
Amfebutamone (Bupropion) HCl	√				Dopamine receptor	Phase 4
Oxybutynin	√					Phase 4
Solifenacin succinate		√				Phase 4
Trospium chloride	√					Phase 4
Ipratropium Bromide		√				Phase 4
Methscopolamine		√				
Rocuronium Bromide	√					Phase 4
Otilonium Bromide		√				Phase 4
Irsogladine	√				PDE	Phase 1
Pyridostigmine Bromide	√					Phase 4
Neostigmine Bromide	√					Phase 4
Huperzine B				√		
Revefenacin		√				Phase 3
Dehydroevodiamine hydrochloride				√		
Umeclidinium bromide		√				Phase 3
Diphenidol HCl		√				Phase 4
Pentoxyverine Citrate		√				Phase 1
Hexamethonium Dibromide	√				Dopamine subtype 2 receptor	
Diphemanil Methylsulfate		√				
Catharanthine			√			
Oxybutynin hydrochloride		√				Phase 4
Orphenadrine Citrate	√					Phase 4

Dopamine Receptor

阻害選択性

Inhibitor Name	D1 receptor	D2 receptor	D3 receptor	D5 receptor	DAT	Dopamine receptor	D4 receptor	Other Targets	Clinical Phase
Benztropine mesylate					++ IC50: 118 nM				Phase 4
Trifluoperazine 2HCl		++++ IC50: 1.1 nM							
Chlorprothixene	+++ Ki: 18 nM	++++ Ki: 2.96 nM	+++ Ki: 4.56 nM	+++ Ki: 9 nM				5-HT6,H1 receptor,5-HT7	Phase 3
Lurasidone HCl		++++ IC50: 1.68 nM						5-HT7,5-HT2A,5-HT1A	Phase 4
Loxapine Succinate	+++ Ki: 24 nM	+++ Ki: 24 nM					+++ Ki: 7.5 nM	5-HT2 (human), 5-HT2 (bovine)	Phase 4
lurasidone		++++ Ki: 1 nM						5-HT7 receptor,5-HT2A, 5-HT1A receptor	Phase 4
Perospirone hydrochloride		++++ Ki: 1.4 nM						5-HT2 receptor, 5HT1A receptor	
Tetrahydroberberine		++ pKi: 6.08						5-HT1A	
Penfluridol	+ Ki: 1.6 μM					+ Ki: 1.6 μM			
Ropinirole HCl		++ Ki: 29 nM							Phase 4
Rotundine	++ IC50: 166 nM	+ IC50: 1.47 μM	+ IC50: 3.25 μM					5-HT1A	
Olanzapine		√						5-HT2	Phase 4
Quetiapine Fumarate						√		Adrenergic Receptor, Histamine receptor	Phase 4
Chlorpromazine HCl						√		Potassium channel	Phase 4
Amfebutamone (Bupropion) HCl						√		AChR	Phase 4
Ziprasidone HCl						√		5-HT receptor	Phase 4
Domperidone		√							Phase 4
Paliperidone						√			Phase 4
Amisulpride						√			Phase 4
Phenothiazine		√							
Levosulpiride		√							Phase 3
Molindone hydrochloride		√							
Sulpiride		√							Phase 4
Prochlorperazine dimaleate salt		√							Phase 4
Metoclopramide HCl		√							Phase 4
Alizapride HCl						√			Phase 4
Azaperone						√			

Opioid Receptor

阻害選択性

Inhibitor Name	δ-opioid receptor	κ-opioid receptor	μ-opioid receptor	ORL1	Opioid receptor	Clinical Phase
JTC-801				+ IC50: 94 nM		
Naltrexone HCl			+++ IC50: 8 nM		+++ IC50: 8 nM	Phase 4
Alvimopan dihydrate (LY246736 dihydrate)	+++ Ki: 4.4 nM	++ Ki: 40 nM	++++ Ki: 0.77 nM			
Naloxone HCl					√	Phase 4
Racecadotril					√	Phase 4

GABA Receptor

阻害選択性

Inhibitor Name	GABA receptor	GABAA receptor	Other Targets	Clinical Phase
(+)-Bicuculline		+++ IC50: 2 μM		
Ginkgolide A	++ Ki: 14.5 μM			
Valproic acid sodium salt (Sodium valproate)	√		Autophagy,HDAC	Phase 4
Flumazenil		√		Phase 4
Niflumic acid	√		COX-2	
Securinine	√			
Thiocolchicoside		√		Phase 4
Homotaurine	√			Phase 3
Pentylenetetrazol	√			Phase 2
Bemegride		√		

P-gp

阻害選択性

Inhibitor Name	P-gp	Other Targets	Clinical Phase
Zosuquidar (LY335979) 3HCl	++ Ki: 60 nM		Phase 3
Tariquidar	+++ Kd: 5.1 nM		Phase 3
Elacridar (GF120918)	√	BCRP	
SC144	√		
Schisandrin B (Sch B)	√	ATR	

P2 Receptor

阻害選択性

Inhibitor Name	P2 receptor	P2X receptor	P2Y receptor	Clinical Phase
MRS 2578			++ IC50: 37 nM	
Ticagrelor			++++ Ki: 2 nM	Phase 4
Ticlopidine HCl	+ IC50: ~2 μM			Phase 4
A-804598		+++ IC50: 9 nM		
A-317491		+++ Ki: 9 nM		
A-438079 HCl		++ pIC50: 6.9		
Prasugrel			√	Phase 4
Clopidogrel			√	Phase 4
Cangrelor Tetrasodium			√	Phase 4
Prasugrel Hydrochloride			√	

OX Receptor

阻害選択性

Inhibitor Name	OX1 receptor	OX2 receptor	Clinical Phase
Almorexant HCl	+++ IC50: 6.6 nM	++++ IC50: 3.4 nM	Phase 3
SB408124	++ Ki: 27 nM		
SB-334867	√		

BACE

阻害選択性

Inhibitor Name	BACE	Other Targets	Clinical Phase
LY2886721	+++ IC50: 10.2 nM		Phase 2
LY2811376	++ IC50: 239 nM-249 nM	Aβ	Phase 1
Loganin	+ IC50: 47.97 μM		
Verubecestat (MK-8931)	++++ Ki: 0.37 nM		Phase 3
Lanabecestat（AZD3293, LY3314814）	+++ Ki: 0.4 nM		Phase 1
Verubecestat (MK-8931) Trifluoroacetat	++++ Ki: 0.37 nM		Phase 3
AZD3839	++ Ki: 26.1 nM		Phase 1

Substance P

阻害選択性

Inhibitor Name	Substance P	Other Targets
Aprepitant	+++ IC50: 0.1 nM	Phase 4
Netupitant	√	Phase 3

NMDAR

阻害選択性

Inhibitor Name	NMDA receptor	Other Targets	Clinical Phase
(-)-MK 801 maleate	++++ Ki: 30.5 nM		
(+)-MK 801 maleate	+++ Kd: 37.2 nM		
Ifenprodil Tartrate	+++ IC50: 0.3 μM		Phase 2
Procaine HCl	++ IC50: 0.296 mM	5-HT3,nAChR,Sodium channel	Phase 4
Felbamate	+ IC50: 1.8 mM		Phase 2
Tiletamine Hydrochloride	√		
6-Methoxy-2-naphthoic acid	√		
Mephenesin	√		
Linalool	√		
Spermidine trihydrochloride	√	Autophagy	
Kynurenic acid	√	glutamate receptors,α7 nicotinic acetylcholine receptor	Phase 1

CaMK

阻害選択性

Inhibitor Name	CaMKII	CaMKIII	CaMKKα	CaMKKβ	Other Targets
NH125		+++ IC50: 60 nM			
STO-609			+++ Ki: 0.25 μM	++++ Ki: 47 nM	
KN-62	+ Ki: 0.9 μM				CaMKⅠ,P2RX7,CaMKⅣ
KN-93 Phosphate	++ Ki: 0.37 μM				

GlyT

阻害選択性

Inhibitor Name	GlyT1	GlyT2	Other Targets	Clinical Phase
Amoxapine	++ IC50: 1 mM	+++ IC50: 92 μM		
Bitopertin	++++ IC50: 22 nM			Phase 3
Sarcosine	√		N-methyl-D-aspartate receptor,GlyR	Phase 2

注釈：

1.各阻害剤の半数阻害濃度（IC_{50}）や作用濃度など、詳細についてはwww.selleck.co.jpのウェブサイトをご覧ください。

2.「+」は阻害効果を示す。阻害効果が高い（IC_{50}値が低い）ほど「+」が多く示されている。

3.赤色の「√」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。

NF-κB



HDAC

詳細情報はP7に記載されています

NF-κB

阻害選択性

Inhibitor Name	NF-κB	Other Targets	Clinical Phase
QNZ (EVP4593)	++++ IC50: 11 nM	TNF-α	
JSH-23	+ IC50: 7.1 μM		
CBL0137 (CBL-0137)	++ EC50: 0.47 μM	FACT,p53	Phase 1
SC75741	+++ EC50: 200 nM		
Curcumin	√	HDAC,Nrf2,p300 histone acetylatransferase	Phase 4
Sodium 4-Aminosalicylate	√		
Caffeic Acid Phenethyl Ester	√		Phase 4
Sodium salicylate	√		Phase 1
Pyrrolidinedithiocarbamate ammonium	√		Phase 3
(-)-Parthenolide	√	p53,MDM2 ubiquitination,HDAC1	
Andrographolide	√		Phase 4

IκB/IKK

阻害選択性

Inhibitor Name	IκB	IKK	Other Targets	Clinical Phase
BAY 11-7082	++ IC50: 10 μM		E2-conjugating enzymes	
IKK-16 (IKK Inhibitor VII)		+++ IC50: 40 nM		
TPCA-1		++++ IC50: 17.9 nM		
BMS-345541		++ IC50: 0.3 μM		
SC-514		++ IC50: 3 μM-12 μM	CDK2/CyclinA,AUR2,PRAK	

阻害選択性

Inhibitor Name	IκB	IKK	Other Targets	Clinical Phase
Bay 11-7085	++ IC50: 10 μM			
Rosmarinic acid		+ IC50: 12 μM		Phase 4
MRT67307 HCl		+++ IC50: 160 nM		
PS-1145		+++ IC50: 88 nM		
LY2409881		++++ IC50: 30 nM		
IMD 0354		√		
Bardoxolone Methyl		√	NF-κB,Nrf2	Phase 3
Mesalamine		√		Phase 4
Dehydrocostus Lactone		√		Phase 2
AZD3264		√		
WS6		√	EBP1	
WS3		√	EBP1	

NOD1

阻害選択性

Inhibitor Name	NOD1
ML130 (Nodinitib-1)	+++ IC50: 0.56 μM

注釈:

1.各阻害剤の半数阻害濃度 (IC_{50}) や作用濃度など、詳細についてはwww.selleck.co.jpのウェブサイトをご覧ください。

2.「+」は阻害効果を示す。阻害効果が高い（IC_{50}値が低い）ほど「+」が多く示されている。

3.赤色の「√」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。

Metabolism



HSP (e.g. HSP90)

詳細情報は**P40**に記載されています

Casein Kinase

詳細情報は**P56**に記載されています

PPAR

阻害選択性

Inhibitor Name	PPARα	PPARβ/δ	PPARγ	PPARδ	Other Targets	Clinical Phase
GW9662	+++ IC50: 32 nM		+++ IC50: 3.3 nM			
T0070907			++++ IC50: 1 nM			
GSK3787		++ pIC50: 6.6		++ pIC50: 6.6		
Harmine			√		MAO-A	
Fenofibric acid	√					Phase 4
FH535			√		Wnt/β-catenin	

P450 (e.g. CYP17)

阻害選択性

Inhibitor Name	CYP1	CYP2	CYP3	CYP17	P450	Other Targets	Clinical Phase
Abiraterone				++++ IC50: 2 nM			Phase 4
Abiraterone Acetate				+++ IC50: 72 nM			Phase 4
Avasimibe	+ IC50: 13.9 μM	+ IC50: 2.9 μM				ACAT	
Ketoconazole					+ IC50: 0.19 mM	Testosterone 6 beta-hydroxylase	Phase 4
Itraconazole			++++ IC50: 6.1 nM				Phase 4
TAK-700 (Orteronel)					+++ 20-lyase (Rat)		Phase 3
Galeterone				++ IC50: 300 nM		Androgen Receptor	Phase 3
Cobicistat (GS-9350)			++ IC50: 30 nM-285 nM				Phase 4
Ozagrel					++++ IC50: 11 nM		Phase 4
Ozagrel HCl					++++ IC50: 11 nM		Phase 4
Alizarin	++ IC50: 2.7 μM						
7-Hydroxyflavone	+++ Ki: 0.015 μM						
Diallyl sulfide		+ IC50: 17.3 μM					
Sulfaphenazole		++ Ki: 0.3 μM					
Benzbromarone		+++ Ki: 19.3 nM					Phase 4
PF-4981517			+++ IC50: 30 nM				
Apigenin		++ Ki: 2 μM					
Ritonavir			√			HIV	Phase 4
Posaconazole			√			lanosterol 14α-demethylase	Phase 4
Voriconazole					√		Phase 4
Fluconazole					√		Phase 4
Clarithromycin			√				Phase 4
Thiabendazole	√						
Methoxsalen		√				CYP2A5	Phase 4
Acetylshikonin					√		
Gentiopicroside		√					
Sodium Danshensu					√		
Naringenin	√						Phase 1
Diosmetin	√						
Piperine			√				Phase 2
Naringin					√		
Baicalein		√					

PDE

阻害選択性

Inhibitor Name	PDE	PDE1	PDE2	PDE3	PDE4	PDE5	PDE6	PDE10A	Other Targets	Clinical Phase
Roflumilast					++++ IC50: 0.7 nM					Phase 4
Sildenafil Citrate						+++ IC50: 3.5 nM	+++ IC50: 33 nM			Phase 4
Cilomilast					+++ IC50: 100 nM					Phase 3
Tadalafil						++++ IC50: 1.8 nM				Phase 4
Vardenafil HCl Trihydrate						++++ IC50: 0.7 nM				Phase 4
Pimobendan				++ IC50: 0.32 μM						
GSK256066					++++ IC50: 3.2 pM					Phase 2
Mardepodect (PF-2545920)								++++ IC50: 0.37 nM		
Rolipram					++ IC50: 130 nM				PDE4D	Phase 2
Cilostazol				++ IC50: 0.2 μM						Phase 4
Milrinone			++ IC50: 5.2 μM	++ IC50: 2.1 μM					ATPase	Phase 4
Avanafil						++++ IC50: 1 nM				Phase 4
S- (+)-Rolipram					++ IC50: 0.75 μM					
Aminophylline	+ IC50: 0.12 mM								adenosine receptor	Phase 4
Fenspiride HCl				+ pIC50: 3.44	+ pIC50: 4.16					

阻害選択性

Inhibitor Name	PDE	PDE1	PDE2	PDE3	PDE4	PDE5	PDE6	PDE10A	Other Targets	Clinical Phase
Ibudilast			+++ IC50: 0.11 μM		+++ IC50: 0.08 μM	++ IC50: 2.2 μM				
TAK-063								++++ IC50: 0.3 nM		Phase 2
Sildenafil						+++ IC50: 5.22 nM				Phase 4
PF-8380	++++ IC50: 2.8 nM									
Deltarasin	+++ Kd: 38 nM									
Luteolin		+ Ki: 15.0 μM	+ Ki: 6.4 μM	+ Ki: 13.9 μM	+ Ki: 11.1 μM	+ Ki: 9.5 μM				Phase 2
Icariin						++ IC50: 0.432 μM				Phase 3
Anagrelide HCl	√									Phase 4
Irsogladine	√								mAChR,AChR	Phase 1
Doxofylline	√									Phase 4
Dipyridamole	√									Phase 4
Dyphylline	√									
Crisaborole (AN2728)					√					
Sildenafil Mesylate						√				

Hydroxylase

阻害選択性

Inhibitor Name	Hydroxylase	Clinical Phase
Nepicastat (SYN-117) HCl	+++ IC50: 8.5 nM	Phase 2
Osilodrostat (LCI699)	++++ IC50: 2.5 nM	Phase 3
Ro 61-8048	+++ IC50: 37 nM	
(R)-Nepicastat HCl	++ IC50: 18.3 nM	
Tetrahydropapaverine HCl	+ IC50: 5.7 μM	
Mildronate	√	Phase 2
4-Chloro-DL-phenylalanine	√	
DMOG	√	
Telotristat Etiprate (LX 1606 Hippurate)	√	Phase 3

Factor Xa

阻害選択性

Inhibitor Name	Factor Xa	Other Targets	Clinical Phase
Rivaroxaban	++ IC50: 0.7 nM	Prothrombinase	Phase 4
Apixaban	++++ Ki: 0.08 nM		Phase 4
Edoxaban	+++ Ki: 0.561 nM		Phase 4
Edoxaban tosylate Monohydrate	√		

DHFR

阻害選択性

Inhibitor Name	DHFR	Other Targets	Clinical Phase
Pemetrexed	++++ Ki: 7.2 nM	TS,GARFT	Phase 4
Methotrexate	++ IC50: 24 nM		Phase 4
Pyrimethamine	+++ IC50: 15.4 nM		Phase 4
Methotrexate disodium	++ IC50: 24 nM		
Pemetrexed Disodium Hydrate	++++ Ki: 7.2 nM	TS,GARFT	Phase 4
Pralatrexate	√		Phase 4
Diaveridine	√		

Dehydrogenase

阻害選択性

Inhibitor Name	Dehydrogenase	Other Targets	Clinical Phase
Mycophenolate Mofetil	+++ IC50: 27 nM		Phase 4
AGI-5198	++ IC50: 70 nM		
MK-8245	++++ IC50: 1 nM		Phase 2
NCT-503	+ IC50: 2.5 μM		
ML390	+ IC50: 0.56 μM		
Enasidenib (AG-221)	++++ IC50: 12 nM		Phase 3
NCT-501	++ IC50: 40 nM		
SW033291	++++ IC50: 1.5 nM		
Vidofludimus	++ IC50: 134 nM		Phase 2
AGI-6780	+++ IC50: 23 nM		
Daidzin	+++ Ki: 20 nM		Phase 1
CPI-613	√		Phase 3
Leflunomide	√		Phase 4
Mycophenolic acid	√		Phase 4
Disulfiram	√		Phase 4
Trilostane	√		Phase 2
Teriflunomide	√		Phase 4
PluriSIn #1 (NSC 14613)	√		
Ammonium Glycyrrhizinate	√		
Gimeracil	√		Phase 3
3-Nitropropionic acid	√		
Vorasidenib (AG-881)	√		Phase 1
RRx-001	√	Nrf2-ARE	Phase 3
Ivosidenib (AG-120)	√		Phase 3
Isovaleramide	√		
gossypol-Acetic acid	√	Bcl2	Phase 3
Enoxolone	√		Phase 2
Emodin	√		
Fomepizole	√		Phase 2

Procollagen C Proteinase

阻害選択性

Inhibitor Name	Procollagen C Proteinase
UK 383367	+++ IC50: 44 nM

Phospholipase (e.g. PLA)

阻害選択性

Inhibitor Name	Phospholipase (e.g. PLA)	Clinical Phase
Varespladib (LY315920)	+++ IC50: 7 nM	Phase 3
Darapladib (SB-480848)	++++ IC50: 0.25 nM	Phase 3
Tanshinone I	++ IC50: 11 μM	Phase 4
Halobetasol Propionate	√	Phase 4
U73122	√	
Polydatin	√	Phase 2

Carbonic Anhydrase

阻害選択性

Inhibitor Name	Carbonic Anhydrase	Carbonic Anhydrase I	Carbonic Anhydrase II	Carbonic Anhydrase IV	Carbonic Anhydrase IX	Carbonic Anhydrase XII	Other Targets	Clinical Phase
Dorzolamide HCl		+ Ki: 6000 nM	++++ Ki: 1.9 nM	+++ Ki: 31 nM				Phase 4
U-104					++ Ki: 45.1 nM	++++ Ki: 4.5 nM		
Tioxolone		+ Ki: 91 nM						
Brinzolamide			++++ IC50: 3.19 nM					Phase 4
Acetazolamide	+++ IC50: 10 nM							Phase 4
Methazolamide		++ Ki: 50 nM	+++ Ki: 14 nM	++ Ki: 36 nM				Phase 4
Topiramate	√						sodium channel, AMPA/kainate receptor, Calcium Channel	Phase 4
Dichlorphenamide	√							Phase 3
Mafenide Acetate	√							
Benzenesulfonamide	√							

MAO

阻害選択性

Inhibitor Name	MAO-A	MAO-B	MAO	Other Targets	Clinical Phase
Safinamide Mesylate		++++ IC50: 98 nM			
Rasagiline Mesylate	+++ IC50: 412 nM	++++ IC50: 4.43 nM			Phase 4
Tranylcypromine (2-PCPA) HCl	++ IC50: 11.5 μM	+++ IC50: 7 μM		LSD1	Phase 4
Moclobemide (Ro 111163)	+++ IC50: 6.1 μM				Phase 3
Safinamide		++++ Ki: 16.7 nM			
Harmine	++++ Ki: 0.048 μM			PPARγ	
Pargyline hydrochloride	++ Ki: 13 μM	+++ Ki: 0.5 μM			
Isatin	+ IC50: 58 μM	++ IC50: 14 μM	++ IC50: 15 μM		
Sennoside A			+ IC50: 17 μM		
Paeonol	+ IC50: 54.6 μM	+ IC50: 42.5 μM			
Glycyrrhizin (Glycyrrhizic Acid)			+++ IC50: 0.16 μM	11 beta-hydroxysteroid dehydrogenase,HMGB1	Phase 4
Iproniazid			√		

Liver X Receptor

阻害選択性

Inhibitor Name	Liver X Receptor
SR9243	√

FAAH

阻害選択性

Inhibitor Name	FAAH	Other Targets	Clinical Phase
URB597	++++ IC50: 4.6 nM		Phase 1
PF-3845	++ Ki: 230 nM		
JNJ-1661010	+++ IC50: 10 nM		
Biochanin A	+ IC50: 1.8 μM	EGFR	

CETP

阻害選択性

Inhibitor Name	CETP	Clinical Phase
Anacetrapib (MK-0859)	+++ IC50: 7.9 nM	Phase 3
Torcetrapib	++ IC50: 37 nM	Phase 3
Evacetrapib (LY2484595)	++++ IC50: 5.5 nM	Phase 3
Dalcetrapib (JTT-705, RO4607381)	+ IC50: 0.2 μM	Phase 3

Lipase

阻害選択性

Inhibitor Name	Lipase	Other Targets	Clinical Phase
JZL184	++++ IC50: 8 nM		
Atglistatin	++ IC50: 0.7 μM		
XEN445	+++ IC50: 0.237 μM		
Orlistat	√	Fatty acid synthesis	Phase 4
Tanshinone IIA	√		Phase 4

Transferase

阻害選択性

Inhibitor Name	Transferase	Clinical Phase
Tipifarnib	+++ IC50: 0.6 nM	Phase 3
Lonafarnib	+++ IC50: 1.9 nM	Phase 3
Daporinad (FK866, APO866)	++++ Ki: 0.4 nM	Phase 2
A922500	++ IC50: 7 nM	
Lomeguatrib	++ IC50: 5 nM	
FTI 277 HCl	++++ IC50: 500 pM	
LB42708	+++ IC50: 1.2 nM	
PF-04620110	+ IC50: 19 nM	Phase 1
Tolcapone	+ Ki: 30 nM	Phase 4
GGTI 298 TFA salt	√	

Ferroptosis

阻害選択性

Inhibitor Name	Ferroptosis
Ferrostatin-1 (Fer-1)	++ EC50: 60 nM
Liproxstatin-1	+++ IC50: 22 nM

Lipoxygenase

阻害選択性

Inhibitor Name	lipoxygenase	Other Targets	Clinical Phase
Abietic Acid	+++ IC50: 29.5 μM	PPARγ	
Zileuton	√		Phase 4
Nordihydroguaiaretic acid (NDGA)	√		Phase 2
Esculetin	√		
MK-886 (L-663,536)	√	PPARα,COX-1,COX-2	

HMG-CoA Reductase

阻害選択性

Inhibitor Name	HMG-CoA Reductase	Other Targets	Clinical Phase
Simvastatin	++++ Ki: 0.1-0.2 nM		Phase 4
Rosuvastatin Calcium	+++ IC50: 11 nM		Phase 4
Lovastatin	++++ IC50: 3.4 nM		Phase 4
Fluvastatin Sodium	+++ IC50: 8 nM		Phase 4
Pravastatin sodium	++ IC50: 5.6 μM		Phase 4
Clinofibrate	+ IC50: 0.47 mM		
SR-12813	++ IC50: 850 nM	pregnane X receptor	
Pitavastatin Calcium	√	cholesterol esters	Phase 4

阻害選択性

Inhibitor Name	HMG-CoA Reductase	Other Targets	Clinical Phase
Atorvastatin Calcium	√		Phase 4
Mevastatin	√		
Rosuvastatin	√		Phase 4

AhR

阻害選択性

Inhibitor Name	AhR	Clinical Phase
StemRegenin 1 (SR1)	++ IC50: 127 nM	Phase 2
CH-223191	+++ IC50: 30 nM	
UM729	√	

NAMPT

阻害選択性

Inhibitor Name	NAMPT	Other Targets	Clinical Phase
KPT-9274	++ IC50: ~120 nM	PAK4	
GMX1778 (CHS828)	+++ IC50: <25 nM		Phase 1
STF-118804	√		

IDO

阻害選択性

Inhibitor Name	IDO	Clinical Phase
NLG919	+++ EC50: 75 nM	
BMS-986205	++++ IC50: 1.7 nM	Phase 3
IDO inhibitor 1	+++ IC50: 3 nM	
PF-06840003	+ IC50: 0.41 μM	Phase 1
Epacadostat (INCB024360)	++ IC50: 10 nM	Phase 3
INCB024360 analogue	++ IC50: 67 nM	Phase 2
Indoximod (NLG-8189)	√	Phase 3

Decarboxylase

阻害選択性

Inhibitor Name	decarboxylase	Clinical Phase
Carbidopa	+++ IC50: 29 μM	Phase 4
Benserazide HCl	√	Phase 4
Eflornithine hydrochloride hydrate	√	
Methyldopa	√	Phase 4

GLUT

阻害選択性

Inhibitor Name	GLUT1
BAY-876	+++ IC50: 0.002 μM
WZB117	++ IC50: 10μM
STF-31	√

PKM

阻害選択性

Inhibitor Name	PKM2
PKM2 inhibitor(compound 3k)	+++ IC50: 2.95 μM

注釈：

1.各阻害剤の半数阻害濃度（IC_{50}）や作用濃度など、詳細についてはwww.selleck.co.jpのウェブサイトをご覧ください。

2.「+」は阻害効果を示す。阻害効果が高い（IC_{50}値が低い）ほど「+」が多く示されている。

3.赤色の「√」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。

GPCR & G Protein



5-HT Receptor
詳細情報は**P59**に記載されています

Adrenergic Receptor
詳細情報は**P61**に記載されています

Histamine Receptor
詳細情報は**P19**に記載されています

Dopamine Receptor
詳細情報は**P63**に記載されています

Opioid Receptor
詳細情報は**P63**に記載されています

Hedgehog/Smoothened
詳細情報は**P56**に記載されています

OX Receptor
詳細情報は**P64**に記載されています

CXCR
詳細情報は**P20**に記載されています

Cannabinoid Receptor
阻害選択性

Inhibitor Name	CB1	CB2	Other Targets	Clinical Phase
Rimonabant	+++ IC50: 13.6 nM	++ IC50: 1.64 μM		Phase 4
Otenabant (CP-945598) HCl	++++ Ki: 0.7 nM			Phase 3
AM251	√			
Olivetol	√		CYP1A1,CYP2C19	

Endothelin Receptor
阻害選択性

Inhibitor Name	ET-A	ET-B	Clinical Phase
Zibotentan (ZD4054)	++ IC50: 21 nM		Phase 3
Bosentan Hydrate	+++ Ki: 4.7 nM	++ Ki: 95 nM	Phase 4
Macitentan	++++ IC50: 0.5 nM	+ IC50: 391 nM	Phase 4
Bosentan	+++ Ki: 4.7 nM	++ Ki: 95 nM	Phase 4
BQ-123	+++ IC50: 7.3 nM		Phase 2
Ambrisentan	√		Phase 4

S1P Receptor
阻害選択性

Inhibitor Name	S1PR	S1PR1	S1PR5	SphK	S1PR2	Clinical Phase
Fingolimod (FTY720) HCl	++++ IC50: 0.033 nM					Phase 4
PF-543				+++ IC50: 2.0 nM		
Ponesimod		++ EC50: 5.7 nM				Phase 3
Ozanimod (RPC1063)		+++ EC50: 0.41 nM	++ EC50: 11 nM			Phase 3
JTE 013					+ IC50: 17 nM	
BAF312 (Siponimod)		++++ EC50: 0.39 nM	+++ EC50: 0.98 nM			Phase 3
Opaganib (ABC294640)				+ IC50: 60 μM		Phase 2

SGLT
阻害選択性

Inhibitor Name	SGLT1	SGLT2	Other Targets	Clinical Phase
Dapagliflozin		++++ EC50: 1.1 nM		Phase 4
Canagliflozin		+++ IC50: 3.7 nM		Phase 4
Empagliflozin (BI 10773)		++ IC50: 3.1 nM		Phase 4
Ertugliflozin		++++ IC50: 0.877 nM		Phase 4
Ipragliflozin (ASP1941)		+ IC50: 7.4 nM	mouse SGLT2,rat SGLT2	Phase 4
Tofogliflozin(CSG 452)		++ IC50: 2.9 nM		Phase 4
Sotagliflozin (LX4211)	+ IC50: 36 nM	+++ IC50: 1.8 nM		Phase 3
Dapagliflozin propanediol monohydrate		√		
Phloretin	√			

LPA Receptor
阻害選択性

Inhibitor Name	LPA1	LPA2	LPA3
Ki16425	+++ Ki: 0.34 μM	+ Ki: 6.5 μM	++ Ki: 0.93 μM
Ki16198	+++ Ki: 0.34 μM		++ Ki: 0.93 μM
ONO-7300243	++++ IC50: 0.16 μM		

PAFR
阻害選択性

Inhibitor Name	PAFR
Ginkgolide B	+++ IC50: 3.6 μM

PKA

阻害選択性

Inhibitor Name	PKA	Other Targets	Clinical Phase
A-674563	+++ Ki: 16 nM	Akt1,CDK2,GSK-3β	
H 89 2HCl	++ Ki: 48 nM	S6K1	
Daphnetin	+ IC50: 9.33 μM	EGFR,PKC	
AT13148	++++ IC50: 3 nM	ROCK2,ROCK1,p70S6K	Phase 1

Adenosine Receptor

阻害選択性

Inhibitor Name	Adenosine Receptor	Other Targets	Clinical Phase
Istradefylline	+++ Ki: 2.2 nM		Phase 3
AZD-4635 (HTL1071)	++++ Ki: 1.7 nM		Phase 2
A2AR antagonist 1	++ Ki: 4 nM		
SCH58261	+++ Ki: 2.0 nM		
Reversine	+ Ki: 0.66 μM	Aurora A,Aurora B,Aurora C	
Proxyphylline	√		
ZM241385	√		

CaSR

阻害選択性

Inhibitor Name	CaSR
NPS-2143	+++ IC50: 43 nM

Vasopressin Receptor

阻害選択性

Inhibitor Name	Vasopressin receptor 1	Vasopressin receptor 2	Clinical Phase
Tolvaptan		++++ IC50: 3 nM	Phase 4
Mozavaptan	++ IC50: 1.2 μM	+++ IC50: 14 nM	
Conivaptan HCl	√		Phase 4

cAMP

阻害選択性

Inhibitor Name	AC	EPAC1	EPAC2	PACAP receptor	Other Targets
PACAP 6-38				++++ IC50: 2 nM	CARTp
Bithionol	+ IC50: 4.0 μM				
ESI-09		++ IC50: 3.2 μM	+++ IC50: 1.4 μM		
HJC0350			+++ IC50: 0.3 μM		
PACAP 1-27				√	
SQ22536	√				

注釈:

1.各阻害剤の半数阻害濃度（IC_{50}）や作用濃度など、詳細についてはwww.selleck.co.jpのウェブサイトをご覧ください。

2.「+」は阻害効果を示す。阻害効果が高い（IC_{50}値が低い）ほど「+」が多く示されている。

3.赤色の「√」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。

Endocrinology & Hormones



Opioid Receptor

詳細情報はP63に記載されています

5-alpha Reductase

阻害選択性

Inhibitor Name	5-alpha Reductase	Clinical Phase
Finasteride	+++ Ki: 10.2 nM	Phase 4
Dutasteride	√	Phase 4

Estrogen/progestogen Receptor

阻害選択性

Inhibitor Name	Estrogen receptor	Progesterone receptor	Other Targets	Clinical Phase
Fulvestrant	+++ IC50: 0.94 nM			Phase 4
Raloxifene HCl	++ IC50: 5.7 nM			Phase 4
Mifepristone		++++ IC50: 0.2 nM	Glucocorticoid receptor	Phase 4
Bazedoxifene HCl	+ IC50: 23 nM			Phase 4
Tamoxifen Citrate	√			Phase 4
Toremifene Citrate	√			Phase 4
Dienogest		√		Phase 4
Clomifene citrate	√			Phase 4
Drospirenone		√		Phase 4
Ulipristal		√		Phase 4

阻害選択性

Inhibitor Name	Estrogen receptor	Progesterone receptor	Other Targets	Clinical Phase
Megestrol Acetate		√	Androgen Receptor	Phase 4
Pregnenolone		√		Phase 4
Estriol	√			Phase 4
Estrone	√			Phase 2
Bazedoxifene Acetate	√			Phase 4
Cyclofenil	√			
PHTPP	√			
AZD9496	√			Phase 1
Chlorotrianisene	√			Phase 4
Endoxifen HCl	√			Phase 2
Ospemifene	√			Phase 4
Tamoxifen	√			Phase 4

Androgen Receptor

阻害選択性

Inhibitor Name	Androgen Receptor	Other Targets	Clinical Phase
Enzalutamide (MDV3100)	+++ IC50: 36 nM		Phase 4
Bicalutamide	++ IC50: 0.16 μM		Phase 4
Ostarine (GTx-024, MK-2866)	++++ Ki: 3.8 nM		Phase 3
Apalutamide (ARN-509)	+++ IC50: 16 nM		Phase 2
Galeterone	+ IC50: 384 nM	CYP17	Phase 3
Flutamide	+++ Ki: 55 nM		Phase 4
Cyproterone Acetate	++++ IC50: 7.1 nM		Phase 4
AZD3514	+ Ki: 2.2 μM		Phase 1
Spironolactone	++ IC50: 77 nM		Phase 4
Triptophenolide	++ IC50: 260 nM	AR-T877A,AR-F876L	
RAD140	++++ Ki: 7 nM		Phase 1
EPI-001	+ IC50: ~6 μM	PPARγ	
Darolutamide (ODM-201)	+++ Ki: 11 nM		Phase 3
Dehydroepiandrosterone (DHEA)	√		Phase 4
Megestrol Acetate	√	progestogen Receptor	Phase 4
RU58841	√		
Nilutamide	√		

RAAS

阻害選択性

Inhibitor Name	AT1 receptor	AT2 receptor	ACE	Renin	RAAS	Clinical Phase
Aliskiren Hemifumarate				+++ IC50: 1.5 nM		Phase 4
Candesartan	++++ IC50: 0.26 nM					Phase 4
Losartan Potassium (DuP 753)	+ IC50: 20 nM					Phase 4
Enalaprilat Dihydrate			+++ IC50: 1.94 nM			Phase 4
Irbesartan	+++ IC50: 1.3 nM					Phase 4
PD123319		+ IC50: 34 nM				
Perindopril Erbumine			++++ IC50: 1.05 nM			Phase 3
Candesartan Cilexetil					++++ IC50: 0.26 nM	Phase 4
Ramipril			++ IC50: 5 nM			Phase 4
Captopril			++ IC50: 6 nM			Phase 4
Azilsartan Medoxomil	+++ IC50: 2.6 nM					Phase 4
Imidapril HCl			+++ IC50: 2.6 nM			Phase 3
Losartan	+ IC50: 20 nM					Phase 4
Eprosartan Mesylate	++++ Kd: 0.83 nM					Phase 4

阻害選択性

Inhibitor Name	AT1 receptor	AT2 receptor	ACE	Renin	RAAS	Clinical Phase
Azilsartan	+++ IC50: 2.6 nM					Phase 4
Telmisartan		√				Phase 4
Valsartan		√				Phase 4
Benazepril HCl			√			Phase 4
Enalapril Maleate			√			Phase 4
Olmesartan Medoxomil	√					Phase 4
Cilazapril Monohydrate			√			
Lisinopril			√			Phase 4
Moexipril HCl			√			Phase 2
Temocapril HCl			√			
Quinapril HCl			√			Phase 4
Delapril Hydrochloride			√			
Zofenopril calcium			√			
Fimasartan	√					Phase 4
Sacubitril/valsartan (LCZ696)					√	Phase 4
Fosinopril Sodium			√			Phase 4

Aromatase

阻害選択性

Inhibitor Name	Aromatase	Other Targets	Clinical Phase
Letrozole	++++ IC50: 0.07 nM-20 nM		Phase 4
Anastrozole	+++ IC50: 15 nM		Phase 4
Exemestane	+++ IC50: 30 nM		Phase 4
Formestane	++ IC50: 80 nM		
Aminoglutethimide	++ IC50: 10 μM		Phase 3
alpha-Naphthoflavone	++++ Ki: 5 nM		
Obacunone	+ IC50: 28.4 μM	Nrf2	

GPR

阻害選択性

Inhibitor Name	GPR	Clinical Phase
AZD1981	+++ IC50: 4 nM	Phase 2
OC000459	++ IC50: 13 nM	Phase 2

注釈：

1.各阻害剤の半数阻害濃度（IC_{50}）や作用濃度など、詳細についてはwww.selleck.co.jpのウェブサイトをご覧ください。

2.「+」は阻害効果を示す。阻害効果が高い（IC_{50}値が低い）ほど「+」が多く示されている。

3.赤色の「√」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。

Transmembrane Transporters



GABA Receptor

詳細情報はP63に記載されています

P-gp

詳細情報はP64に記載されています

Calcium Channel

阻害選択性

Inhibitor Name	Calcium Channel	Other Targets	Clinical Phase
Amlodipine Besylate	+++ IC50: 1.9 nM		Phase 4
Manidipine 2HCl	+++ IC50: 2.6 nM		Phase 4
Felodipine	++++ IC50: 0.15 nM		Phase 4
Manidipine	+++ IC50: 2.6 nM		Phase 4
Nisoldipine	++ IC50: 10 nM		Phase 4
Nilvadipine	++++ IC50: 0.03 nM		Phase 3
Flunarizine 2HCl	+ Ki: 68 nM		Phase 4
Nitrendipine	+ IC50: 95 nM		Phase 4
Levetiracetam	√		Phase 4
Cilnidipine	√		Phase 4
Amiloride HCl	√	Sodium channel,uPA	Phase 4
Verapamil HCl	√		Phase 4
Ranolazine 2HCl	√		Phase 4
Amlodipine	√		Phase 4
Isradipine	√		Phase 3
Ranolazine	√		Phase 4
Econazole nitrate	√		Phase 3
Nimodipine	√		Phase 4

阻害選択性

Inhibitor Name	Calcium Channel	Other Targets	Clinical Phase
Dronedarone HCl	√	Potassium channel,Sodium channel	Phase 4
Lacidipine	√		Phase 4
Nicardipine HCl	√		Phase 4
Clevidipine Butyrate	√		Phase 4
Nifedipine	√		Phase 4
HC-030031	√		
Benidipine HCl	√		Phase 4
Azelnidipine	√		Phase 4
Tetracaine HCl	√		Phase 4
Fendiline hydrochloride	√		
Efonidipine	√		
ML204	√		
Levamlodipine	√		Phase 4
Cinnarizine	√	Histamine receptor	Phase 4
Lercanidipine hydrochloride	√		
SKF96365	√		
Lomerizine 2HCl	√		
Cinepazide maleate	√		Phase 2
Tetrandrine	√		
Diltiazem HCl	√		Phase 4

Sodium Channel

阻害選択性

Inhibitor Name	Sodium Channel	Other Targets	Clinical Phase
Carbamazepine	++ IC50: 131 μM		Phase 4
A-803467	++++ IC50: 8 nM		
Camostat Mesilate	+++ IC50: 50 nM		
Ouabain	++++ Ki: 15 nM		
Ambroxol HCl	+++ IC50: 35.2 μM-22.5 μM		Phase 3
Triamterene	+++ IC50: 4.5 μM	ENaCαS583	Phase 4
Procaine HCl	++ IC50: 60 μM	5-HT3,nAChR,NMDA receptor	Phase 4
Proparacaine HCl	+ ED50: 3.4 mM		Phase 3
Oxcarbazepine	+ IC50: 160 μM		Phase 4
Riluzole	√	NMDA receptor,Glutamate release	Phase 4
Bupivacaine HCl	√		Phase 4
Amiloride HCl	√	T-type calcium channel,uPA	Phase 4
Rufinamide	√		Phase 3
Zonisamide	√		Phase 4
Phenytoin Sodium	√		Phase 4
Amiloride HCl dihydrate	√		Phase 4
Dronedarone HCl	√	Potassium channel,Calcium channel	Phase 4
Phenytoin	√		Phase 4
Lamotrigine	√	5-HT (human platelets), 5-HT (rat brain synaptosomes)	Phase 4
Primidone	√		Phase 2
(-)-Sparteine Sulfate	√		
Quinidine sulfate	√		Phase 3
Procainamide HCl	√	DNA methyltransferase	Phase 4
Mexiletine HCl	√		Phase 4
Benzocaine	√		Phase 4
Tolperisone HCl	√		Phase 2
Levobupivacaine HCl	√		Phase 4
Dibucaine HCl	√		
Ibutilide Fumarate	√		Phase 4

阻害選択性

Inhibitor Name	Sodium Channel	Other Targets	Clinical Phase
Vinpocetine	√		Phase 3
Propafenone HCl	√		Phase 4

ATPase

阻害選択性

Inhibitor Name	ATPase	Clinical Phase
Brefeldin A	+++ IC50: 0.2 μM	
(-)-Blebbistatin	+ IC50: 0.5 μM-5 μM	
Sodium orthovanadate	+++ IC50: 40 nM	
PF-3716556	++ pIC50: ~6.5	
CB-5083	++++ IC50: 11 nM	Phase 1
Oligomycin A	√	
Ciclopirox	√	Phase 4
Ciclopirox ethanolamine	√	
Esomeprazole sodium	√	Phase 4
BTB06584	√	
Golgicide A	√	

Potassium Channel

阻害選択性

Inhibitor Name	Potassium Channel	Other Targets	Clinical Phase
TRAM-34	+++ Kd: 20 nM		
Glimepiride	++++ IC50: 3 nM		Phase 4
Gliquidone	+++ IC50: 27.2 nM		Phase 4
Vonoprazan Fumarate (TAK-438)	++++ IC50: 19 nM		Phase 3
ML133 HCl	++ IC50: 290 nM		
Gliclazide	++ IC50: 184 nM		Phase 4
4-Aminopyridine			Phase 4
Dofetilide	√		Phase 4
Chlorpromazine HCl	√	Dopamine receptor	Phase 4
Amiodarone HCl	√		Phase 4
Repaglinide	√		Phase 4
Quinine HCl Dihydrate	√		Phase 4
Tolbutamide	√		Phase 1
Dronedarone HCl	√	Calcium channel,Sodium channel	Phase 4
Glyburide (Glibenclamide)	√		Phase 4
Nateglinide	√		Phase 4
Mitiglinide Calcium	√		Phase 4

Proton Pump

阻害選択性

Inhibitor Name	Proton Pump	Other Targets	Clinical Phase
Bafilomycin A1(Baf-A1)	+++ IC50: 0.44 nM		
PF-3716556	++ pIC50: ~6.5		
Lansoprazole	√		Phase 4
Omeprazole	√		Phase 4
NEXIUM (esomeprazole magnesium)	√		Phase 4
Zinc Pyrithione	√		
Dexlansoprazole	√		Phase 4

阻害選択性

Inhibitor Name	Proton Pump	Other Targets	Clinical Phase
Revaprazan Hydrochloride	√		Phase 2
Rabeprazole	√		Phase 4
Ilaprazole	√	TOPK	Phase 4
Rebeprazole sodium	√		Phase 4
Pantoprazole sodium	√	HIF-1α	
Tenatoprazole	√		Phase 2

CFTR

阻害選択性

Inhibitor Name	CFTR	Clinical Phase
VX-809 (Lumacaftor)	++++ EC50: 0.1 μM	Phase 3
CFTRinh-172	+++ Ki: 300 nM	
IOWH032	++ IC50: 1.01 μM	Phase 2
GlyH-101	+ Ki: 4.3 μM	
Ataluren (PTC124)	√	Phase 4
Tezacaftor (VX-661)	√	Phase 3

TRPV

阻害選択性

Inhibitor Name	TRPV	Other Targets	Clinical Phase
SB705498	+ pIC50: 7.1		Phase 2
AMG-517	++++ IC50: 1 nM-2 nM		
GSK2193874	+++ IC50: 0.002 μM		
SB366791	++ IC50: 5.7 nM		
Probenecid	√	organic anion transport,TAS2R16	Phase 4
Capsazepine	√	Na,K-ATPase	

CRM1

阻害選択性

Inhibitor Name	CRM1	Other Targets	Clinical Phase
Selinexor (KPT-330)	√		Phase 2
KPT-185	√		
KPT-276	√		
Eltanexor (KPT-8602)	√		Phase 2
Piperlongumine	√	reactive oxygen species (ROS),PI3K/Akt/mTOR,TrxR1	
Verdinexor (KPT-335)	√		Phase 1

注釈:

1.各阻害剤の半数阻害濃度 (IC_{50}) や作用濃度など、詳細についてはwww.selleck.co.jpのウェブサイトをご覧ください。

2.「+」は阻害効果を示す。阻害効果が高い（IC_{50}値が低い）ほど「+」が多く示されている。

3.赤色の「√」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。

Proteases



Proteasome
詳細情報は**P57**に記載されています

Caspase
詳細情報は**P36**に記載されています

Gamma-secretase
詳細情報は**P55**に記載されています

HCV Protease
阻害選択性

Inhibitor Name	HCV Protease	Other Targets	Clinical Phase
Daclatasvir (BMS-790052)	+++ EC50: 9 pM-50 pM		Phase 4
Telaprevir (VX-950)	++ IC50: 0.35 μM		Phase 4
Lomibuvir (VX-222, VCH-222)	+ IC50: 0.94 μM		Phase 2
Danoprevir (ITMN-191)	++ IC50: 0.2 nM-3.5 nM		Phase 3
Paritaprevir (ABT-450)	+++ EC50: 0.21 nM		Phase 4
Grazoprevir	++++ Ki: 0.01 nM	gt1b R155K,gt1b D168V,gt1b D168Y	Phase 4
Elbasvir	√		Phase 4
Ombitasvir (ABT-267)	√		Phase 4
Daclatasvir Digydrochloride	√		
Simeprevir	√		Phase 4
Velpatasvir	√		Phase 4
Ledipasvir (GS5885)	√		Phase 4

DPP-4
阻害選択性

Inhibitor Name	DPP-4	Other Targets	Clinical Phase
Sitagliptin phosphate monohydrate	+ IC50: 19 nM		Phase 4
Linagliptin	++++ IC50: 1 nM		Phase 4
Vildagliptin (LAF-237)	+++ IC50: 2.3 nM		Phase 4
Saxagliptin	+ IC50: 26 nM		Phase 4
Alogliptin（SYR-322）benzoate	++ IC50: <10 nM		Phase 4
Alogliptin	+++ IC50: 2.93 nM		Phase 4
Sitagliptin	++ IC50: 18 nM		Phase 4
Trelagliptin succinate	++ IC50: 4 nM		Phase 3
Omarigliptin (MK-3102)	++++ IC50: 1.6 nM		Phase 4
Teneligliptin hydrobromide	+++ IC50: 1.75 nM	DPP-9	
Saxagliptin hydrate	√		
Trelagliptin	√		Phase 4

HIV Protease
阻害選択性

Inhibitor Name	HIV Protease	Other Targets	Clinical Phase
Lopinavir	++++ Ki: 1.3 pM		Phase 4
Atazanavir Sulfate	++ Ki: 2.66 nM		
Amprenavir	+ IC50: 14.6 ng/mL	PXR	Phase 4
Nelfinavir Mesylate	+++ Ki: 2 nM		Phase 4
Ritonavir	√	CYP3A4	Phase 4
Darunavir Ethanolate	√		Phase 4
Atazanavir	√		Phase 4
Limonin	√		

MMP
阻害選択性

Inhibitor Name	MMP	Clinical Phase
Batimastat (BB-94)	+++ IC50: 3 nM	
Ilomastat (GM6001, Galardin)	++++ Ki: 0.36 nM	
SB-3CT	+ Ki: 13.9 nM	
Marimastat (BB-2516)	+++ IC50: 5 nM	Phase 3
NSC 405020	√	
Doxycycline Hyclate	√	Phase 4
Nobiletin	√	

Serine Protease
阻害選択性

Inhibitor Name	Serine Protease	Other Targets	Clinical Phase
Gabexate Mesylate	++ IC50: 0.19 μM		Phase 3
Aprotinin	+++ Ki: 9.5 nM	Thrombin,Trypsin,kallikrein	Phase 4
Alvelestat (AZD9668)	++++ IC50: 12 nM		Phase 2
Nafamostat Mesylate	√		
PMSF	√	cysteine protease	
Sivelestat sodium tetrahydrate	√		Phase 4
Sivelestat (ONO-5046)	√		
Leupeptin Hemisulfate	√	Cysteine protease	
AEBSF HCl	√		

Tyrosinase

阻害選択性

Inhibitor Name	tyrosinase	monophenolase	diphenolase	Clinical Phase
Deoxyarbutin	++++ IC50: 50 nM			
Kojic acid	++ IC50: 0.28 mM			
Hexylresorcinol	+++ IC50: 0.85 μM	++ IC50: 1.24 μM	+++ IC50: 0.85 μM	
Arbutin	+ IC50: 1.09 mM			Phase 3
Monobenzone	√			
Aloin	√			

Cysteine Protease

阻害選択性

Inhibitor Name	Cysteine Protease	Other Targets	Clinical Phase
Odanacatib (MK-0822)	++++ IC50: 0.2 nM		Phase 3
E-64	+++ IC50: 9 nM		
PD 151746	+ IC50: 260 nM		
Calpeptin	++ ID50: 34 nM		
Cathepsin Inhibitor 1	+++ pIC50: 5.2		
PMSF	√	chymotrypsin	
Aloxistatin(E64d)	√		
Loxistatin Acid (E-64C)	√		
Leupeptin Hemisulfate	√	serine protease	
Z-FA-FMK	√		
MG-101 (ALLN)	√		Phase 3

Glutaminase

阻害選択性

Inhibitor Name	glutaminase	Clinical Phase
BPTES	++ IC50: 0.16 μM	
CB-839	+++ IC50: 24 nM	Phase 2

注釈:

1.各阻害剤の半数阻害濃度（IC_{50}）や作用濃度など、詳細についてはwww.selleck.co.jpのウェブサイトをご覧ください。

2.「+」は阻害効果を示す。阻害効果が高い（IC_{50}値が低い）ほど「+」が多く示されている。

3.赤色の「√」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。

Microbiology



HCV Protease

詳細情報はP86に記載されています

CCR

詳細情報はP19に記載されています

HIV Protease

詳細情報はP87に記載されています

Integrase

阻害選択性

Inhibitor Name	Integrase	Other Targets	Clinical Phase
Raltegravir (MK-0518)	+ IC50: 40 nM		Phase 4
Elvitegravir (GS-9137, JTK-303)	++++ IC50: 0.7 nM		Phase 4
Dolutegravir (GSK1349572)	+++ IC50: 2.7 nM		Phase 4
BMS-707035	++ IC50: 15 nM		Phase 2
MK-2048	+++ IC50: 1.5 nM		Phase 1
Dolutegravir Sodium	+++ IC50: 2.7 nM		
Raltegravir potassium	√		Phase 3
Cabotegravir (GSK744, GSK1265744)	√		Phase 3
Salicylanilide	√	reverse transcriptase	

Reverse Transcriptase

阻害選択性

Inhibitor Name	Reverse Transcriptase	Other Targets	Clinical Phase
Didanosine	++ IC50: 490 nM		Phase 4
Dapivirine (TMC120)	+++ IC50: 24 nM		Phase 3
Tenofovir	√		Phase 4
Tenofovir Disoproxil Fumarate	√		Phase 4
Emtricitabine	√		Phase 4
Entecavir Hydrate	√		
Adefovir Dipivoxil	√		Phase 4
Nevirapine	√		Phase 4
Lamivudine	√		Phase 4
Stavudine (d4T)	√		Phase 4
Telbivudine	√		Phase 4
Etravirine (TMC125)	√		Phase 4
Zidovudine	√		Phase 4
Zalcitabine	√		Phase 4
Abacavir sulfate	√		Phase 4
Foscarnet Sodium	√	RNA polymerase,DNA polymerase	Phase 4
Rilpivirine	√		Phase 4
Adefovir	√		Phase 4
Abacavir	√		Phase 4
Efavirenz	√		Phase 4
Tenofovir Alafenamide (GS-7340)	√		Phase 4
Salicylanilide	√	integrase	

注釈：

1.各阻害剤の半数阻害濃度（IC_{50}）や作用濃度など、詳細についてはwww.selleck.co.jpのウェブサイトをご覧ください。

2.「+」は阻害効果を示す。阻害効果が高い（IC_{50}値が低い）ほど「+」が多く示されている。

3.赤色の「√」は、関連するisoformに対して阻害効果を示すが、特定の値を示さないことを示している。